

DOKUMEN KORESPONDENSI

Nama Jurnal : ACS Omega
Judul : Hydroxypropyl Methylcellulose as Hydrogel Matrix and Citric Acid-Locust Bean Gum as Negative Matrix for Controlled Release
Publisher : ACS Publications
Volume/Issue : 8(8)
Tahun : 2023
DOI : <https://doi.org/10.1021/acsomega.2c07432>
Index : SJR(2022) 0.710
Penulis Pertama : Wuryanto Hadinugroho
Penulis Korespondensi : Wuryanto Hadinugroho
Tahapan & Lampiran :

No.	Tahapan	Waktu
1.	Submission to ACS Omega Email success submitted Manuscript draft	19-11-2022
2.	First revision request from reviewer Email first revision request from reviewer	15-12-2022
3.	First revision request from editor Email first revision request from editorial	16-12-2022
4.	Submission of first revision to ACS Omega Email success submitted first revision Manuscript draft first revision Response to reviewers comments (first revision)	25-12-2022
5.	Second revision request Email second revision request from reviewer	06-02-2023
6.	Submission of second revision to ACS Omega Email success submitted second revision Manuscript draft of second revision	06-02-2023
7.	Accepted for publication Email accepted for publication	07-02-2023
9.	Journal publishing agreement request Email Journal publishing agreement request	07-02-2023
10.	Journal publishing agreement received Email journal publishing agreement received Journal publishing agreement	08-02-2023
11.	Review proof request Email review proof request	15-02-2023
12.	Corrections proof received Email corrections proof received	15-02-2023
13.	Paper publish Email paper publish	17-02-2023

Hadinugroho, Wuryanto ao-2022-07432u - Manuscript Submission to ACS Omega 19-Nov-2022

Dari: ACS Omega (onbehalf@manuscriptcentral.com)

Kepada: wuryanto.hadinugroho@gmail.com

Cc: wuryanto.hadinugroho@gmail.com; waldi_ugm@yahoo.com; fudholi_fa@ugm.ac.id;
sugeng_riyanto51@yahoo.com; jefri@ukwms.ac.id

Tanggal: Sabtu, 19 November 2022 pukul 23.57 GMT+7

19-Nov-2022

Journal: ACS Omega

Manuscript ID: ao-2022-07432u

Title: "Citric acid-locust bean gum as a negative matrix for controlled release tablet"

Authors: Hadinugroho, Wuryanto; Martodihardjo, Suwaldi; Fudholi, Achmad; Riyanto, Sugeng; Prasetyo, Jefri

Manuscript Status: Submitted

Dear Dr. Hadinugroho:

Your manuscript has been successfully submitted to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopenscience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

Please reference the above manuscript ID in all future correspondence. If there are any changes in your contact information, please log in to ACS Paragon Plus with your ACS ID at <http://acsparagonplus.acs.org/> and select "Edit Your Profile" to update that information.

You can view the status of your manuscript by checking your "Authoring Activity" tab on ACS Paragon Plus after logging in to <http://acsparagonplus.acs.org/>.

Journal Publishing Agreement and Copyright

Upon acceptance, ACS Publications will require the corresponding author to sign and submit a Journal Publishing Agreement. This agreement gives authors a number of rights regarding the use of their manuscripts. At acceptance, the corresponding author will receive an email linking through to the Journal Publishing Agreement Wizard, which helps you select the most appropriate license for your manuscript.

For more information please see: https://pubs.acs.org/page/copyright/journals/jpa_faqs.html

ACS Authoring Services

Did you know that ACS provides authoring services to help scientists prepare their manuscripts and communicate their research more effectively? Trained chemists with field-specific expertise are available to edit your manuscript for grammar, spelling, and other language errors, and our figure services can help you increase the visual impact of your research.

Visit <https://authoringservices.acs.org> to see how we can help you! Please note that the use of these services does not guarantee that your manuscript will be accepted for publication.

Thank you for submitting your manuscript to ACS Omega.

Sincerely,

Dr. Krishna Ganesh and Dr. Deqing Zhang
ACS Omega

PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at pubs-comms-unsub@acs.org if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

**Citric acid-locust bean gum as a negative matrix for
controlled release tablet**

Journal:	ACS Omega
Manuscript ID	Draft
Manuscript Type:	Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Hadinugroho, Wuryanto; Widya Mandala Catholic University Surabaya, Pharmacy Martodihardjo, Suwaldi; Gadjah Mada University, Pharmacy Fudholi, Achmad; Gadjah Mada University, Pharmacy Riyanto, Sugeng; Gadjah Mada University, Pharmacy Prasetyo, Jefri; Widya Mandala Catholic University Surabaya, Pharmacy

SCHOLARONE™
Manuscripts

Citric acid-locust bean gum as a negative matrix for controlled release tablet

Wuryanto Hadinugroho^{1*}, Suwaldi Martodihardjo², Achmad Fudholi², Sugeng Riyanto², and Jefri Prasetyo¹

1 Department of Pharmaceutical, Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Kalisari Selatan no. 1 Pakuwon City, Surabaya, Indonesia.

2 Department of Pharmaceutical, Faculty of Pharmacy, Gadjah Mada University, Sekip Utara, Yogyakarta, Indonesia.

*Corresponding authors:
Dr. Wuryanto Hadinugroho, Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Kalisari Selatan no. 1 Pakuwon City, Surabaya, 60112, Indonesia.
Email address: wuryanto.hadinugroho@ymail.com

Abstract

Purpose: This study aimed to determine the optimum concentration of HPMC as hydrogel matrix and CA-LBG as negative matrix on controlled-release tablet formulation. In addition, the study was to determine the effect of CA-LBG and HPMC. CA-LBG accelerates the disintegration of tablets into granules so that the HPMC granule matrix swells immediately and controls drug release. The advantage of this method is that the tablets do not produce large hydroxypropyl methylcellulose (HPMC) gel lumps without drug (ghost matrix) but form HPMC gel granules which can be rapidly degraded after all the drug is released.

Methods: The experiment followed the simplex lattice design to obtain the optimum tablet formula with CA-LBG and HPMC concentrations as optimization factors. Tablets production by wet granulation method dan ketoprofen is the model of the active ingredient. The kinetics of ketoprofen release was studied using several models.

Results: Based on the coefficients of each polynomial equation that HPMC and CA-LBG increased the value of angle of repose (29.91 : 27.87), tap index (18.99 : 18.77), hardness (13.60 : 13.32), friability (0.41 : 0.73), and release of ketoprofen (52.48 : 99.44). Interaction of HPMC and CA-LBG increased the value of angle of repose (3.25), tap index (5.64), and hardness (2.42). Interaction of HPMC and CA-LBG too decreased the value friability (-1.10), and release of ketoprofen (-26.36). The Higuchi, Korsmeyer-Peppas, and Hixson-Crowell model is the kinetics of eight experimental tablet formulas.

Conclusion: The optimum concentrations of HPMC and CA-LBG for controlled release tablets are 32.97% and 17.03%. HPMC, CA-LBG, and a combination of both affect the physical quality of tablet and tablet mass. CA-LBG is a new excipient candidate that can control drug release from tablets by matrix disintegration mechanism on the tablet.

Keywords:

CA-LBG, citric acid, locust bean gum, control release, optimization

Introduction

Controlled-release tablets are drug delivery systems to prolong the therapeutic effect. The drug is released slowly and continuously over some time. Ion exchange resins, osmotic pumps, and reservoirs are examples of controlled release systems.^{1,2} HPMC is one of the polymers often used to control drug release because the HPMC matrix can trap drug particles and release them slowly. HPMC matrices alone or with other polymers are often used to control drug release.³⁻⁵

CA-LBG is a new ester polymer derived from locust bean gum. CA-LBG is synthesized using a hydrochloric acid (HCl) catalyst and an ultraviolet light (UV 254 nm) energy source. O atoms of the carbonyl group of CA are to be protonated to form positive C atoms because of acid conditions created by HCl. The ester bond occurs at the OH (C-6) mannose and galactose groups in LBG with a positive C atom from the carbonyl group in CA to form a tetrahedral cation. OH were protonated to $^+\text{OH}_2$, continued loss of H_2O to form CA-LBG (ester).⁶⁻¹¹ Previous experiments reported that CA-LBG has an ester carbonyl group which LBG does not. The viscosity and solubility of CA-LBG are lower than that of LBG.⁷ The CA-LBG character has the potential to control drug release.

This study aimed to determine the optimum concentration of HPMC and CA-LBG on the tablet. on controlled-release tablet formulation. In addition, the study was to determine the effect of CA-LBG and HPMC. The activity of CA-LBG as a negative matrix with HPMC matrix to control drug release was studied by drug release kinetics. The novelty of this experiment is that the formulation using CA-LBG is a new polymer ester with low solubility. The CA-LBG as a negative matrix causes the tablets to disintegrate into granules. HPMC matrix gel derived from granules controls drug release. A negative matrix (CA-LBG) is a substance that causes the tablet's positive matrix (HPMC) to disintegrate into granules. The mechanism of action on tablets is that the wetted tablet surface causes disintegration into granules due to low solubility of CA-LBG and repulsion between CA-LBG particles. Granules containing HPMC swell to control drug release. CA-LBG controls drug release because CA-LBG is poorly soluble and has low viscosity, so CA-LBG inhibits

the wetting and dissolution of drug particles. The advantage of this method is that the tablets do not produce large hydroxypropyl methylcellulose (HPMC) gel lumps without drug (ghost matrix) but form HPMC gel granules which can be rapidly degraded after all the drug is released. Ketoprofen (100 mg) (see supplementary information Chapter S1) is a drug model added to the granules and compressed into tablets (400 mg). HPMC was chosen as the matrix because HPMC is a polymer that can swell when hydrated with water with a viscosity to control drug release.^{1,5} Lactose monohydrate is a suitable filler for tablets because it has good compatibility and high density (1.545 g/cm³).⁵ These character can be suitable for wet granulation methods, so tablets are hard and of the ideal size. Ketoprofen is used in the drug model because ketoprofen has a dose of 25-200 mg and an elimination half-life of 2-4 hours.^{12,13} Making tablets using the wet granulation method can improve the flow properties by increasing the particle size and the compatibility of the tablet mass. CA-LBG particles are shaped like coral-corrugated, HPMC particles like a rhizome, and irregularly shaped lactose monohydrate particles.^{5,7} The experiment followed the simplex lattice design to obtain the optimum tablet formula. This method is quite simple for experiments by mixing internal factors (ingredients) in a formula without the influence of internal factors (process or technology). In addition, this method is quite effective for synthesized materials such as CA-LBG in limited quantities. The optimization factor is the concentration of CA-LBG and HPMC. The optimization response is the angle of repose, tap index, hardness, friability, and ketoprofen release.

Material and methods

Raw materials and chemicals

The materials used in this experiment include locust bean gum (Viscogum, Cargill, France), citric acid monohydrate (Brand KgaA, Darmstadt, Germany), hydrochloric acid (Sigma-Aldrich Chemie, GmbH, USA), distilled water (Sterilized Water For Injection, PT. Otsuka Indonesia), acetone (Cawan Anugerah Chemika, Indonesia), hydroxypropyl methylcellulose (Methocel K4M CR

Premium USP/EP, Colorcon, Singapore), lactose monohydrate (Leprino Foods, UDM, USA), ketoprofen (PT Kalbe Farma Tbk, Indonesia), potassium dihydrogen phosphate (KGaA Darmstadt Germany Brand), and sodium hydroxide (KGaA Darmstadt Germany Brand).

Manufacture of CA-LBG

The manufacturing of CA-LBG adopted the manufacturing method in the previous study. The LBG (3.55×10^{-6} mol) was swelled in 50 mL of warm distilled water (55-60 °C), added CA (21.00×10^{-3} mol), and HCl (57.40×10^{-3} mol), homogenized for 10 minutes. The gel was irradiated with UV 254 nm for 100 min (8-Watt, CH-4132 Muttentz, Camag, Switzerland), then precipitated (acetone) and washed off (distilled water-acetone). The CA-LBG residue was dried at room temperature.^{7,14}

The success of CA-LBG production was confirmed through the Fourier transform infrared spectroscopy (FTIR) characterization, nuclear magnetic resonance (NMR), solubility, and viscosity. Production is carried out for three batches to determine reproducibility through standard deviation.

Fourier transform infrared spectroscopy

The structure and specific groups of CA-LBG were identified by Fourier transform infrared spectroscopy (UATR Perkin Elmer Spectrum Version 10.4.3.). The observations show that a spectrum wavelength is $4000\text{-}450\text{ cm}^{-1}$. A certain amount of powder is placed on a diamond plate and pressed with a stick on the instrument. Spectra are visible on the monitor and recorded.

Nuclear magnetic resonance

The NMR spectroscopic examination confirmed the structure and specific group of CA-LBG. An amount of CA-LBG powder (5-10 mg) was dispersed in H₂O (deuterium) and stirred for 45 minutes at a vortex. The filtrate was transferred to a glass tube and analyzed by NMR spectroscopy (JEOL RESONANCE ECZ 500R Japan).

Esterified CA

The amount of esterified CA was determined by the degree of esterification. Determination of the degree of esterification adopts the previous experiment.^{7,14} Samples were derived from CA-LBG precipitating solven and washing solution (acetone and distilled water-acetone). Measurements using potentiometry with titrant NaOH (0.2 N) standardized by oxalic acid. The titrant volume endpoint determines the dissolved acid's total concentration [mEq]. The dissolved CA concentration [mEq] was obtained from the difference between the total acid concentration and the HCl concentration. The dissolved CA [gram] weight was obtained from the conversion of dissolved CA [mEq]. The reacted CA was obtained from the difference between the initial CA weight and dissolved CA. The degree of esterification [%] is the ratio of CA reacted with initial CA.

Solubility study

The CA-LBG powder (500 mg) was dispersed in distilled water (50 mL) and stirred for 24 hours (Wd). The swelled powder and filtrate are carefully separated. The filtrate was dried in a water bath (70°C and reweighed (Wds) (Mettler Toledo AL204, Switzerland). The dissolved CA-LBG was determined according to Equation 1:

$$S [\%] = \frac{Wds}{Wd} \cdot 100 \% \quad \text{Equation 1}$$

where the solubility (S), the soluble weight (Wds), and initial dry weight (Wd).¹⁵

Viscosity

The viscosity of CA-LBG was determined by a viscometer (Brookfield LVDV-I Prime, Middleboro, MA, USA). The CA-LBG powder (3% w/v) was swelled in warm distilled water (300 mL, 50-60°C) and allowed to cool to ambient temperature. Spindle No. S61 mounted on Brookfield was dipped on swollen mass and rotated (100 rpm). Viscosity is shown on the monitor and recorded.

Manufacture of tablets

In this experiment, the method of making tablets by wet granulation adopted the previous study with the necessary adjustments.¹⁴ Preparing granules by wet granulation contains HPMC and lactose monohydrate (50 %) according Table 2 (cubic mixer, rotary motor (Erweka)). A homogeneous mixture was moistened with CA-LBG dispersed in distilled water (± 5 mL) while being compressed to form a wet granule mass and sieved (mesh No. 18) to form granules. The wet granules were dried in an oven (50°C; 15 min; RH 2-5%) (moisture analyzer OHAUS) and re-sieved (mesh No. 20). The granules were mixed with ketoprofen (100 mg) (3:1) and evaluated for the mass quality of the tablets. The tablet mass was compressed to form a 400 mg tablet and hardness ≥ 13 kp (single punch, Korch, Germany), assessed for the physical quality of the tablet and dissolution.

Optimization

Optimization of the granule formula according to the simplex lattice design of two factors used eight runs randomized of formulas, model quadratic, and optimization software (Design Expert ver. 10.0.8.0; Stat-Ease Inc., Minneapolis, MN, USA). Comparison of the proportion of HPMC and CA-LBG for each formula based on optimization software (Table 2), including 0:1 (2 formulas); 0.25:0.75 (1 formula); 0.50:0.5 (2 formulas); 0.75:0.25 (1 formula); and 1:0 (2 formulas). The concentration of HPMC in proportion 0 (30%) and proportion 1 (40%), while the concentration of CA-LBG in proportion 0 (10%) and proportion 1 (20%). The HPMC concentration and the CA-LBG concentration were optimization factors. The angle of repose, tap index, hardness, friability, and released ketoprofen were optimization responses. The values of the optimization response parameters were processed using optimization software to obtain polynomial equations and predict the optimum concentrations of HPMC and CA-LBG in granules.

Flowability

The mass of the tablet was weighed at about 50 g and placed on the funnel of a flowability tester (Erweka, Germany). The funnel valve opens, and the tablet mass flows freely. The flowability tester monitor observed the measured flow time of the tablet mass. The cone from tablet mass was measured using infrared to determine the angle of repose and watched on the flowability tester monitor.

Tap Index

The tablet mass was put in a measuring cup (50 mL). The measuring cup was tilted and filled with tablet mass. The filled measuring cup was placed on the volumenometer tap density and tapped 500 taps. Tap index (TI) was determined from the difference between the volume before and after tapping compared to the volume before tapping (Equation 2).^{16–19}

$$TI [\%] = \frac{V_0 - V_1}{V_0} \times 100\% \quad \text{Equation 2}$$

Weight

From randomly selected tablets (20), and each tablet was weighed using an analytical balance (Mettler Toledo, Switzerland).

Hardness

Tablet hardness test used randomly selected tablets (6 tablets).²⁰ The tablets were placed on a board in a hardness tester (Schleuniger, Netherlands), then a metal block pressed on the tablet until the tablet cracks. The tablet hardness was observed on the monitor hardness tester.

Friability

The tablet friability test used randomly selected tablets with a total weight of comparable tablets of 6500 mg.²⁰ Each tablet was cleaned from dust, then all tablets were weighed (W0). All tablets were placed in a drum friability tester (Erweka, Germany) and rotated (4 min; 25 rpm). All tablets were removed, cleaned from dust, and reweighed (W1). The friability (F) of tablets is determined according to Equation 3.

$$Fr (\%) = \frac{W0 - W1}{W0} 100\%$$
 Equation 3

Drug release

The release of ketoprofen was tested using a dissolution apparatus II USP paddle model.^{12,13} The dissolution media used phosphate buffer pH 6.8 (900 mL; 37°C; 50 rpm) (Electrolab TDT-08L, India). Samples were taken at 0.5; 1; 1.5; 2; 2.5; 3; 4; 5; 6; 8; and 10 hour. Ketoprofen released from the tablet determined absorption value read by UV spectrophotometer (260 nm) (Hitachi U-1900, Japan).^{13,21}

Kinetics of ketoprofen release

The release kinetics of ketoprofen from tablets was influenced by HPMC and CA-LBG in the granules. The kinetics of drug release is determined by the following equations:²²⁻²⁵

Zero order : $Q_t = Q_o + K_o.t$ Equation 4

First order : $\ln Q_t = \ln Q_o + K_o.t$ Equation 5

Qt: the amount of drug dissolved at the time (t), Qo: the amount of the initial drug, and Ko: drug release constant.

Higuchi : $Q_t = K_H.\sqrt{t}$ Equation 6

Qt: the amount of drug dissolved at the time (t), KH: Higuchi constant, and t: time.

$$\text{Korsmeyer-Peppas} : Q_t/Q_\infty = K_k \cdot t^n \quad \text{Equation 7}$$

Q_t/Q_∞ : fraction of drug released, K_k : Korsmeyer-Peppas constant, and n : diffusion exponential.

$$\text{Hixson-Crowell} : Q_0^{1/3} - Q_t^{1/3} = K_s \cdot t \quad \text{Equation 8}$$

Q_0 : the amount of initial drug, Q_t : the amount of drug remaining at the time (t), and K_s : dissolution rate constant.

$$\text{Weibull} : \log [\ln - (1 - m)] = b \log (t - T_i) - \log a \quad \text{Equation 9}$$

$(1-m)$: fraction of insoluble drug, T_i : the lag time before dissolution, b : shape parameter obtained from the slope of the obtained curve. The value of $b = 1$ means that the curve is exponential. The importance of $b > 1$ is the shape of the sigmoid curve.

The release kinetics of ketoprofen from tablets of each granule formula was analyzed using DDSolver software.




Figure 1. Infrared spectra of CA-LBG and LBG. The CA-LBG spectra have a carbonyl ester group ($C=O$) at a wavelength of 1736.02 cm^{-1} , presented by a blue line. LBG as control, presented with a red line.

Result and Discussion

Fourier transform infrared spectroscopy

Infrared spectra of CA-LBG and LBG are presented in Figure 1. Peaks at wavelengths of 3318.20 cm⁻¹ and 3285.80 cm⁻¹ indicate the hydroxyl (OH) groups of mannose and galactose. Peaks at wavelengths of 2923.66 cm⁻¹ and 2936.00 indicate C-H bonds, where CA-LBG is sharper than LBG due to the influence of symmetrical C-H bonds from CA.^{25,26} The specific peak of CA-LBG at 1736.02 cm⁻¹ indicates an ester carbonyl group. Previous studies reported that the peak wavelength of the OH group appears at 3300 cm⁻¹, C-H appears at around 2900 cm⁻¹, and C=O appears at about 1750-1735 cm⁻¹.⁷ The results of the infrared analysis were further confirmed using NMR.




Figure 2. NMR observation spectra of CA-LBG. CA characters present in CA-LBG resented peaks 1, 2, 3, 4, and 5.

Nuclear magnetic resonance

The NMR examination further confirms the FTIR examination and is carried out representatively for the three manufacturing batches. The CA-LBG NMR spectra are presented in Figure 2. The ^1H NMR spectra, paired twin peaks at $\delta = 2.926$ ppm and $\delta = 2.894$ ppm, $\delta = 2.746$ and ppm, $\delta = 2.714$ ppm correspond to the presence of CH_2 (5) of CA in LBG. The sharp peak at $\delta = 3.996$ - 3.309 ppm corresponds to the H atoms of mannose and galactose in LBG. Previous experiments reported that the paired twin peaks of CH_2 were seen at $\delta = 2.7$ - 3.0 ppm. Sharp peaks of H atoms from mannose and galactose appear at $\delta = 4.5$ - 3.0 ppm.^{6,7}

The ^{13}C NMR spectra of CA-LBG at the peak $\delta = 176.905$ ppm and $\delta = 173.507$ ppm indicated the carbonyl group ($\text{C}=\text{O}$) (1,2), which was a specific group of CA-LBG. The central C atom of CA is shown at $\delta = 73.354$ ppm (3). CH_2 of CA is shown at $\delta = 43.349$ ppm (4). The C atoms that make up mannose and galactose from LBG are shown at $\delta = 100.182$ ppm, $\delta = 96.477$ ppm, $\delta = 76.570$ ppm, $\delta = 75.053$ ppm, $\delta = 71.453$ ppm, $\delta = 69.966$ ppm, $\delta = 69.323$ ppm, $\delta = 61.001$ ppm, $\delta = 60.540$ ppm. Previous experiments show $\text{C}=\text{O}$ group at $\delta = 180$ - 170 ppm, central C atom at $\delta = 80$ - 70 ppm, CH_2 appears at $\delta = 44$ - 43 ppm.^{6,7,27} The C atoms make up mannose, and galactose appears at $\delta = 105$ - 60 ppm.^{7,28-30} Finally, the peaks in the spectra indicate the success of the synthesis.

Esterified CA

The degrees of esterification in each batch are shown in Table 1. All batches had similar degrees of esterification, indicating reproducible manufacturing conditions. The experimental esterification degree of 29.30-29.55% corresponds to the previous experimental report of around 9.13%.^{7,14} The degree of esterification of all batches indicated that the esterification conditions were stable and reproducible. The acidic condition created by HCl induces the O atom in the carbonyl group of CA to be protonated to a positive C atom. The OH group on C6 of mannose and galactose will react with a positive C atom.

Table 1. Evaluation degree of esterification, solubility, and viscosity of CA-LBG

Batch Code	Degree of esterification		Solubility		Viscosity	
	[%]	SD	[%]	SD	[cP]	SD
1	29.33	0.20	29.65	0.27	9.48	0.01
2	29.30	0.21	29.81	0.18	9.46	0.02
3	29.55	0.10	29.51	0.42	9.43	0.02

Solubility

The solubility of CA-LBG in each batch is presented in Table 1. All batches showed similar solubility and indicated reproducible manufacturing. The solubility is 29.51-29.81%, according to the solubility in the previous experiment (22.64-36.63%).¹⁴ The ester bond of CA molecules influences the solubility of CA-LBG in LBG. The positive C atom of the carboxylate group (CA) binds to the O atom at C-6, inhibiting the interaction of CA-LBG with distilled water CA-LBG and reducing solubility.

Viscosity

Table 1 shows the respective viscosity of CA-LBG has similar values and indicates reproducible manufacturing. The viscosity shows a value of 9.43-9.48 cPs following the viscosity in the previous experiment (7.76-11.20 cPs).¹⁴ Viscosity is influenced by the carbonyl ester group formed from the positive C atom of the carboxylic group (CA) with the O atom at C-6 in mannose and galactose so that the ability of CA-LBG to trap distilled water decreases.

Flowability

The results of testing the flow time and angle of repose of the tablet mass for each formula are presented in Table 2. Each formula produces a flow time of about 4.60-5.00 seconds and an angle of repose 27.89-30.04⁰, indicating the tablet mass good flows because ≤ 10 seconds for 100 g and $\leq 40^0$ ¹⁷. The tablet mass can occupy the die space inside the tablet machine. The tablet mass can be

continued to be compressed to form a tablet (400 mg). The response of the angle of repose according to the simplex lattice design is obtained by Equation 10.

$$Y = 29.91 A + 27.87 B + 3.25 AB \quad \text{Equation 10}$$

The coefficient value of each component in the equation shows that HPMC (29.91) is the most dominant factor in increasing the angle of repose, followed with CA-LBG (27.87), and a combination of both (3.25). The CA-LBG is an ester polymer that is difficult to hydrate with distilled water, so CA-LBG inhibits the formation of bonds between the granule constituent particles and produces fine granules. A large number of refined grains inhibits the tablet mass flow. HPMC is a polymer that can absorb moisture from the surrounding environment.⁵ The HPMC in the granules increases moisture impedes flow, forming high mounds. Combining CA-LBG with HPMC, which can absorb moisture, increases the tablet mass flow time. Flow time is one parameter that determines the diversity of weights in the tablet manufacturing process.

Based on the ANOVA analysis (see supplementary information Table S1), the response angle of repose has a Pred R-Squared (0.9596), similar to Adj R-Squared (0.9742) with less than 0.2. Meanwhile, the Adeq Precision (23.8130) greater than 4, indicating this model is acceptable.

Tap Index

The tablet mass tap index for each formula is presented in Table 2. Each formula has a tap index of about 18.50-20.00%, indicating that the tablet mass has good homogeneity because $\leq 20\%$ ¹⁷, so the space between the granules is filled with particles or fines. In addition, this condition shows that the tablet mass has good compressibility and creates low porosity tablets. The tap index for each formula is processed according to the simplex lattice design to obtain Equation 11.

$$Y = 18.99 A + 18.77 B + 5.64 AB \quad \text{Equation 11}$$

The value of the HPMC coefficient (18.99) is the dominant factor in increasing the tap index, followed with CA-LBG (18.77) and a combination of both (5.64). HPMC can reduce the sensitivity

of the granules because the HPMC particles absorb moisture so that the granules change shape when granules receive mechanical stress. The difficulty of hydrating CA-LBG particles in the granulation process causes the bond between the granules to be not good so that the granules release fines and receive mechanical stress. The combination of the two factors can increase the tap index because the HPMC reduces the sensitivity due to moisture absorption. In addition, it is supported by less strong bonds between particles in the granules due to the difficulty of hydrating during the granulation process.

Based on the ANOVA analysis (see supplementary information Table S1), the response tap index has a Pred R-Squared (0.7862), similar to Adj R-Squared (0.8928) with less than 0.2. Meanwhile, the Adeq Precision (10.7420) greater than 4, indicates this model is acceptable.

Weight

The tablet weight of all formulas is shown in Table 2. Tablet mass was compressed into tablets with a weight of about 400 mg. The tablet mass of all formulas is free to flow and fill the die chamber, so tablet weight is according to design. The compression success is suitable for the value of flow time, angle of repose, and tap index.

Table 2. Details of HPMC and CA-LBG concentration, quality of the tablet mass, quality of the tablet, and release of ketoprofen (Dr)

Formula code	HPMC [%]	CA-LBG [%]	Flow time [sec.]	Angle of repose [°]	Tap index [%]	Weight [mg]	Hardness [kp]	Friability [%]	Dr [10 hr.] [%]
G1	40.00	10.00	4.80 ± 0.06	29.92 ± 0.10	19.00	401.34 ± 1.69	13.61 ± 0.70	0.39	53.75 ± 0.89
G2	32.50	17.50	4.60 ± 0.10	28.98 ± 0.08	20.00	400.87 ± 1.25	13.84 ± 1.05	0.45	83.34 ± 0.70
G3	35.00	15.00	5.00 ± 0.06	29.47 ± 0.18	20.00	402.08 ± 1.50	14.08 ± 0.84	0.28	69.33 ± 0.93
G4	40.00	10.00	4.60 ± 0.10	29.86 ± 0.53	18.50	400.07 ± 1.16	13.60 ± 0.61	0.43	51.71 ± 0.71
G5	30.00	20.00	4.80 ± 0.06	27.86 ± 0.18	19.00	399.69 ± 1.45	13.33 ± 0.46	0.74	99.21 ± 1.04
G6	37.50	12.50	4.80 ± 0.15	30.04 ± 0.06	20.00	400.12 ± 1.65	14.01 ± 0.83	0.34	58.16 ± 0.89
G7	35.00	15.00	5.00 ± 0.15	29.93 ± 0.94	20.00	400.36 ± 0.89	14.06 ± 0.87	0.28	69.82 ± 0.33
G8	30.00	20.00	5.00 ± 0.10	27.89 ± 0.54	19.00	399.67 ± 1.21	13.32 ± 0.84	0.73	99.32 ± 0.46
Ga	32.97	17.03	4.80 ± 0.06	29.17 ± 0.12	20.00	401.27 ± 1.15	13.97 ± 0.64	0.40	80.08 ± 0.60
Gb	32.97	17.03	4.60 ± 0.15	29.08 ± 0.23	20.00	399.00 ± 1.20	14.01 ± 0.58	0.41	80.44 ± 1.17
Gc	32.97	17.03	5.00 ± 0.10	29.22 ± 0.99	19.50	400.67 ± 0.79	13.86 ± 0.85	0.39	80.45 ± 0.55
Go	32.97	17.03	-	29.16	20.01	-	13.91	0.41	80.00

The proportion of HPMC and CA-LBG are G1 (1 : 0); G2 (0.25 : 0.75) G3 (0.5 : 0.5); G4 (1 : 0); G5 (0 : 1); G6 (0.75 : 0.25); G7 (0.5 : 0.5); G8 (0 : 1); Ga (0.30 : 0.70); Gb (0.30 : 0.70); Gc (0.30 : 0.70); and Go (0.30 : 0.70).

Hardness

The tablet hardness of each formula is presented in Table 2. Tablets of each formula have a hardness are around 13.32-14.08 kp, indicating that the tablet has strong resistance and good physical stability. The hardness of tablets comes from strong interlocking between the granules/particles making up the tablet when receiving compression so that the porosity of the tablet is low. The hardness of each formula is processed according to the simplex lattice design to obtain Equation 12.

$$Y = 13.60 A + 13.32 B + 2.42 AB \qquad \text{Equation 12}$$

The coefficient value of HPMC (13.60) is the most dominant factor in increasing hardness, followed with CA-LBG (13.32) and a combination of both (2.42). HPMC can absorb moisture and is used as an adhesive between the deformation of granules/particles to produce a solid interlocking bond. The tablets have good stability to humidity even though the granules contain HPMC because the moisture absorption activity is inhibited by decreasing the absorption surface area in the tablets form than the granules. Although CA-LBG is difficult to hydrate, the deformation of the particles can form solid interlocking bonds. In addition, the presence of CA-LBG on the tablet surface inhibits moisture absorption. The combination of both can increase the hardness because the characters of HPMC and CA-LBG complement each other. The tablet has a solid interlocking bond between the deformation of the granules/particles, and the tablet can retain moisture. In addition, the tap index shows that the tablet mass has low porosity and good compressibility so that when compressed tablet mass produces a compact tablet.

Based on the ANOVA analysis (see supplementary information Table S1), the response hardness has a Pred R-Squared (0.9976), similar to Adj R-Squared (0.9985) with less than 0.2. Meanwhile the Adeq Precision (100.1700) greater than 4, indicates this model is acceptable.

Friability

The tablet friability of all formulas is presented in Table 2. Each formula has a friability of 0.28-0.74% ($\leq 1\%$)¹⁷, indicating that the tablet surface is strong enough to withstand mechanical movements because of solid interlocking bonds between the deformation of the particles on the tablet surface. Friability of all formulas is according to the simplex lattice design to obtain Equation 13.

$$Y = 0.41 A + 0.73 B - 1.10 AB \quad \text{Equation 13}$$

The coefficient value of HPMC (13.60) is the most dominant factor in increasing hardness, followed with CA-LBG (13.32) and a combination of both (2.42). HPMC can absorb moisture and is used as an adhesive between the deformation of granules/particles to produce a solid interlocking bond. The tablets have good stability to humidity even though the granules contain HPMC because the moisture absorption activity is inhibited by decreasing the absorption surface area in the tablets form than the granules. Although CA-LBG is difficult to hydrate, the deformation of the particles can form solid interlocking bonds. In addition, the presence of CA-LBG on the tablet surface inhibits moisture absorption. The combination of both can increase the hardness because the characters of HPMC and CA-LBG complement each other. The tablet has a solid interlocking bond between the deformation of the granules/particles, and the tablet can retain moisture. In addition, the tap index shows that the tablet mass has low porosity and good compressibility; thus, when compressed, tablet mass produces a compact tablet.

Based on the ANOVA analysis (see supplementary information Table S1), the response friability has a Pred R-Squared (0.9593) similar to Adj R-Squared (0.9747) with less than 0.2. Meanwhile, the Adeq Precision (24.6860) greater than 4, indicates this model is acceptable.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. The ketoprofen dissolution profile of various tablet formulas contains HPMC [%] and CA-LBG [%]: G1 (40 : 10); G2 (32.5 : 17.5); G3 (35 : 15); G4 (40 : 10); G5 (30 : 20); G6 (37.5 : 12.5); G7 (35 : 15); G8 (30 : 20); and Ga (32.97 : 17.03).

Ketoprofen release

The concentration and profile of ketoprofen release for each tablet formula after 10 hours are presented in Table 2, Figure 3, and supplementary information Table S2-S3. All tablets of ketoprofen release around 51.71-99.32%, showing that HPMC and CA-LBG can control ketoprofen release from tablets. HPMC is a polymer that swells when hydrating by the dissolution medium. Ketoprofen release is inhibited because HPMC swells trap ketoprofen particles. The CA-LBG is a polymer that is difficult to hydrate and has low solubility. The CA-LBG character causes the tablet to disintegrate

and become granule. Releases of ketoprofen-controlled granule swelling form a gel. Based on the experimental design, ketoprofen released for 10 hours is $\geq 80\%$ (see supplementary information Chapter 1). The processed concentration value of each tablet formula is according to the simplex lattice design to obtain Equation 14.

$$Y = 52.48 A + 99.44 B - 26.36 AB \quad \text{Equation 14}$$

The CA-LBG coefficient value (99.44) was the most dominant factor in increasing ketoprofen release, followed with HPMC (52.48). The combination of both (26.36) was the most dominant factor in reducing the release of ketoprofen. The deformation of CA-LBG particles on the tablet refuses each other when submerged in the dissolution medium, causing tablet disintegration. The granule porosity surface is used as a space for penetration of the dissolution medium into the granule, dissolved ketoprofen particles, and diffuses out of the granule. The high concentration of CA-LBG accelerates of disintegration of the tablet and forms HPMC gel. Combining the HPMC with CA-LBG can reduce the release of ketoprofen because the moisture of the deformation of the HPMC particles can bind hardly to the interlocking deformation of the CA-LBG and other particles, so that the tablet disintegrates longtime. In addition, the direct interaction of CA-LBG with particles inhibits the swelling of HPMC and hydrating of ketoprofen by the dissolution medium.

Based on the ANOVA analysis (see supplementary information Table S1), the response to the release of ketoprofen has a Pred R-Squared (0.9956), similar to Adj R-Squared (0.9978) with a difference of less than 0.2. Meanwhile the Adeq Precision (85.0460) greater than 4, indicates this model is acceptable.




Figure 4. Comparison of actual (dotted line) and predicted (solid line) optimization response profiles. The red dot indicates the response value for each formula based on the respective proportions of HPMC and CA-LBG. The overlay shows the meeting point of all responses according to the predicted optimal proportions of HPMC and CA-LBG.

Optimum tablet formula

Determination of the optimum formula begins with the initial 8 experimental formula designs (G1-G8). The optimization factors and response parameter values were analyzed using design expert software using a simplex lattice design. The experimental comparison profiles and the predictions of each optimization response (Figure 4) show that the actual profiles are similar to the predictions. This profile follows the results of ANOVA analysis for each optimization response (flowability, tap index, hardness, friability, and release of ketoprofen). The optimization response overlay predicts the optimum proportion point to achieve the optimum response prediction. Design expert provides several alternative options for the optimum formula. The selected formula was determined from the response parameter specifications (angle of repose 27.86-30.04; tap index 18.5-20.5; hardness 13.32-

14.08 kp; friability 0.28-0.74%; drug release > 80%). Verification to the prediction of the optimum formula proportion (Go) to obtain the optimum formula was carried out in three batches (Ga, Gb, Gc) (Table 2 and Figure 3).




Figure 5. Drug release kinetics model (HPMC [%] : CA-LBG [%]): G1 (40 : 10) (Korsmeyer-Peppas); G2 (32.5 : 17.50) (Korsmeyer-Peppas); G3 (35 : 15) (Hixson-Crowell); G4 (40 : 10) (Korsmeyer-Peppas); G5 (30 : 20) (Hixson-Crowell); G6 (37.50 : 12.50) (Higuchi); G7 (35 : 15) (Hixson-Crowell); G8 (30 : 20) (Hixson-Crowell); Ga (32.97 : 17.03) (Zero order); Gb (32.97 : 17.03) (Zero order); and Gc (32.97 : 17.03) (Zero order).

One sample T-test results compare the experimental response formula verification with the predictive response. The values T of each parameter is T angle of repose (0.008), T tap index (1.096), T hardness (0.728), T friability (1.559), and T release of ketoprofen (2.657). The response parameter values between the prediction (Go) and the verification experiment (Ga-Gc) were not significantly different. These results indicate that the polynomial equations of each response parameter are valid for predicting the effect of HPMC, CA-LBG, and their combination. In addition, the selected optimum formula shows reproducibility in producing tablets and controlling ketoprofen's release. The variation of release shown by G1-G8 proves that tablets with irrelevant variations in physical quality produce varied drug releases.

Kinetics of ketoprofen release

The kinetics of ketoprofen release from the tablet is a non-linear approach using DDSolver (Table 3, Figure 5, and supplementary information Figure S1-S11). The kinetics parameters of ketoprofen release include high Rsqr_adj, low Mean Square Error-Root (MSE_root), and low Akaike Information Criterion (AIC). The Rsqr_adj is the correlation value between dissolution time and released ketoprofen. MSE_root indicates the error value in correlation analysis. AIC is the value suitability to the equation to determine the release kinetics.³¹⁻³⁵ The results of DDSolver processing are presented in Table 3 and Figure 5.

The release kinetics of ketoprofen from tablets G1, G2, and G4 followed the Korsmeyer-Peppas kinetics. The exponential value (n) for tablets G1 (0.62), G2 (0.60), and G4 (0.58) indicates a non-Fickian diffusion mechanism (anomalous diffusion).³⁶ The release of ketoprofen released by diffusion is proportional to erosion. The surface of the granules forms a thin gel and cannot withstand the dissolution medium, so ketoprofen dissolves quickly. The ketoprofen release is not only through diffusion but also due to erosion of the surface of the gel formed. The CA-LBG is not tightly

1
2 integrated into the tablet and granule. This condition causes the dissolution rate to be faster with the
3
4 increase in the dissolution medium that enters the tablet and granule.
5

6
7 The release kinetics of ketoprofen from tablets G3, G5, G7, and G8 followed Hixson-Crowell
8
9 kinetics. The ketoprofen release was caused by hydrating the tablet surface, so the tablet disintegrated
10
11 and become granule. This condition causes ketoprofen to be dissolved constantly. HPMC low
12
13 concentration can tablet disintegration quickly when particles swell to form a gel and push against
14
15 other particles. In addition, CA-LBG on the granule accelerates the decomposition of the HPMC gel
16
17 because the repulsion forces between CA-LBG particles are difficult to dissolve.
18
19

20
21 The tablet G6 followed the release kinetics of Higuchi's model. The high viscosity gel of
22
23 HPMC controlled the diffusion of ketoprofen from the granules. CA-LBG on the granule surface
24
25 inhibited granule hydration and ketoprofen diffusion.
26

27
28 The release kinetics of ketoprofen from Ga, Gb, and Gc tablets followed zero order. HPMC
29
30 on the tablet surface swells to form a gel when in contact with the dissolution medium. The trapped
31
32 ketoprofen particles dissolve and are saturated, then diffuse from the gel. Simultaneously the rate of
33
34 CA-LBG disintegrating tablets into granules is proportional to gel formation. The dissolving of
35
36 ketoprofen comes from the ketoprofen particles in contact with the gel surface. The balanced
37
38 concentrations of HPMC and CA-LBG formed a gel with a constant thickness. These conditions can
39
40 control the diffusion and maintain the availability of saturated ketoprofen dissolved in the gel.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. The value of the kinetics parameters of the release of ketoprofen from tablets.

Formula code	Parameter	Zero order		First order		Higuchi		Korsmeyer-Peppas		Hixson-Crowell		Weibull		Kinetics model
		average	SD	average	SD	average	SD	average	SD	average	SD	average	SD	
G1	Rsqr_adj	0.8762	0.02	0.9441	0.01	0.9585	0.00	0.9776	0.01	0.9279	0.01	0.9333	0.00	Korsmeyer-Peppas
	MSE_root	5.2625	0.35	3.5357	0.26	3.0468	0.20	2.2216	0.34	4.0144	0.29	3.8687	0.11	
	AIC	70.5951	1.56	61.0431	1.72	57.4597	1.61	50.6125	3.52	64.0907	1.71	64.8308	0.66	
G2	Rsqr_adj	0.8049	0.01	0.9687	0.00	0.9861	0.00	0.9948	0.00	0.9426	0.01	0.9536	0.00	Korsmeyer-Peppas
	MSE_root	10.6069	0.28	4.2456	0.22	2.8232	0.37	1.7379	0.16	5.7451	0.32	5.1742	0.23	
	AIC	87.4453	0.63	65.4533	1.28	55.5400	3.24	44.8284	2.23	72.7095	1.35	71.7991	1.08	
G3	Rsqr_adj	0.9395	0.00	0.9296	0.01	0.8689	0.01	0.9113	0.01	0.9401	0.01	0.8651	0.01	Hixson-Crowell
	MSE_root	4.5672	0.13	4.9223	0.35	6.7233	0.38	5.5235	0.47	4.5427	0.27	6.8225	0.28	
	AIC	67.2211	0.72	68.9849	1.70	76.4828	1.36	72.5897	2.03	67.0722	1.38	78.4392	0.96	
G4	Rsqr_adj	0.8597	0.02	0.9358	0.01	0.9657	0.01	0.9777	0.01	0.9171	0.01	0.9414	0.01	Korsmeyer-Peppas
	MSE_root	5.4444	0.33	3.6827	0.21	2.6858	0.34	2.1496	0.36	4.1855	0.25	3.5175	0.31	
	AIC	71.4154	1.46	62.0355	1.40	54.3575	3.04	49.7755	3.97	65.1033	1.48	62.4881	2.17	
G5	Rsqr_adj	0.8594	0.01	0.6528	0.10	0.8570	0.01	0.9057	0.00	0.9231	0.00	0.9025	0.00	Hixson-Crowell
	MSE_root	13.6548	0.48	21.3289	3.31	13.7776	0.45	11.1888	0.34	10.1039	0.28	11.3789	0.30	
	AIC	93.5029	0.85	104.0112	3.90	93.7193	0.79	89.5817	0.73	86.2787	0.67	90.7234	0.63	
G6	Rsqr_adj	0.6618	0.02	0.8583	0.01	0.9945	0.00	0.9935	0.00	0.8093	0.01	0.9762	0.00	Higuchi
	MSE_root	9.9176	0.17	6.4175	0.16	1.2626	0.07	1.3745	0.10	7.4459	0.16	2.6266	0.17	
	AIC	85.8359	0.41	75.3863	0.60	36.3490	1.26	39.2239	1.71	78.9547	0.53	55.5081	1.61	
G7	Rsqr_adj	0.9360	0.01	0.9304	0.00	0.8758	0.01	0.9093	0.01	0.9398	0.00	0.8675	0.00	Hixson-Crowell
	MSE_root	4.7248	0.28	4.9359	0.11	6.5870	0.32	5.6328	0.20	4.5899	0.09	6.8079	0.13	
	AIC	68.0154	1.40	69.0873	0.55	75.9974	1.20	73.1077	0.84	67.3448	0.45	78.3976	0.46	
G8	Rsqr_adj	0.8582	0.01	0.7246	0.05	0.8753	0.01	0.9180	0.00	0.9286	0.01	0.9112	0.00	Hixson-Crowell
	MSE_root	13.3691	0.17	18.5895	1.66	12.5351	0.46	10.1662	0.37	9.4845	0.43	10.5795	0.28	
	AIC	93.0042	0.30	100.8549	2.10	91.4435	0.88	87.2783	0.87	84.7498	1.10	88.9752	0.63	

continue to the next page

Table 3. The value of the kinetics parameters of the release of ketoprofen from tablets.

Formula code	Parameter	Zero order		First order		Higuchi		Korsmeyer-Peppas		Hixson-Crowell		Weibull		Kinetics model
		average	SD	average	SD	average	SD	average	SD	average	SD	average	SD	
Ga	Rsqr_adj	0.9241	0.01	0.8628	0.01	0.7995	0.02	0.8441	0.02	0.8883	0.01	0.7823	0.03	Zero order
	MSE_root	5.7889	0.30	7.7879	0.24	9.4113	0.50	8.2963	0.58	7.0194	0.51	9.8002	0.73	
	AIC	72.8966	1.22	80.0290	0.73	84.5579	1.28	82.3715	1.68	77.5002	1.76	87.0994	1.81	
Gb	Rsqr_adj	0.9273	0.00	0.8670	0.01	0.8107	0.01	0.8481	0.02	0.8956	0.01	0.7874	0.03	Zero order
	MSE_root	5.6548	0.09	7.6500	0.20	9.1233	0.40	8.1484	0.47	6.7739	0.32	9.6602	0.66	
	AIC	72.3524	0.40	79.6025	0.62	83.8190	1.06	81.9522	1.39	76.6707	1.14	86.7613	1.66	
Gc	Rsqr_adj	0.9273	0.01	0.8648	0.01	0.8044	0.01	0.8408	0.02	0.8920	0.01	0.7809	0.03	Zero order
	MSE_root	5.6764	0.38	7.7581	0.22	9.3364	0.37	8.4134	0.49	6.9321	0.30	9.8658	0.69	
	AIC	72.4101	1.62	79.9382	0.68	84.3764	0.94	82.7199	1.40	77.2270	1.07	87.2649	1.70	

The ketoprofen release kinetics model of various tablet formulas contains HPMC [%] and CA-LBG [%]: G1 (40 : 10); G2 (32.5 : 17.5); G3 (35 : 15); G4 (40 : 10); G5 (30 : 20); G6 (37.5 : 12.5); G7 (35 : 15); G8 (30 : 20); Ga (32.97 : 17.03); Gb (32.97 : 17.03); and Gc (32.97 : 17.03).

Conclusion

HPMC and CA-LBG increased the value of angle of repose, tap index, hardness, friability, and release of ketoprofen. The combination of HPMC with CA-LBG increased the angle of repose, tap index, and hardness. Besides, the combination decreased friability and release of ketoprofen. The optimum concentrations of HPMC and CA-LBG for controlled-release tablets is 32.97% and 17.03%, resulting in the angle of repose of 29.16°; tap index of 20.01%; hardness of 13.91 kp; friability of 0.41%; and the drug release (10 hours) of 80%. The drug release kinetics from optimum tablets followed zero order. The constant thickness of gel can control the diffusion and maintain the saturated ketoprofen in the gel. CA-LBG as a negative matrix disintegrates tablets into granules. HPMC as a gel matrix controlled ketoprofen release by diffusion and erosion. The tablets did not produce a ghost matrix because the gel matrix came from granules which degraded quickly after all the ketoprofen was released.

Associated Content

Supporting Information

Tablet dosage calculation; Statistical analysis of ketoprofen tablets; The release of ketoprofen from tablets (G1-G8); The release of ketoprofen from optimum tablets (Ga-Gc); and The kinetics profile of ketoprofen release from tablets (G1-G8) (Ga-Gb)

Acknowledgment

The author would like to PT. Makmur Food (Indonesia) has assisted with locust bean gum (viscogum); LPPT Gadjah Mada University (Indonesia) for NMR testing; Faculty of Pharmacy, Gadjah Mada University (Indonesia) for pharmaceutical technology facilities; Faculty of Pharmacy Widya Mandala Catholic University Surabaya (Indonesia) for testing FTIR, viscometer, and pharmaceutical technology equipment.

Declarations

Competing interest statement

The authors declare that authors have no conflict of interest.

Author contribution statement

Wuryanto Hadinugroho: designed the experiments, performed the experiments, analyzed and interpreted the data, wrote the manuscript. Suwaldi Martodihardjo, Achmad Fudholi, Sugeng Riyanto and, Jefri Prasetyo: analyzed and interpreted the data.

Author Information

Corresponding author

Wuryanto Hadinugroho - Department of Pharmaceutical Technology, Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Kalisari Selatan no. 1 Pakuwon City, Surabaya, Indonesia; orcid.org/0000-0001-9245-2802; Email: wuryanto.hadinugroho@gmail.com.

Authors

Suwaldi Martodihardjo - Department of Pharmaceutical, Faculty of Pharmacy, Gadjah Mada University, Sekip Utara, Yogyakarta, Indonesia; Email: waldi_ugm@yahoo.com

Achmad Fudholi - Department of Pharmaceutical, Faculty of Pharmacy, Gadjah Mada University, Sekip Utara, Yogyakarta, Indonesia; Email: fudholi_fa@ugm.ac.id

Sugeng Riyanto - Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gadjah Mada University, Sekip Utara, Yogyakarta, Indonesia; Email: sugeng_riyanto51@yahoo.com

Jefri Prasetyo - Department of Pharmaceutical Technology, Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Kalisari Selatan no. 1 Pakuwon City, Surabaya, Indonesia; Email: jefri@ukwms.ac.id

REFERENCES

- (1) Li, C.L.; Martini, L.G.; Ford, J.L.; Roberts, M. The use of hypromellose in oral drug delivery. *J Pharm Pharmacol.* **2010**, *57*, 533-546. doi: 10.1211/0022357055957
- (2) Oliveira, P.R.; Mendes, C.; Klein, L.; Sangoi, M.D.S.; Bernardi, L.S.; Silva, M.A.S. Formulation development and stability studies of norfloxacin extended-release matrix tablets. *Biomed Res Int.* **2013**, *2013*, 1-9. doi: 10.1155/2013/716736
- (3) Contreras, L.; Melgoza L.M.; Leyva A.A.D.; Caraballo I. Collaboration between HPMC and NaCMC in order to reach the polymer critical point in theophylline hydrophilic matrices. *Sci World J.* **2012**, *2012*, 1-8. doi: 10.1100/2012/171292
- (4) Enayatifard. R.; Saeedi, M.; Akbari, J.; Tabatabaee, Y.H. Effect of hydroxypropyl methylcellulose and ethyl cellulose content on release profile and kinetics of diltiazem HCl from matrices. *Trop J Pharm Res.* **2009**, *8*, 425-432. doi: 10.4314/tjpr.v8i5.48086
- (5) Sheskey, P.J.; Cook, W.G.; Cable, C.G. Handbook of Pharmaceutical Excipients 8th. Pharmaceutical Press and American Pharmacists Association: London-Washington DC, **2017**; pp.282-284
- (6) Hadinugroho, W.; Martodihardjo, S.; Fudholi, A.; Riyanto, S. Study of a catalyst of citric acid crosslinking on locust bean gum. *J Chem Technol Metall.* **2017**, *52*, 1086-1091
- (7) Hadinugroho, W.; Martodihardjo, S.; Fudholi, A.; Riyanto, S.; Esterification of citric acid with locust bean gum. *Heliyon.* **2019**, *5*, 1-9. doi: 10.1016/j.heliyon.2019.e02337
- (8) Santiago, E.V.; Lopez, S.H.A.; Romero, A.R. Photochemical cross-linking study of polymers containing diacetylene groups in their main chain and azobenzene compounds as pendant groups. *Superf y vacío.* **2006**, *19*, 1-7
- (9) Tamaki, Y.; Teruya, T.; Tako, M. The chemical structure of galactomannan isolated from seeds of *Delonix regia*. *Biosci Biotechnol Biochem.* **2010**, *74*, 1110-1112. doi: 10.1271/bbb.90935
- (10) Tjandraatmadja, G.F.; Burn, L.S.; Jollands, M.J. The effects of ultraviolet radiation on

- polycarbonate glazing. *Proc 8th Int Conf Durab Build Constr Mater Vancouver, Canada*. **1999**, 30, 884-898
- (11) Yeh, C.C.; Chen, C.N.; Li, Y.T.; Chang, C.W.; Cheng, M.Y.; Chang, H.I. The effect of polymer molecular weight and UV radiation on physical properties and bioactivities of PCL films. *Cell Polym*. **2011**, 30, 261-276. doi: 10.1177/026248931103000503
- (12) Lam, M.; Nokhodchi, A. Producing High-Dose Liqui-Tablet (Ketoprofen 100 mg) for Enhanced Drug Release Using Novel Liqui-Mass Technology. *J Pharm Innov*. **2021**, 1-13. doi: 10.1007/s12247-021-09561-6
- (13) Kaleemullah, M.; Jiyauddin, K.; Thiban, E.; Rasha, S.; Al-Dhalli, S.; Budiasih, S.; Gamal, O.E.; Fadli, A.; Eddy, Y. Development and evaluation of Ketoprofen sustained release matrix tablet using Hibiscus rosa-sinensis leaves mucilage. *Saudi Pharm J*. **2017**, 25, 770-779. doi: 10.1016/j.jsps.2016.10.006
- (14) Hadinugroho, W.; Martodihardjo, S.; Fudholi, A.; Riyanto S. Preparation of Citric Acid-Locust Bean Gum (CA-LBG) for the Disintegrating Agent of Tablet Dosage Forms. *J Pharm Innov*. **2021**, 1-16. doi: 10.1007/s12247-021-09591-0
- (15) Gulrez, S.K.H.; Al-Assaf, S.; Phillips, G.O. Hydrogels: Methods of Preparation, Characterisation and Applications. In: *Progress in Molecular and Environmental Bioengineering - From Analysis and Modeling to Technology Applications*. **2011**. doi: 10.5772/24553
- (16) Davies, P. Oral Solid Dosage Forms. In: *Pharmaceutical Preformulation and Formulation*. 2nd, vol 199. Gibson, M. (Ed). New York: Informa Healthcare USA, Inc; **2009**; pp. 368-369 doi: 10.1201/b14413-17
- (17) Aulton, E.; Taylor, K.M.G. Aulton's Pharmaceutics The Design and Manufacture of Medicines. Churchill Livingstone Elsevier: New York, **2017**; pp. 187-199
- (18) Merkkü, P.; Lindqvist, A.S.; Leiviska, K.; Yliruusi, J. Influence of granulation and compression


- process variables on flow rate of granules and on tablet properties, with special reference to weight variation. *Int J Pharm.* **1994**, *102*, 117-125. doi: 10.1016/0378-5173(94)90046-9
- (19) Szumilo, M.; Belniak, P.; Swiader, K.; Holody, E.; Poleszak, E. Assessment of physical properties of granules with paracetamol and caffeine. *Saudi Pharm J.* **2017**, *25*, 900-905. doi: 10.1016/j.jsps.2017.02.009
- (20) The United States Pharmacopeial Convention. Pharmacopeia 41-National Formulary 36. Twinbrook Parkway: Rockville, **2018**; pp.7634-7635
- (21) Wahab, A.; Khan, G.M.; Akhlaq, M.; Khan, N.R.; Hussain, A.; Khan, M.F.; Ur-Rehman, N.; Khan, A. Formulation and evaluation of controlled release matrices of ketoprofen and influence of different co-excipients on the release mechanism. *Pharmazie.* **2011**, *66*, 677–683. doi.org/10.1691/ph.2011.1040
- (22) Craciun, A.M.; Barhalescu, M.L.; Agop, M.; Ochiuz, L. Theoretical Modeling of Long-Time Drug Release from Nitrosalicyl-Imine-Chitosan Hydrogels through Multifractal Logistic Type Laws. *Comput Math Methods Med.* **2019**, *2019*, 1-9. doi.org/10.1155/2019/4091464
- (23) Panotopoulos, G.P; Haidar, Z.S. Mathematical modeling for pharmacokinetic predictions from controlled drug release nano systems: A comparative parametric study. *Biomed Pharmacol J.* **2018**, *11*, 1801–1806. doi.org/10.13005/bpj/1552
- (24) Simionato, L.D.; Petrone, L.; Baldut, M.; Bonafede, S.L.; Segall, A.I. Comparison between the dissolution profiles of nine meloxicam tablet brands commercially available in Buenos Aires, Argentina. *Saudi Pharm J.* **2018**, *26*, 578-84. doi: 10.1016/j.jsps.2018.01.015
- (25) Jahromi, L.P.; Ghazali, M.; Ashrafi, H.; Azadi, A. A comparison of models for the analysis of the kinetics of drug release from PLGA-based nanoparticles. *Heliyon.* **2020**, *6*, 1-9. doi: 10.1016/j.heliyon.2020.e03451
- (26) Nandiyanto, A.B.D.; Oktiani, R. Ragadhita, R. How to read and interpret ftir spectroscopy of organic material. *Indones J Sci Technol.* **2019**, *4*, 97-118. doi: 10.17509/ijost.v4i1.15806

- (27) Coates J. Interpretation of Infrared Spectra A Practical Approach. In: *Encycl Anal Chem*. Meyers, R.A (Ed). John Wiley & Sons Ltd: Chichester. **2000**; pp.10815-37. doi: 10.1002/9780470027318.a5606
- (28) Azero, E.G.; Andrade, C.T. Characterisation of Prosopis juliflora seed gum and the effect of its addition to κ -carrageenan systems. *J Braz Chem Soc*. **2006**, *17*, 844-850. doi: 10.1590/S0103-50532006000500005
- (29) Parvathy, K.S.; Susheelamma, N.S.; Tharanathan, R.N.; Gaonkar, A.K. A simple non-aqueous method for carboxymethylation of galactomannans. *Carbohydr Polym*. **2005**, *62*, 137-141. doi: 10.1016/j.carbpol.2005.07.014
- (30) Gillet, S.; Aguedo, M.; Blecker, C.; Jacquet, N.; Richel, A. Use of ^{13}C -NMR in Structural Elucidation of Polysaccharides: Case of Locust Bean Gum. *Young Belgium Magnetic Resonance Scientist*. Liège. 2014.
- (31) Gu, Y.; Wei, H.L.; Balikhin, M.M. Nonlinear predictive model selection and model averaging using information criteria. *Syst Sci Control Eng*. **2018**, *6*, 319-28. doi: 10.1080/21642583.2018.1496042
- (32) Mircioiu, C.; Voicu, V.; Anuta, V.; Tudose, A.; Celia, C.; Paolino, D.; Fresta, M.; Sandulovici, R.; Mircioiu, I. Mathematical modeling of release kinetics from supramolecular drug delivery systems. *Pharmaceutics*. **2019**, *11*, 1-45. doi.org/10.3390/pharmaceutics11030140
- (33) Siswanto, A.; Fudholi, A.; Nugroho, A.K.; Martono, S. in Vitro Release Modeling of Aspirin Floating Tablets Using DDSolver. *Indones J Pharm*. **2015**, *26*, 94-102. doi.org/10.14499/indonesianjpharm26iss2pp94
- (34) Zuo, J.; Gao, Y.; Bou-Chacra, N.; Löbenberg, R. Evaluation of the DDSolver software applications. *Biomed Res Int*. **2014**, *2014*, 1-10. doi: 10.1155/2014/204925
- (35) Zhang, Y.; Huo, M.; Zhou, J.; Zou, A.; Li, W.; Yao, C.; Xie, S. DDSolver: An add-in program for modeling and comparison of drug dissolution profiles. *AAPS J*. **2010**, *12*, 263–271.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

doi.org/10.1208/s12248-010-9185-1

(36) Dash, S.; Murthy, P.N.; Nath, L.; Chowdhury, P. Kinetic modeling on drug release from controlled drug delivery systems. *Acta Pol Pharm - Drug Res.* **2010**, *67*, 217-223



338x190mm (96 x 96 DPI)

Hadinugroho, Wuryanto ao-2022-07432u - Manuscript Revision Request 15-Dec-2022

Dari: ACS Omega (onbehalf@manuscriptcentral.com)

Kepada: wuryanto.hadinugroho@gmail.com

Tanggal: Kamis, 15 Desember 2022 pukul 22.15 GMT+7

15-Dec-2022

Journal: ACS Omega

Manuscript ID: ao-2022-07432u

Title: "Citric acid-locust bean gum as a negative matrix for controlled release tablet"

Author(s): Hadinugroho, Wuryanto; Martodihardjo, Suwaldi; Fudholi, Achmad; Riyanto, Sugeng; Prasetyo, Jefri

Dear Dr. Hadinugroho:

Thank you for submitting your manuscript to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopenscience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

"Citric acid-locust bean gum as a negative matrix for controlled release tablet" has been examined by expert reviewers. In its current form, your manuscript is not suitable for publication in ACS Omega. The reviewers have raised points that require significant consideration. However, with an adequate point-by-point response and the appropriate revisions, your paper may become acceptable for publication.

We would like to receive your revision no later than 05-Jan-2023. The revision should address the reviewers' comments and include a point-by-point response. Your manuscript will be subject to further peer review.

Please note that you will receive a follow-up message within 24 hours describing the non-scientific changes you must make to your manuscript before you submit the revision.

To revise your manuscript, log into ACS Paragon Plus with your ACS ID at <http://acsparagonplus.acs.org/> and select "My Authoring Activity". There you will find your manuscript title listed under "Revisions Requested by Editorial Office." Your original files are available to you when you upload your revised manuscript. If you are replacing files, please remove the old version of the file from the manuscript before uploading the new file.

When submitting your revised manuscript through ACS Paragon Plus, you will be able to respond to the comments made by the reviewer(s) in the text box provided or by attaching a file containing your detailed responses to all of the points raised by the reviewers.

Please upload manuscript file that is free of any annotations or highlights.

Funding Sources: Authors are required to report ALL funding sources and grant/award numbers relevant to this manuscript. Enter all sources of funding for ALL authors relevant to this manuscript in BOTH the Open Funder Registry tool in ACS Paragon Plus and in the manuscript to meet this requirement. See http://pubs.acs.org/page/4authors/funder_options.html for complete instructions.

ORCID: Authors submitting manuscript revisions are required to provide their own validated ORCID iDs before completing the submission, if an ORCID iD is not already associated with their ACS Paragon Plus user profiles. This iD may be provided during original manuscript submission or when submitting the manuscript revision. You can provide only your own ORCID iD, a unique researcher identifier. If your ORCID iD is not already validated and associated with your ACS Paragon Plus user profile, you may do so by following the ORCID-related links in the Email/Name section of your ACS Paragon Plus account. All authors are encouraged to register for and associate their own ORCID iDs with their

ACS Paragon Plus profiles. The ORCID iD will be displayed in the published article for any author on a manuscript who has a validated ORCID iD associated with ACS Paragon Plus when the manuscript is accepted. Learn more at <http://www.orcid.org>.

In publishing only original research, ACS is committed to deterring plagiarism, including self-plagiarism. ACS Publications uses Crossref Similarity Check Powered by iThenticate to screen submitted manuscripts for similarity to published material, and other software to screen previous submissions to ACS journals. Note that your manuscript may be screened during the submission process.

We look forward to seeing your paper in ACS Omega.

Sincerely,

Dr. Krishna Ganesh
Coeditor
ACS Omega
Phone: (202) 657-6323
Email: Ganesh-office@omega.acs.org

Reviewer(s)' Comments to Author:

Reviewer: 1

Recommendation: Publish after major revisions.

Comments:

The paper 'Citric acid-locust bean gum as a negative matrix for controlled release tablet' can be accepted after major revision. The following comments should be addressed.

Comments:

1. 'HPMC as hydrogel matrix and CA-LBG as negative matrix on controlled-release tablet formulation. In addition, the study was to determine the effect of CA-LBG and HPMC': Here already it is said positive effect of HPMC.....so why again it is said to determine the effect of CA-LBG and HPMC?
2. 'granulation method dan ketoprofen' There is typo error.
3. Why Solubility study of CA-LBG was done? The method which is adopted, has any reference.
4. The similar works have already been done by authors. What is the novelty of this paper?
5. Why flow ability and tap index were measured for tablet mass instead of granules?
6. 'dissolution apparatus II USP paddle model' IT will be USP II
7. release of ketoprofen is expressed as Dr. Can it be modified?
8. Can HPMC and CA-LBG network will interpenetrate? If it is so, then discuss on this. [citations removed by the editorial office]
9. This paper needs one graphical abstract.
10. simplex lattice design of two factors used eight runs should be shown in the manuscript.

Additional Questions:

Is the technical quality of the research reported within valid and appropriate?: Yes

Please evaluate the degree of novelty and originality of the research reported: Good

Are the conclusions adequately supported by the data presented?: Yes

Are the literature references appropriate and up to date?: No

Reviewer: 2

Recommendation: Publish after minor revisions.

Comments:

Journal: ACS Omega

Manuscript ID: ao-2022-07432u

Title of the Manuscript: Citric acid-locust bean gum as a negative matrix for controlled release tablet

In general, the present work determines the optimum concentration of HPMC as hydrogel matrix and citric acid-locust bean gum as negative matrix on controlled-release tablet formulation. The LGB and CA-LBG are characterized by the FTIR and NMR. Further, these tablets are evaluated by the dan ketoprofen drug release applications. As over all the work is well organed; results and discussions are well adequate. Hence the manuscript is recommended for publication with minor revision.

In specific

- 1) HPMC need be elaborated at once in starting of the manuscript and also need to appear in the title of the manuscript.
- 2) Page 2 line 25 'dan ketoprofen'? check this.
- 3) Page no 5 line 12 "Manufacture of CA-LBG" it is need to correct as 'Preparation of CA-LBG matrix'; 'manufacture' word may be removed for the manuscript and use appropriate word.
- 4) It is not clear that 'CA-LBG gel' structure, either is chemical crosslinking or physical crosslinking, need to discuss in detail.
- 5) In the FTIR, X-axis need to labled as 'Wavenumber (cm-1)'; H1 NMR spectrum need to provide 0-10 ppm also need to provide the units on X-axis

Additional Questions:

Is the technical quality of the research reported within valid and appropriate?: Yes

Please evaluate the degree of novelty and originality of the research reported: Good

Are the conclusions adequately supported by the data presented?: Yes

Are the literature references appropriate and up to date?: Yes

FOR ASSISTANCE WITH YOUR MANUSCRIPT SUBMISSION PLEASE CONTACT:

ACS Publications Customer Services & Information (CSI)

Email: support@services.acs.org

Phone: 202-872-4357

Toll-Free Phone: 800-227-9919 (USA/Canada only)

PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at pubs-comms-unsub@acs.org if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

Hadinugroho, Wuryanto ao-2022-07432u - Manuscript Formatting Request - Non-scientific changes

Dari: ACS Omega (onbehalf@manuscriptcentral.com)

Kepada: wuryanto.hadinugroho@gmail.com

Tanggal: Jumat, 16 Desember 2022 pukul 20.02 GMT+7

16-Dec-2022

Manuscript ID: ao-2022-07432u

Manuscript Type: Article

Title: "Citric acid-locust bean gum as a negative matrix for controlled release tablet"

Author(s): Hadinugroho, Wuryanto; Martodihardjo, Suwaldi; Fudholi, Achmad; Riyanto, Sugeng; Prasetyo, Jefri

Dear Dr. Hadinugroho:

You recently received a Revision Request from Dr. Krishna Ganesh. In addition to addressing the Editor's concerns and the requests of the reviewers, please complete the following before submitting your revision:

* In case your current addresses differ from the research affiliations they should be included as footnotes. (affiliations in the system and MS must match)

* Please update the abstract upon submission of your revised manuscript to match the manuscript file.

- ORCID iDs should not be typed into the manuscript. ACS publishes only those ORCID iDs that have been properly verified and linked before the manuscript is accepted. After your ORCID iD is linked, it will be displayed automatically in all subsequently accepted manuscripts for any/all ACS journals. We do not publish ORCID iDs provided during proof review or via other communications after a manuscript is accepted for publication. For more information see Authors Guidelines at https://publish.acs.org/publish/author_guidelines?coden=acsodf#orcid

Please use highlighting, bolding, italics, or marking of any type within the manuscript to indicate changes made in response to the reviews of your manuscript, and upload the marked-up copy as "Supporting Information For Review Only".

We look forward to receiving your revised manuscript, so that processing of your manuscript may proceed without further delay. Thank you for considering ACS Omega as a forum for the publication of your work.

Sincerely,

Marko Vucic
Peer Review Analyst

FOR ASSISTANCE WITH YOUR MANUSCRIPT SUBMISSION PLEASE CONTACT:

ACS Publications Customer Services & Information (CSI)

Email: support@services.acs.org

Phone: 202-872-4357

Toll-Free Phone: 800-227-9919 (USA/Canada only)

PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for

delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at pubs-comms-unsub@acs.org if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

Hadinugroho, Wuryanto ao-2022-07432u.R1 - Revised Manuscript Submission to ACS Omega 25-Dec-2022

Dari: ACS Omega (onbehalfof@manuscriptcentral.com)

Kepada: wuryanto.hadinugroho@gmail.com

Cc: wuryanto.hadinugroho@gmail.com; waldi_ugm@yahoo.com; fudholi_fa@ugm.ac.id; sugeng_riyanto51@yahoo.com; jefri@ukwms.ac.id

Tanggal: Minggu, 25 Desember 2022 pukul 15.15 GMT+7

25-Dec-2022

Journal: ACS Omega

Manuscript ID: ao-2022-07432u.R1

Title: "Hydroxypropyl methylcellulose as hydrogel matrix and citric acid-locust bean gum as a negative matrix for controlled release tablet"

Authors: Hadinugroho, Wuryanto; Martodihardjo, Suwaldi; Fudholi, Achmad; Riyanto, Sugeng; Prasetyo, Jefri

Manuscript Status: Submitted

Dear Dr. Hadinugroho:

Your manuscript has been successfully submitted to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopencscience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

Please reference the above manuscript ID in all future correspondence. If there are any changes in your contact information, please log in to ACS Paragon Plus with your ACS ID at <http://acsparagonplus.acs.org/> and select "Edit Your Profile" to update that information.

You can view the status of your manuscript by checking your "Authoring Activity" tab on ACS Paragon Plus after logging in to <http://acsparagonplus.acs.org/>.

ACS Authoring Services

Did you know that ACS provides authoring services to help scientists prepare their manuscripts and communicate their research more effectively? Trained chemists with field-specific expertise are available to edit your manuscript for grammar, spelling, and other language errors, and our figure services can help you increase the visual impact of your research.

Visit <https://authoringservices.acs.org> to see how we can help you! Please note that the use of these services does not guarantee that your manuscript will be accepted for publication.

Thank you for submitting your manuscript to ACS Omega.

Sincerely,

Dr. Krishna Ganesh and Dr. Deqing Zhang
ACS Omega

PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related

attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at pubs-comms-unsub@acs.org if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

Hydroxypropyl methylcellulose as hydrogel matrix and citric acid-locust bean gum as a negative matrix for controlled release tablet

Journal:	ACS Omega
Manuscript ID	ao-2022-07432u.R1
Manuscript Type:	Article
Date Submitted by the Author:	25-Dec-2022
Complete List of Authors:	Hadinugroho, Wuryanto; Widya Mandala Catholic University Surabaya, Faculty of Pharmacy Martodihardjo, Suwaldi; Gadjah Mada University, Faculty of Pharmacy Fudholi, Achmad; Gadjah Mada University, Faculty of Pharmacy Riyanto, Sugeng; Gadjah Mada University, Faculty of Pharmacy Prasetyo, Jefri; Widya Mandala Catholic University Surabaya, Faculty of Pharmacy

SCHOLARONE™
Manuscripts

Hydroxypropyl methylcellulose as hydrogel matrix and citric acid-locust bean gum as a negative matrix for controlled release tablet

Wuryanto Hadinugroho^{1*}, Suwaldi Martodihardjo², Achmad Fudholi², Sugeng Riyanto², and Jefri Prasetyo¹

1 Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Kalisari Selatan no. 1 Pakuwon City, Surabaya, Indonesia.

2 Faculty of Pharmacy, Gadjah Mada University, Sekip Utara, Yogyakarta, Indonesia.

*Corresponding authors:

Dr. Wuryanto Hadinugroho, Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Kalisari Selatan no. 1 Pakuwon City, Surabaya, 60112, Indonesia.

Email address: wuryanto.hadinugroho@gmail.com

Abstract

Purpose: This study aimed to determine the optimum concentration of hydroxypropyl methylcellulose (HPMC) as hydrogel matrix and citric acid-locust bean gum (CA-LBG) as negative matrix on controlled-release tablet formulation. In addition, the study was to determine the effect of CA-LBG and HPMC. CA-LBG accelerates the disintegration of tablets into granules so that the HPMC granule matrix swells immediately and controls drug release. The advantage of this method is that the tablets do not produce large HPMC gel lumps without drug (ghost matrix) but form HPMC gel granules which can be rapidly degraded after all the drug is released.

Methods: The experiment followed the simplex lattice design to obtain the optimum tablet formula with CA-LBG and HPMC concentrations as optimization factors. Tablets production by wet granulation method and ketoprofen is the model of the active ingredient. The kinetics of ketoprofen release was studied using several models.

Results: Based on the coefficients of each polynomial equation that HPMC and CA-LBG increased the value of angle of repose (29.91 : 27.87), tap index (18.99 : 18.77), hardness (13.60 : 13.32), friability (0.41 : 0.73), and release of ketoprofen (52.48 : 99.44). Interaction of HPMC and CA-LBG increased the value of angle of repose (3.25), tap index (5.64), and hardness (2.42). Interaction of HPMC and CA-LBG too decreased the value friability (-1.10), and release of ketoprofen (-26.36). The Higuchi, Korsmeyer-Peppas, and Hixson-Crowell model is the kinetics of eight experimental tablet formulas.

Conclusion: The optimum concentrations of HPMC and CA-LBG for controlled release tablets are 32.97% and 17.03%. HPMC, CA-LBG, and a combination of both affect the physical quality of tablet and tablet mass. CA-LBG is a new excipient candidate that can control drug release from tablets by matrix disintegration mechanism on the tablet.

Keywords:

CA-LBG, citric acid, locust bean gum, control release, optimization

Introduction

Controlled-release tablets are drug delivery systems to prolong the therapeutic effect. The drug is released slowly and continuously over some time. Ion exchange resins, osmotic pumps, and reservoirs are examples of controlled release systems.^{1,2} HPMC is one of the polymers often used to control drug release because the HPMC matrix can trap drug particles and release them slowly. HPMC matrices alone or with other polymers are often used to control drug release.³⁻⁵

CA-LBG is a new ester polymer derived from locust bean gum. CA-LBG is synthesized using a hydrochloric acid (HCl) catalyst and an ultraviolet light (UV 254 nm) energy source. O atoms of the carbonyl group of CA are to be protonated to form positive C atoms because of acid conditions created by HCl. The ester bond occurs at the OH (C-6) mannose and galactose groups in LBG with a positive C atom from the carbonyl group in CA to form a tetrahedral cation. OH were protonated to $^+\text{OH}_2$, continued loss of H_2O to form CA-LBG (ester).⁶⁻¹¹ Previous experiments reported that CA-LBG has an ester carbonyl group which LBG does not. The viscosity and solubility of CA-LBG are lower than that of LBG.⁷ The CA-LBG character has the potential to control drug release.

This study aimed to determine the optimum concentration of HPMC and CA-LBG on the tablet. on controlled-release tablet formulation. In addition, the study was to determine the effect of CA-LBG and HPMC. The activity of CA-LBG as a negative matrix with HPMC matrix to control drug release was studied by drug release kinetics. The novelty of this experiment is that the formulation using CA-LBG is a new polymer ester with low solubility. The CA-LBG as a negative matrix causes the tablets to disintegrate into granules. HPMC matrix gel derived from granules controls drug release. A negative matrix (CA-LBG) is a substance that causes the tablet's positive matrix (HPMC) to disintegrate into granules. The mechanism of action on tablets is that the wetted tablet surface causes disintegration into granules due to low solubility of CA-LBG and repulsion between CA-LBG particles. Granules containing HPMC swell to control drug release. CA-LBG controls drug release because CA-LBG is poorly soluble and has low viscosity, so CA-LBG inhibits

the wetting and dissolution of drug particles. The advantage of this method is that the tablets do not produce large hydroxypropyl methylcellulose (HPMC) gel lumps without drug (ghost matrix) but form HPMC gel granules which can be rapidly degraded after all the drug is released. Ketoprofen (100 mg) (see supplementary information Chapter S1) is a drug model added to the granules and compressed into tablets (400 mg). HPMC was chosen as the matrix because HPMC is a polymer that can swell when hydrated with water with a viscosity to control drug release.^{1,5} Lactose monohydrate is a suitable filler for tablets because it has good compatibility and high density (1.545 g/cm³).⁵ These character can be suitable for wet granulation methods, so tablets are hard and of the ideal size. Ketoprofen is used in the drug model because ketoprofen has a dose of 25-200 mg and an elimination half-life of 2-4 hours.^{12,13} Making tablets using the wet granulation method can improve the flow properties by increasing the particle size and the compatibility of the tablet mass. CA-LBG particles are shaped like coral-corrugated, HPMC particles like a rhizome, and irregularly shaped lactose monohydrate particles.^{5,7} The experiment followed the simplex lattice design to obtain the optimum tablet formula. This method is quite simple for experiments by mixing internal factors (ingredients) in a formula without the influence of internal factors (process or technology). In addition, this method is quite effective for synthesized materials such as CA-LBG in limited quantities. The optimization factor is the concentration of CA-LBG and HPMC. The optimization response is the angle of repose, tap index, hardness, friability, and ketoprofen release.

Material and methods

Raw materials and chemicals

The materials used in this experiment include locust bean gum (Viscogum, Cargill, France), citric acid monohydrate (Brand KgaA, Darmstadt, Germany), hydrochloric acid (Sigma-Aldrich Chemie, GmbH, USA), distilled water (Sterilized Water For Injection, PT. Otsuka Indonesia), acetone (Cawan Anugerah Chemika, Indonesia), hydroxypropyl methylcellulose (Methocel K4M CR

Premium USP/EP, Colorcon, Singapore), lactose monohydrate (Leprino Foods, UDM, USA), ketoprofen (PT Kalbe Farma Tbk, Indonesia), potassium dihydrogen phosphate (KGaA Darmstadt Germany Brand), and sodium hydroxide (KGaA Darmstadt Germany Brand).

Preparation of CA-LBG matrix

The preparation of CA-LBG adopted the preparation method in the previous study. The LBG (3.55×10^{-6} mol) was swelled in 50 mL of warm distilled water (55-60 °C), added CA (21.00×10^{-3} mol), and HCl (57.40×10^{-3} mol), homogenized for 10 minutes. The gel was irradiated with UV 254 nm for 100 min (8-Watt, CH-4132 Muttentz, Camag, Switzerland), then precipitated (acetone) and washed off (distilled water-acetone). The CA-LBG residue was dried at room temperature.^{7,14}

The success of CA-LBG production was confirmed through the Fourier transform infrared spectroscopy (FTIR) characterization, nuclear magnetic resonance (NMR), solubility, and viscosity. Production is carried out for three batches to determine reproducibility through standard deviation.

Fourier transform infrared spectroscopy

The structure and specific groups of CA-LBG were identified by Fourier transform infrared spectroscopy (UATR Perkin Elmer Spectrum Version 10.4.3.). The observations show that a spectrum wavelength is $4000\text{--}450\text{ cm}^{-1}$. A certain amount of powder is placed on a diamond plate and pressed with a stick on the instrument. Spectra are visible on the monitor and recorded.

Nuclear magnetic resonance

The NMR spectroscopic examination confirmed the structure and specific group of CA-LBG. An amount of CA-LBG powder (5-10 mg) was dispersed in H₂O (deuterium) and stirred for 45 minutes at a vortex. The filtrate was transferred to a glass tube and analyzed by NMR spectroscopy (JEOL RESONANCE ECZ 500R Japan).

Esterified CA

The amount of esterified CA was determined by the degree of esterification. Determination of the degree of esterification adopts the previous experiment.^{7,14} Samples were derived from CA-LBG precipitating solven and washing solution (acetone and distilled water-acetone). Measurements using potentiometry with titrant NaOH (0.2 N) standardized by oxalic acid. The titrant volume endpoint determines the dissolved acid's total concentration [mEq]. The dissolved CA concentration [mEq] was obtained from the difference between the total acid concentration and the HCl concentration. The dissolved CA [gram] weight was obtained from the conversion of dissolved CA [mEq]. The reacted CA was obtained from the difference between the initial CA weight and dissolved CA. The degree of esterification [%] is the ratio of CA reacted with initial CA.

Solubility study

The CA-LBG powder (500 mg) was dispersed in distilled water (50 mL) and stirred for 24 hours (Wd). The swelled powder and filtrate are carefully separated. The filtrate was dried in a water bath (70°C and reweighed (Wds) (Mettler Toledo AL204, Switzerland). The dissolved CA-LBG was determined according to Equation 1:

$$S [\%] = \frac{Wds}{Wd} \cdot 100 \% \quad \text{Equation 1}$$

where the solubility (S), the soluble weight (Wds), and initial dry weight (Wd).¹⁵

Viscosity

The viscosity of CA-LBG was determined by a viscometer (Brookfield LVDV-I Prime, Middleboro, MA, USA). The CA-LBG powder (3% w/v) was swelled in warm distilled water (300 mL, 50-60°C) and allowed to cool to ambient temperature. Spindle No. S61 mounted on Brookfield was dipped on swollen mass and rotated (100 rpm). Viscosity is shown on the monitor and recorded.

Manufacture of tablets

In this experiment, the method of making tablets by wet granulation adopted the previous study with the necessary adjustments.¹⁴ Preparing granules by wet granulation contains HPMC and lactose monohydrate (50 %) according Table 2 (cubic mixer, rotary motor (Erweka)). A homogeneous mixture was moistened with CA-LBG dispersed in distilled water (\pm 5 mL) while being compressed to form a wet granule mass and sieved (mesh No. 18) to form granules. The wet granules were dried in an oven (50⁰C; 15 min; RH 2-5%) (moisture analyzer OHAUS) and re-sieved (mesh No. 20). The granules were mixed with ketoprofen (100 mg) (3:1) and evaluated for the mass quality of the tablets. The tablet mass was compressed to form a 400 mg tablet and hardness \geq 13 kp (single punch, Korch, Germany), assessed for the physical quality of the tablet and dissolution.

Optimization

Optimization of the granule formula according to the simplex lattice design of two factors used eight runs randomized of formulas, model quadratic, and optimization software (Design Expert ver. 10.0.8.0; Stat-Ease Inc., Minneapolis, MN, USA). Comparison of the proportion of HPMC and CA-LBG for each formula based on optimization software (Table 2), including 0:1 (2 formulas); 0.25:0.75 (1 formula); 0.50:0.5 (2 formulas); 0.75:0.25 (1 formula); and 1:0 (2 formulas). The concentration of HPMC in proportion 0 (30%) and proportion 1 (40%), while the concentration of CA-LBG in proportion 0 (10%) and proportion 1 (20%). The HPMC concentration and the CA-LBG concentration were optimization factors. The angle of repose, tap index, hardness, friability, and released ketoprofen were optimization responses. The values of the optimization response parameters were processed using optimization software to obtain polynomial equations and predict the optimum concentrations of HPMC and CA-LBG in granules.

Flowability

The mass of the tablet was weighed at about 50 g and placed on the funnel of a flowability tester (Erweka, Germany). The funnel valve opens, and the tablet mass flows freely. The flowability tester monitor observed the measured flow time of the tablet mass. The cone from tablet mass was measured using infrared to determine the angle of repose and watched on the flowability tester monitor.

Tap Index

The tablet mass was put in a measuring cup (50 mL). The measuring cup was tilted and filled with tablet mass. The filled measuring cup was placed on the volumenometer tap density and tapped 500 taps. Tap index (TI) was determined from the difference between the volume before and after tapping compared to the volume before tapping (Equation 2).^{16–19}

$$TI [\%] = \frac{V_0 - V_1}{V_0} \times 100\% \quad \text{Equation 2}$$

Weight

From randomly selected tablets (20), and each tablet was weighed using an analytical balance (Mettler Toledo, Switzerland).

Hardness

Tablet hardness test used randomly selected tablets (6 tablets).²⁰ The tablets were placed on a board in a hardness tester (Schleuniger, Netherlands), then a metal block pressed on the tablet until the tablet cracks. The tablet hardness was observed on the monitor hardness tester.

Friability

The tablet friability test used randomly selected tablets with a total weight of comparable tablets of 6500 mg.²⁰ Each tablet was cleaned from dust, then all tablets were weighed (W0). All tablets were placed in a drum friability tester (Erweka, Germany) and rotated (4 min; 25 rpm). All tablets were removed, cleaned from dust, and reweighed (W1). The friability (F) of tablets is determined according to Equation 3.

$$Fr (\%) = \frac{W0 - W1}{W0} 100\% \tag{Equation 3}$$

Drug release

The release of ketoprofen was tested using a dissolution apparatus **USP II** paddle model.^{12,13} The dissolution media used phosphate buffer pH 6.8 (900 mL; 37°C; 50 rpm) (Electrolab TDT-08L, India). Samples were taken at 0.5; 1; 1.5; 2; 2.5; 3; 4; 5; 6; 8; and 10 hour. Ketoprofen released from the tablet determined absorption value read by UV spectrophotometer (260 nm) (Hitachi U-1900, Japan).^{13,21}

Kinetics of ketoprofen release

The release kinetics of ketoprofen from tablets was influenced by HPMC and CA-LBG in the granules. The kinetics of drug release is determined by the following equations:²²⁻²⁵

Zero order : $Q_t = Q_o + K_o.t$ Equation 4

First order : $\ln Q_t = \ln Q_o + K_o.t$ Equation 5

Qt: the amount of drug dissolved at the time (t), Qo: the amount of the initial drug, and Ko: drug release constant.

Higuchi : $Q_t = K_H.\sqrt{t}$ Equation 6

Qt: the amount of drug dissolved at the time (t), KH: Higuchi constant, and t: time.

$$\text{Korsmeyer-Peppas} : Q_t/Q_\infty = K_k \cdot t^n \quad \text{Equation 7}$$

Q_t/Q_∞ : fraction of drug released, K_k : Korsmeyer-Peppas constant, and n : diffusion exponential.

$$\text{Hixson-Crowell} : Q_0^{1/3} - Q_t^{1/3} = K_s \cdot t \quad \text{Equation 8}$$

Q_0 : the amount of initial drug, Q_t : the amount of drug remaining at the time (t), and K_s : dissolution rate constant.

$$\text{Weibull} : \log [\ln - (1 - m)] = b \log (t - T_i) - \log a \quad \text{Equation 9}$$

$(1-m)$: fraction of insoluble drug, T_i : the lag time before dissolution, b : shape parameter obtained from the slope of the obtained curve. The value of $b = 1$ means that the curve is exponential. The importance of $b > 1$ is the shape of the sigmoid curve.

The release kinetics of ketoprofen from tablets of each granule formula was analyzed using DDSolver software.

Result and Discussion

Fourier transform infrared spectroscopy

Infrared spectra of CA-LBG and LBG are presented in Figure 1. Peaks at wavelengths of 3318.20 cm^{-1} and 3285.80 cm^{-1} indicate the hydroxyl (OH) groups of mannose and galactose. Peaks at wavelengths of 2923.66 cm^{-1} and 2936.00 indicate C-H bonds, where CA-LBG is sharper than LBG due to the influence of symmetrical C-H bonds from CA.^{25,26} The specific peak of CA-LBG at 1736.02 cm^{-1} indicates an ester carbonyl group. Previous studies reported that the peak wavelength of the OH group appears at 3300 cm^{-1} , C-H appears at around 2900 cm^{-1} , and C=O appears at about 1750-1735 cm^{-1} . **The reaction mechanism for making CA-LBG is a chemical esterification reaction. The reaction begins with the citric acid carbonyl group undergoing protonation and reacting with the hydroxyl group (OH) on the C-6 mannose and galactose atoms to form a tetrahedral cation. Oxygen**

in the OH undergoes protonation ($^+OH_2$) to form loose OH so that the loss of H_2O and an ester (CA-LBG) is formed.⁷ The results of the infrared analysis were further confirmed using NMR.




Figure 1. Infrared spectra of CA-LBG and LBG. The CA-LBG spectra have a carbonyl ester group (C=O) at a wavelength of 1736.02 cm^{-1} , presented by a blue line. LBG as control, presented with a red line.

Nuclear magnetic resonance

The NMR examination further confirms the FTIR examination and is carried out representatively for the three manufacturing batches. The CA-LBG NMR spectra are presented in Figure 2. The 1H NMR spectra, paired twin peaks at $\delta = 2.926\text{ ppm}$ and $\delta = 2.894\text{ ppm}$, $\delta = 2.746$ and $\delta = 2.714\text{ ppm}$ correspond to the presence of CH_2 (5) of CA in LBG. The sharp peak at $\delta = 3.996\text{--}3.309\text{ ppm}$ corresponds to the H atoms of mannose and galactose in LBG. Previous experiments reported that the paired twin peaks of CH_2 were seen at $\delta = 2.7\text{--}3.0\text{ ppm}$. Sharp peaks of H atoms from mannose and galactose appear at $\delta = 4.5\text{--}3.0\text{ ppm}$.^{6,7}




Figure 2. NMR observation spectra of CA-LBG. CA characters present in CA-LBG resented peaks 1, 2, 3, 4, and 5.

The ¹³C NMR spectra of CA-LBG at the peak $\delta = 176.905$ ppm and $\delta = 173.507$ ppm indicated the carbonyl group (C=O) (1,2), which was a specific group of CA-LBG. The central C atom of CA is shown at $\delta = 73.354$ ppm (3). CH₂ of CA is shown at $\delta = 43.349$ ppm (4). The C atoms that make up mannose and galactose from LBG are shown at $\delta = 100.182$ ppm, $\delta = 96.477$ ppm, $\delta = 76.570$ ppm, $\delta = 75.053$ ppm, $\delta = 71.453$ ppm, $\delta = 69.966$ ppm, $\delta = 69.323$ ppm, $\delta = 61.001$ ppm, $\delta = 60.540$ ppm. Previous experiments show C=O group at $\delta = 180$ -170 ppm, central C atom at $\delta = 80$ -70 ppm, CH₂ appears at $\delta = 44$ -43 ppm.^{6,7,27} The C atoms make up mannose, and galactose appears at $\delta = 105$ -60 ppm.^{7,28-30} Finally, the peaks in the spectra indicate the success of the synthesis.

Esterified CA

The degrees of esterification in each batch are shown in Table 1. All batches had similar degrees of esterification, indicating reproducible manufacturing conditions. The experimental esterification degree of 29.30-29.55% corresponds to the previous experimental report of around 9.13%.^{7,14} The degree of esterification of all batches indicated that the esterification conditions were stable and reproducible. The acidic condition created by HCl induces the O atom in the carbonyl group of CA to be protonated to a positive C atom. The OH group on C6 of mannose and galactose will react with a positive C atom.

Table 1. Evaluation degree of esterification, solubility, and viscosity of CA-LBG

Batch Code	Degree of esterification		Solubility		Viscosity	
	[%]	SD	[%]	SD	[cP]	SD
1	29.33	0.20	29.65	0.27	9.48	0.01
2	29.30	0.21	29.81	0.18	9.46	0.02
3	29.55	0.10	29.51	0.42	9.43	0.02

Solubility

The solubility of CA-LBG in each batch is presented in Table 1. All batches showed similar solubility and indicated reproducible manufacturing. The solubility is 29.51-29.81%, according to the solubility in the previous experiment (22.64-36.63%).¹⁴ The ester bond of CA molecules influences the solubility of CA-LBG in LBG. The positive C atom of the carboxylate group (CA) binds to the O atom at C-6, inhibiting the interaction of CA-LBG with distilled water CA-LBG and reducing solubility.

Viscosity

Table 1 shows the respective viscosity of CA-LBG has similar values and indicates reproducible manufacturing. The viscosity shows a value of 9.43-9.48 cPs following the viscosity in the previous experiment (7.76-11.20 cPs).¹⁴ Viscosity is influenced by the carbonyl ester group

formed from the positive C atom of the carboxylic group (CA) with the O atom at C-6 in mannose and galactose so that the ability of CA-LBG to trap distilled water decreases.

Flowability

The results of testing the flow time and angle of repose of the tablet mass for each formula are presented in Table 2. Each formula produces a flow time of about 4.60-5.00 seconds and an angle of repose 27.89-30.04⁰, indicating the tablet mass good flows because ≤ 10 seconds for 100 g and $\leq 40^0$ ¹⁷. The tablet mass can occupy the die space inside the tablet machine. The tablet mass can be continued to be compressed to form a tablet (400 mg). The response of the angle of repose according to the simplex lattice design is obtained by Equation 10.

$$Y = 29.91 A + 27.87 B + 3.25 AB \quad \text{Equation 10}$$

The coefficient value of each component in the equation shows that HPMC (+29.91) is the most dominant factor in increasing the angle of repose, followed with CA-LBG (+27.87), and a combination of both (+3.25). The CA-LBG is an ester polymer that is difficult to hydrate with distilled water, so CA-LBG inhibits the formation of bonds between the granule constituent particles and produces fine granules. A large number of refined grains inhibits the tablet mass flow. HPMC is a polymer that can absorb moisture from the surrounding environment.⁵ The HPMC in the granules increases moisture impedes flow, forming high mounds. Combining CA-LBG with HPMC, which can absorb moisture, increases the tablet mass flow time. Flow time is one parameter that determines the diversity of weights in the tablet manufacturing process.

Based on the ANOVA analysis (see supplementary information Table S1), the response angle of repose has a Pred R-Squared (0.9596), similar to Adj R-Squared (0.9742) with less than 0.2. Meanwhile, the Adeq Precision (23.8130) greater than 4, indicating this model is acceptable.

Tap Index

The tablet mass tap index for each formula is presented in Table 2. Each formula has a tap index of about 18.50-20.00%, indicating that the tablet mass has good homogeneity because $\leq 20\%$ ¹⁷, so the space between the granules is filled with particles or fines. In addition, this condition shows that the tablet mass has good compressibility and creates low porosity tablets. The tap index for each formula is processed according to the simplex lattice design to obtain Equation 11.

$$Y = 18.99 A + 18.77 B + 5.64 AB \qquad \text{Equation 11}$$

The value of the HPMC coefficient (+18.99) is the dominant factor in increasing the tap index, followed with CA-LBG (+18.77) and a combination of both (+5.64). HPMC can reduce the sensitivity of the granules because the HPMC particles absorb moisture so that the granules change shape when granules receive mechanical stress. The difficulty of hydrating CA-LBG particles in the granulation process causes the bond between the granules to be not good so that the granules release fines and receive mechanical stress. The combination of the two factors can increase the tap index because the HPMC reduces the sensitivity due to moisture absorption. In addition, it is supported by less strong bonds between particles in the granules due to the difficulty of hydrating during the granulation process.

Based on the ANOVA analysis (see supplementary information Table S1), the response tap index has a Pred R-Squared (0.7862), similar to Adj R-Squared (0.8928) with less than 0.2. Meanwhile, the Adeq Precision (10.7420) greater than 4, indicates this model is acceptable.

Weight

The tablet weight of all formulas is shown in Table 2. Tablet mass was compressed into tablets with a weight of about 400 mg. The tablet mass of all formulas is free to flow and fill the die chamber, so tablet weight is according to design. The compression success is suitable for the value of flow time, angle of repose, and tap index.

Table 2. Details of HPMC and CA-LBG concentration, quality of the tablet mass, quality of the tablet, and ketoprofen released

Formula code	HPMC [%]	CA-LBG [%]	Flow time [sec.]	Angle of repose [°]	Tap index [%]	Weight [mg]	Hardness [kp]	Friability [%]	Ketoprofen released [10 hr.] [%]
G1	40.00	10.00	4.80 ± 0.06	29.92 ± 0.10	19.00	401.34 ± 1.69	13.61 ± 0.70	0.39	53.75 ± 0.89
G2	32.50	17.50	4.60 ± 0.10	28.98 ± 0.08	20.00	400.87 ± 1.25	13.84 ± 1.05	0.45	83.34 ± 0.70
G3	35.00	15.00	5.00 ± 0.06	29.47 ± 0.18	20.00	402.08 ± 1.50	14.08 ± 0.84	0.28	69.33 ± 0.93
G4	40.00	10.00	4.60 ± 0.10	29.86 ± 0.53	18.50	400.07 ± 1.16	13.60 ± 0.61	0.43	51.71 ± 0.71
G5	30.00	20.00	4.80 ± 0.06	27.86 ± 0.18	19.00	399.69 ± 1.45	13.33 ± 0.46	0.74	99.21 ± 1.04
G6	37.50	12.50	4.80 ± 0.15	30.04 ± 0.06	20.00	400.12 ± 1.65	14.01 ± 0.83	0.34	58.16 ± 0.89
G7	35.00	15.00	5.00 ± 0.15	29.93 ± 0.94	20.00	400.36 ± 0.89	14.06 ± 0.87	0.28	69.82 ± 0.33
G8	30.00	20.00	5.00 ± 0.10	27.89 ± 0.54	19.00	399.67 ± 1.21	13.32 ± 0.84	0.73	99.32 ± 0.46
Ga	32.97	17.03	4.80 ± 0.06	29.17 ± 0.12	20.00	401.27 ± 1.15	13.97 ± 0.64	0.40	80.08 ± 0.60
Gb	32.97	17.03	4.60 ± 0.15	29.08 ± 0.23	20.00	399.00 ± 1.20	14.01 ± 0.58	0.41	80.44 ± 1.17
Gc	32.97	17.03	5.00 ± 0.10	29.22 ± 0.99	19.50	400.67 ± 0.79	13.86 ± 0.85	0.39	80.45 ± 0.55
Go	32.97	17.03	-	29.16	20.01	-	13.91	0.41	80.00

The proportion of HPMC and CA-LBG are G1 (1 : 0); G2 (0.25 : 0.75) G3 (0.5 : 0.5); G4 (1 : 0); G5 (0 : 1); G6 (0.75 : 0.25); G7 (0.5 : 0.5); G8 (0 : 1); Ga (0.30 : 0.70); Gb (0.30 : 0.70); Gc (0.30 : 0.70); and Go (0.30 : 0.70).

Hardness

The tablet hardness of each formula is presented in Table 2. Tablets of each formula have a hardness are around 13.32-14.08 kp, indicating that the tablet has strong resistance and good physical stability. The hardness of tablets comes from strong interlocking between the granules/particles making up the tablet when receiving compression so that the porosity of the tablet is low. The hardness of each formula is processed according to the simplex lattice design to obtain Equation 12.

$$Y = 13.60 A + 13.32 B + 2.42 AB \qquad \text{Equation 12}$$

The coefficient value of HPMC (+13.60) is the most dominant factor in increasing hardness, followed with CA-LBG (+13.32) and a combination of both (+2.42). HPMC can absorb moisture and is used as an adhesive between the deformation of granules/particles to produce a solid interlocking bond. The tablets have good stability to humidity even though the granules contain HPMC because the moisture absorption activity is inhibited by decreasing the absorption surface area in the tablets form than the granules. Although CA-LBG is difficult to hydrate, the deformation of the particles can form solid interlocking bonds. In addition, the presence of CA-LBG on the tablet surface inhibits moisture absorption. The combination of both can increase the hardness because the characters of HPMC and CA-LBG complement each other. The tablet has a solid interlocking bond between the deformation of the granules/particles, and the tablet can retain moisture. In addition, the tap index shows that the tablet mass has low porosity and good compressibility so that when compressed tablet mass produces a compact tablet.

Based on the ANOVA analysis (see supplementary information Table S1), the response hardness has a Pred R-Squared (0.9976), similar to Adj R-Squared (0.9985) with less than 0.2. Meanwhile the Adeq Precision (100.1700) greater than 4, indicates this model is acceptable.

Friability

The tablet friability of all formulas is presented in Table 2. Each formula has a friability of 0.28-0.74% ($\leq 1\%$)¹⁷, indicating that the tablet surface is strong enough to withstand mechanical movements because of solid interlocking bonds between the deformation of the particles on the tablet surface. Friability of all formulas is according to the simplex lattice design to obtain Equation 13.

$$Y = 0.41 A + 0.73 B - 1.10 AB \quad \text{Equation 13}$$

The coefficient value of CA-LBG (+0.73) is the most dominant factor in increasing friability, followed by HPMC (+0.41) and a combination of both decreasing friability (-1.10). HPMC can absorb moisture and is used as an adhesive between the deformation of granules/particles to produce a solid interlocking bond. The tablets have good stability to humidity even though the granules contain HPMC because the moisture absorption activity is inhibited by decreasing the absorption surface area in the tablets form than the granules. Although CA-LBG is difficult to hydrate, the deformation of the particles can form solid interlocking bonds. In addition, the presence of CA-LBG on the tablet surface inhibits moisture absorption. The combination of the two can reduce the friability of the tablet because the HPMC and CA-LBG particles fill the space between the lactose monohydrate particles. The strong interlocking bonds of the granule mass components form compact and low-porosity granules. When compressed formed a tablet resistant to mechanical movement. The friability quality of this tablet is in line with the hardness quality of the tablet.

Based on the ANOVA analysis (see supplementary information Table S1), the response friability has a Pred R-Squared (0.9593) similar to Adj R-Squared (0.9747) with less than 0.2. Meanwhile, the Adeq Precision (24.6860) greater than 4, indicates this model is acceptable.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. The ketoprofen dissolution profile of various tablet formulas contains HPMC [%] and CA-LBG [%]: G1 (40 : 10); G2 (32.5 : 17.5); G3 (35 : 15); G4 (40 : 10); G5 (30 : 20); G6 (37.5 : 12.5); G7 (35 : 15); G8 (30 : 20); and Ga (32.97 : 17.03).

Ketoprofen release

The concentration and profile of ketoprofen release for each tablet formula after 10 hours are presented in Table 2, Figure 3, and supplementary information Table S2-S3. All tablets of ketoprofen release around 51.71-99.32%, showing that HPMC and CA-LBG can control ketoprofen release from tablets. HPMC is a polymer that swells when hydrating by the dissolution medium. Ketoprofen release is inhibited because HPMC swells trap ketoprofen particles. The CA-LBG is a polymer that is difficult to hydrate and has low solubility. The CA-LBG character causes the tablet to disintegrate

and become granule. Releases of ketoprofen-controlled granule swelling form a gel. Based on the experimental design, ketoprofen released for 10 hours is $\geq 80\%$ (see supplementary information Chapter 1). The processed concentration value of each tablet formula is according to the simplex lattice design to obtain Equation 14.

$$Y = 52.48 A + 99.44 B - 26.36 AB \quad \text{Equation 14}$$

The CA-LBG coefficient value (+99.44) was the most dominant factor in increasing ketoprofen release, followed with HPMC (+52.48). The combination of both (-26.36) was the most dominant factor in reducing the release of ketoprofen. The deformation of CA-LBG particles on the tablet refuses each other when submerged in the dissolution medium, causing tablet disintegration. The granule porosity surface is used as a space for penetration of the dissolution medium into the granule, dissolved ketoprofen particles, and diffuses out of the granule. The high concentration of CA-LBG accelerates of disintegration of the tablet and forms HPMC gel. Combining the HPMC with CA-LBG can reduce the release of ketoprofen because the moisture of the deformation of the HPMC particles can bind hardly to the interlocking deformation of the CA-LBG and other particles, so that the tablet disintegrates longtime. In addition, the direct interaction of CA-LBG with particles inhibits the swelling of HPMC and hydrating of ketoprofen by the dissolution medium. HPMC and CA-LBG particles can mix physically. Random distribution of HPMC and CA-LBG particles in granules. When these particles expand, the network of the two types of polymers can physically interact with each other (penetrate each other). In this condition, ketoprofen particles can be between these tissues so that these tissues control the release of ketoprofen. Ketoprofen release via diffusion or erosion mechanisms. The release of ketoprofen was studied through the kinetics of drug release.

Based on the ANOVA analysis (see supplementary information Table S1), the response to the release of ketoprofen has a Pred R-Squared (0.9956), similar to Adj R-Squared (0.9978) with a difference of less than 0.2. Meanwhile the Adeq Precision (85.0460) greater than 4, indicates this model is acceptable.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4. Comparison of actual (dotted line) and predicted (solid line) optimization response profiles. The red dot indicates the response value for each formula based on the respective proportions of HPMC and CA-LBG. The overlay shows the meeting point of all responses according to the predicted optimal proportions of HPMC and CA-LBG.

Optimum tablet formula

Determination of the optimum formula begins with the initial 8 experimental formula designs (G1-G8). The optimization factors and response parameter values were analyzed using design expert software using a simplex lattice design. The experimental comparison profiles and the predictions of each optimization response (Figure 4) show that the actual profiles are similar to the predictions. This profile follows the results of ANOVA analysis for each optimization response (flowability, tap index, hardness, friability, and release of ketoprofen). The optimization response overlay predicts the optimum proportion point to achieve the optimum response prediction. Design expert provides several alternative options for the optimum formula. The selected formula was determined from the response parameter specifications (angle of repose 27.86-30.04; tap index 18.5-20.5; hardness 13.32-

14.08 kp; friability 0.28-0.74%; drug release > 80%). Verification to the prediction of the optimum formula proportion (Go) to obtain the optimum formula was carried out in three batches (Ga, Gb, Gc) (Table 2 and Figure 3).




Figure 5. Drug release kinetics model (HPMC [%] : CA-LBG [%]): G1 (40 : 10) (Korsmeyer-Peppas); G2 (32.5 : 17.50) (Korsmeyer-Peppas); G3 (35 : 15) (Hixson-Crowell); G4 (40 : 10) (Korsmeyer-Peppas); G5 (30 : 20) (Hixson-Crowell); G6 (37.50 : 12.50) (Higuchi); G7 (35 : 15) (Hixson-Crowell); G8 (30 : 20) (Hixson-Crowell); Ga (32.97 : 17.03) (Zero order); Gb (32.97 : 17.03) (Zero order); and Gc (32.97 : 17.03) (Zero order).

One sample T-test results compare the experimental response formula verification with the predictive response. The values T of each parameter is T angle of repose (0.008), T tap index (1.096), T hardness (0.728), T friability (1.559), and T release of ketoprofen (2.657). The response parameter values between the prediction (Go) and the verification experiment (Ga-Gc) were not significantly different. These results indicate that the polynomial equations of each response parameter are valid for predicting the effect of HPMC, CA-LBG, and their combination. In addition, the selected optimum formula shows reproducibility in producing tablets and controlling ketoprofen's release. The variation of release shown by G1-G8 proves that tablets with irrelevant variations in physical quality produce varied drug releases.

Kinetics of ketoprofen release

The kinetics of ketoprofen release from the tablet is a non-linear approach using DDSolver (Table 3, Figure 5, and supplementary information Figure S1-S11). The kinetics parameters of ketoprofen release include high Rsqr_adj, low Mean Square Error-Root (MSE_root), and low Akaike Information Criterion (AIC). The Rsqr_adj is the correlation value between dissolution time and released ketoprofen. MSE_root indicates the error value in correlation analysis. AIC is the value suitability to the equation to determine the release kinetics.^{31–35} The results of DDSolver processing are presented in Table 3 and Figure 5.

The release kinetics of ketoprofen from tablets G1, G2, and G4 followed the Korsmeyer-Peppas kinetics. The exponential value (n) for tablets G1 (0.62), G2 (0.60), and G4 (0.58) indicates a non-Fickian diffusion mechanism (anomalous diffusion).³⁶ The release of ketoprofen released by diffusion is proportional to erosion. The surface of the granules forms a thin gel and cannot withstand the dissolution medium, so ketoprofen dissolves quickly. The ketoprofen release is not only through diffusion but also due to erosion of the surface of the gel formed. The CA-LBG is not tightly

1
2 integrated into the tablet and granule. This condition causes the dissolution rate to be faster with the
3
4 increase in the dissolution medium that enters the tablet and granule.
5

6
7 The release kinetics of ketoprofen from tablets G3, G5, G7, and G8 followed Hixson-Crowell
8
9 kinetics. The ketoprofen release was caused by hydrating the tablet surface, so the tablet disintegrated
10
11 and become granule. This condition causes ketoprofen to be dissolved constantly. HPMC low
12
13 concentration can tablet disintegration quickly when particles swell to form a gel and push against
14
15 other particles. In addition, CA-LBG on the granule accelerates the decomposition of the HPMC gel
16
17 because the repulsion forces between CA-LBG particles are difficult to dissolve.
18
19

20
21 The tablet G6 followed the release kinetics of Higuchi's model. The high viscosity gel of
22
23 HPMC controlled the diffusion of ketoprofen from the granules. CA-LBG on the granule surface
24
25 inhibited granule hydration and ketoprofen diffusion.
26

27
28 The release kinetics of ketoprofen from Ga, Gb, and Gc tablets followed zero order. HPMC
29
30 on the tablet surface swells to form a gel when in contact with the dissolution medium. The trapped
31
32 ketoprofen particles dissolve and are saturated, then diffuse from the gel. Simultaneously the rate of
33
34 CA-LBG disintegrating tablets into granules is proportional to gel formation. The dissolving of
35
36 ketoprofen comes from the ketoprofen particles in contact with the gel surface. The balanced
37
38 concentrations of HPMC and CA-LBG formed a gel with a constant thickness. These conditions can
39
40 control the diffusion and maintain the availability of saturated ketoprofen dissolved in the gel.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 3. The value of the kinetics parameters of the release of ketoprofen from tablets.

Formula code	Parameter	Zero order		First order		Higuchi		Korsmeyer-Peppas		Hixson-Crowell		Weibull		Kinetics model
		average	SD	average	SD	average	SD	average	SD	average	SD	average	SD	
G1	Rsqr_adj	0.8762	0.02	0.9441	0.01	0.9585	0.00	0.9776	0.01	0.9279	0.01	0.9333	0.00	Korsmeyer-Peppas
	MSE_root	5.2625	0.35	3.5357	0.26	3.0468	0.20	2.2216	0.34	4.0144	0.29	3.8687	0.11	
	AIC	70.5951	1.56	61.0431	1.72	57.4597	1.61	50.6125	3.52	64.0907	1.71	64.8308	0.66	
G2	Rsqr_adj	0.8049	0.01	0.9687	0.00	0.9861	0.00	0.9948	0.00	0.9426	0.01	0.9536	0.00	Korsmeyer-Peppas
	MSE_root	10.6069	0.28	4.2456	0.22	2.8232	0.37	1.7379	0.16	5.7451	0.32	5.1742	0.23	
	AIC	87.4453	0.63	65.4533	1.28	55.5400	3.24	44.8284	2.23	72.7095	1.35	71.7991	1.08	
G3	Rsqr_adj	0.9395	0.00	0.9296	0.01	0.8689	0.01	0.9113	0.01	0.9401	0.01	0.8651	0.01	Hixson-Crowell
	MSE_root	4.5672	0.13	4.9223	0.35	6.7233	0.38	5.5235	0.47	4.5427	0.27	6.8225	0.28	
	AIC	67.2211	0.72	68.9849	1.70	76.4828	1.36	72.5897	2.03	67.0722	1.38	78.4392	0.96	
G4	Rsqr_adj	0.8597	0.02	0.9358	0.01	0.9657	0.01	0.9777	0.01	0.9171	0.01	0.9414	0.01	Korsmeyer-Peppas
	MSE_root	5.4444	0.33	3.6827	0.21	2.6858	0.34	2.1496	0.36	4.1855	0.25	3.5175	0.31	
	AIC	71.4154	1.46	62.0355	1.40	54.3575	3.04	49.7755	3.97	65.1033	1.48	62.4881	2.17	
G5	Rsqr_adj	0.8594	0.01	0.6528	0.10	0.8570	0.01	0.9057	0.00	0.9231	0.00	0.9025	0.00	Hixson-Crowell
	MSE_root	13.6548	0.48	21.3289	3.31	13.7776	0.45	11.1888	0.34	10.1039	0.28	11.3789	0.30	
	AIC	93.5029	0.85	104.0112	3.90	93.7193	0.79	89.5817	0.73	86.2787	0.67	90.7234	0.63	
G6	Rsqr_adj	0.6618	0.02	0.8583	0.01	0.9945	0.00	0.9935	0.00	0.8093	0.01	0.9762	0.00	Higuchi
	MSE_root	9.9176	0.17	6.4175	0.16	1.2626	0.07	1.3745	0.10	7.4459	0.16	2.6266	0.17	
	AIC	85.8359	0.41	75.3863	0.60	36.3490	1.26	39.2239	1.71	78.9547	0.53	55.5081	1.61	
G7	Rsqr_adj	0.9360	0.01	0.9304	0.00	0.8758	0.01	0.9093	0.01	0.9398	0.00	0.8675	0.00	Hixson-Crowell
	MSE_root	4.7248	0.28	4.9359	0.11	6.5870	0.32	5.6328	0.20	4.5899	0.09	6.8079	0.13	
	AIC	68.0154	1.40	69.0873	0.55	75.9974	1.20	73.1077	0.84	67.3448	0.45	78.3976	0.46	
G8	Rsqr_adj	0.8582	0.01	0.7246	0.05	0.8753	0.01	0.9180	0.00	0.9286	0.01	0.9112	0.00	Hixson-Crowell
	MSE_root	13.3691	0.17	18.5895	1.66	12.5351	0.46	10.1662	0.37	9.4845	0.43	10.5795	0.28	
	AIC	93.0042	0.30	100.8549	2.10	91.4435	0.88	87.2783	0.87	84.7498	1.10	88.9752	0.63	

continue to the next page

Table 3. The value of the kinetics parameters of the release of ketoprofen from tablets.

Formula code	Parameter	Zero order		First order		Higuchi		Korsmeyer-Peppas		Hixson-Crowell		Weibull		Kinetics model
		average	SD	average	SD	average	SD	average	SD	average	SD	average	SD	
Ga	Rsqr_adj	0.9241	0.01	0.8628	0.01	0.7995	0.02	0.8441	0.02	0.8883	0.01	0.7823	0.03	Zero order
	MSE_root	5.7889	0.30	7.7879	0.24	9.4113	0.50	8.2963	0.58	7.0194	0.51	9.8002	0.73	
	AIC	72.8966	1.22	80.0290	0.73	84.5579	1.28	82.3715	1.68	77.5002	1.76	87.0994	1.81	
Gb	Rsqr_adj	0.9273	0.00	0.8670	0.01	0.8107	0.01	0.8481	0.02	0.8956	0.01	0.7874	0.03	Zero order
	MSE_root	5.6548	0.09	7.6500	0.20	9.1233	0.40	8.1484	0.47	6.7739	0.32	9.6602	0.66	
	AIC	72.3524	0.40	79.6025	0.62	83.8190	1.06	81.9522	1.39	76.6707	1.14	86.7613	1.66	
Gc	Rsqr_adj	0.9273	0.01	0.8648	0.01	0.8044	0.01	0.8408	0.02	0.8920	0.01	0.7809	0.03	Zero order
	MSE_root	5.6764	0.38	7.7581	0.22	9.3364	0.37	8.4134	0.49	6.9321	0.30	9.8658	0.69	
	AIC	72.4101	1.62	79.9382	0.68	84.3764	0.94	82.7199	1.40	77.2270	1.07	87.2649	1.70	

The ketoprofen release kinetics model of various tablet formulas contains HPMC [%] and CA-LBG [%]: G1 (40 : 10); G2 (32.5 : 17.5); G3 (35 : 15); G4 (40 : 10); G5 (30 : 20); G6 (37.5 : 12.5); G7 (35 : 15); G8 (30 : 20); Ga (32.97 : 17.03); Gb (32.97 : 17.03); and Gc (32.97 : 17.03).

Conclusion

HPMC and CA-LBG increased the value of angle of repose, tap index, hardness, friability, and release of ketoprofen. The combination of HPMC with CA-LBG increased the angle of repose, tap index, and hardness. Besides, the combination decreased friability and release of ketoprofen. The optimum concentrations of HPMC and CA-LBG for controlled-release tablets is 32.97% and 17.03%, resulting in the angle of repose of 29.16⁰; tap index of 20.01%; hardness of 13.91 kp; friability of 0.41%; and the drug release (10 hours) of 80%. The drug release kinetics from optimum tablets followed zero order. The constant thickness of gel can control the diffusion and maintain the saturated ketoprofen in the gel. CA-LBG as a negative matrix disintegrates tablets into granules. HPMC as a gel matrix controlled ketoprofen release by diffusion and erosion. The tablets did not produce a ghost matrix because the gel matrix came from granules which degraded quickly after all the ketoprofen was released.

Associated Content

Supporting Information

Tablet dosage calculation; Statistical analysis of ketoprofen tablets; The release of ketoprofen from tablets (G1-G8); The release of ketoprofen from optimum tablets (Ga-Gc); and The kinetics profile of ketoprofen release from tablets (G1-G8) (Ga-Gb)

Acknowledgment

The author would like to thank PT. Makmur Food (Indonesia) has assisted with locust bean gum (viscogum); LPPT Gadjah Mada University (Indonesia) for NMR testing; Faculty of Pharmacy, Gadjah Mada University (Indonesia) for pharmaceutical technology facilities; Faculty of Pharmacy Widya Mandala Surabaya Catholic University (Indonesia) for testing FTIR, viscometer, and

pharmaceutical technology equipment; and Widya Mandala Surabaya Catholic University (Indonesia) for funding the publication of this article.

Declarations

Competing interest statement

The authors declare that authors have no conflict of interest.

Author contribution statement

Wuryanto Hadinugroho: designed the experiments, performed the experiments, analyzed and interpreted the data, wrote the manuscript. Suwaldi Martodihardjo, Achmad Fudholi, Sugeng Riyanto and, Jefri Prasetyo: analyzed and interpreted the data.

Author Information

Corresponding author

Wuryanto Hadinugroho - Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Kalisari Selatan no. 1 Pakuwon City, Surabaya, Indonesia; Email: wuryanto.hadinugroho@gmail.com.

Authors

Suwaldi Martodihardjo - Faculty of Pharmacy, Gadjah Mada University, Sekip Utara, Yogyakarta, Indonesia; Email: waldi_ugm@yahoo.com

Achmad Fudholi - Faculty of Pharmacy, Gadjah Mada University, Sekip Utara, Yogyakarta, Indonesia; Email: fudholi_fa@ugm.ac.id

Sugeng Riyanto - Faculty of Pharmacy, Gadjah Mada University, Sekip Utara, Yogyakarta, Indonesia; Email: sugeng_riyanto51@yahoo.com

Jefri Prasetyo - Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Kalisari
Selatan no. 1 Pakuwon City, Surabaya, Indonesia; Email: jefri@ukwms.ac.id

REFERENCES

(1) Li, C.L.; Martini, L.G.; Ford, J.L.; Roberts, M. The use of hypromellose in oral drug delivery. *J Pharm Pharmacol.* **2010**, *57*, 533-546. doi: 10.1211/0022357055957

(2) Oliveira, P.R.; Mendes, C.; Klein, L.; Sangoi, M.D.S., Bernardi, L.S.; Silva, M.A.S. Formulation development and stability studies of norfloxacin extended-release matrix tablets. *Biomed Res Int.* **2013**, *2013*, 1-9. doi: 10.1155/2013/716736

(3) Contreras, L.; Melgoza L.M.; Leyva A.A.D.; Caraballo I. Collaboration between HPMC and NaCMC in order to reach the polymer critical point in theophylline hydrophilic matrices. *Sci World J.* **2012**, *2012*, 1-8. doi: 10.1100/2012/171292

(4) Enayatifard. R.; Saeedi, M.; Akbari, J.; Tabatabaee, Y.H. Effect of hydroxypropyl methylcellulose and ethyl cellulose content on release profile and kinetics of diltiazem HCl from matrices. *Trop J Pharm Res.* **2009**, *8*, 425-432. doi: 10.4314/tjpr.v8i5.48086

(5) Sheskey, P.J.; Cook, W.G.; Cable, C.G. Handbook of Pharmaceutical Excipients 8th. Pharmaceutical Press and American Pharmacists Association: London-Washington DC, **2017**; pp.282-284

(6) Hadinugroho, W.; Martodihardjo, S.; Fudholi, A.; Riyanto, S. Study of a catalyst of citric acid crosslinking on locust bean gum. *J Chem Technol Metall.* **2017**, *52*, 1086-1091

(7) Hadinugroho, W.; Martodihardjo, S.; Fudholi, A.; Riyanto, S.; Esterification of citric acid with locust bean gum. *Heliyon.* **2019**, *5*, 1-9. doi: 10.1016/j.heliyon.2019.e02337

(8) Santiago, E.V.; Lopez, S.H.A.; Romero, A.R. Photochemical cross-linking study of polymers containing diacetylene groups in their main chain and azobenzene compounds as pendant

- groups. *Superf y vacío*. **2006**, *19*, 1-7
- (9) Tamaki, Y.; Teruya, T.; Tako, M. The chemical structure of galactomannan isolated from seeds of *Delonix regia*. *Biosci Biotechnol Biochem*. **2010**, *74*, 1110-1112. doi: 10.1271/bbb.90935
- (10) Tjandraatmadja, G.F.; Burn, L.S.; Jollands, M.J. The effects of ultraviolet radiation on polycarbonate glazing. *Proc 8th Int Conf Durab Build Constr Mater Vancouver, Canada*. **1999**, *30*, 884-898
- (11) Yeh, C.C.; Chen, C.N.; Li, Y.T.; Chang, C.W.; Cheng, M.Y.; Chang, H.I. The effect of polymer molecular weight and UV radiation on physical properties and bioactivities of PCL films. *Cell Polym*. **2011**, *30*, 261-276. doi: 10.1177/026248931103000503
- (12) Lam, M.; Nokhodchi, A. Producing High-Dose Liqui-Tablet (Ketoprofen 100 mg) for Enhanced Drug Release Using Novel Liqui-Mass Technology. *J Pharm Innov*. **2021**, 1-13. doi: 10.1007/s12247-021-09561-6
- (13) Kaleemullah, M.; Jiyauddin, K.; Thiban, E.; Rasha, S.; Al-Dhalli, S.; Budiasih, S.; Gamal, O.E.; Fadli, A.; Eddy, Y. Development and evaluation of Ketoprofen sustained release matrix tablet using *Hibiscus rosa-sinensis* leaves mucilage. *Saudi Pharm J*. **2017**, *25*, 770-779. doi: 10.1016/j.jsps.2016.10.006
- (14) Hadinugroho, W.; Martodihardjo, S.; Fudholi, A.; Riyanto S. Preparation of Citric Acid-Locust Bean Gum (CA-LBG) for the Disintegrating Agent of Tablet Dosage Forms. *J Pharm Innov*. **2021**, 1-16. doi: 10.1007/s12247-021-09591-0
- (15) Gulrez, S.K.H.; Al-Assaf, S.; Phillips, G.O. Hydrogels: Methods of Preparation, Characterisation and Applications. In: *Progress in Molecular and Environmental Bioengineering - From Analysis and Modeling to Technology Applications*. **2011**. doi: 10.5772/24553
- (16) Davies, P. Oral Solid Dosage Forms. In: *Pharmaceutical Preformulation and Formulation*. 2nd, vol 199. Gibson, M. (Ed). New York: Informa Healthcare USA, Inc; **2009**; pp. 368-369 doi:

10.1201/b14413-17

- (17) Aulton, E.; Taylor, K.M.G. *Aulton's Pharmaceutics The Design and Manufacture of Medicines*. Churchill Livingstone Elsevier: New York, **2017**; pp. 187-199
- (18) Merkkü, P.; Lindqvist, A.S.; Leiviska, K.; Yliruusi, J. Influence of granulation and compression process variables on flow rate of granules and on tablet properties, with special reference to weight variation. *Int J Pharm.* **1994**, *102*, 117-125. doi: 10.1016/0378-5173(94)90046-9
- (19) Szumilo, M.; Belniak, P.; Swiader, K.; Holody, E.; Poleszak, E. Assessment of physical properties of granules with paracetamol and caffeine. *Saudi Pharm J.* **2017**, *25*, 900-905. doi: 10.1016/j.jsps.2017.02.009
- (20) The United States Pharmacopeial Convention. *Pharmacopeia 41-National Formulary 36*. Twinbrook Parkway: Rockville, **2018**; pp.7634-7635
- (21) Wahab, A.; Khan, G.M.; Akhlaq, M.; Khan, N.R.; Hussain, A.; Khan, M.F.; Ur-Rehman, N.; Khan, A. Formulation and evaluation of controlled release matrices of ketoprofen and influence of different co-excipients on the release mechanism. *Pharmazie.* **2011**, *66*, 677-683. doi.org/10.1691/ph.2011.1040
- (22) Craciun, A.M.; Barhalescu, M.L.; Agop, M.; Ochiuz, L. Theoretical Modeling of Long-Time Drug Release from Nitrosalicyl-Imine-Chitosan Hydrogels through Multifractal Logistic Type Laws. *Comput Math Methods Med.* **2019**, *2019*, 1-9. doi.org/10.1155/2019/4091464
- (23) Panotopoulos, G.P.; Haidar, Z.S. Mathematical modeling for pharmacokinetic predictions from controlled drug release nano systems: A comparative parametric study. *Biomed Pharmacol J.* **2018**, *11*, 1801-1806. doi.org/10.13005/bpj/1552
- (24) Simionato, L.D.; Petrone, L.; Baldut, M.; Bonafede, S.L.; Segall, A.I. Comparison between the dissolution profiles of nine meloxicam tablet brands commercially available in Buenos Aires, Argentina. *Saudi Pharm J.* **2018**, *26*, 578-84. doi: 10.1016/j.jsps.2018.01.015
- (25) Jahromi, L.P.; Ghazali, M.; Ashrafi, H.; Azadi, A. A comparison of models for the analysis of


- the kinetics of drug release from PLGA-based nanoparticles. *Heliyon*. **2020**, 6, 1-9. doi: 10.1016/j.heliyon.2020.e03451
- (26) Nandiyanto, A.B.D.; Oktiani, R. Ragadhita, R. How to read and interpret ftir spectroscopy of organic material. *Indones J Sci Technol*. **2019**, 4, 97-118. doi: 10.17509/ijost.v4i1.15806
- (27) Coates J. Interpretation of Infrared Spectra A Practical Approach. In: *Encycl Anal Chem*. Meyers, R.A (Ed). John Wiley & Sons Ltd: Chichester. **2000**; pp.10815-37. doi: 10.1002/9780470027318.a5606
- (28) Azero, E.G.; Andrade, C.T. Characterisation of Prosopis juliflora seed gum and the effect of its addition to κ -carrageenan systems. *J Braz Chem Soc*. **2006**, 17, 844-850. doi: 10.1590/S0103-50532006000500005
- (29) Parvathy, K.S.; Susheelamma, N.S.; Tharanathan, R.N.; Gaonkar, A.K. A simple non-aqueous method for carboxymethylation of galactomannans. *Carbohydr Polym*. **2005**, 62, 137-141. doi: 10.1016/j.carbpol.2005.07.014
- (30) Gillet, S.; Aguedo, M.; Blecker, C.; Jacquet, N.; Richel, A. Use of ^{13}C -NMR in Structural Elucidation of Polysaccharides: Case of Locust Bean Gum. *Young Belgium Magnetic Resonance Scientist*. Liège. 2014.
- (31) Gu, Y.; Wei, H.L.; Balikhin, M.M. Nonlinear predictive model selection and model averaging using information criteria. *Syst Sci Control Eng*. **2018**, 6, 319-28. doi: 10.1080/21642583.2018.1496042
- (32) Mircioiu, C.; Voicu, V.; Anuta, V.; Tudose, A.; Celia, C.; Paolino, D.; Fresta, M.; Sandulovici, R.; Mircioiu, I. Mathematical modeling of release kinetics from supramolecular drug delivery systems. *Pharmaceutics*. **2019**, 11, 1-45. doi.org/10.3390/pharmaceutics11030140
- (33) Siswanto, A.; Fudholi, A.; Nugroho, A.K.; Martono, S. in Vitro Release Modeling of Aspirin Floating Tablets Using DDSolver. *Indones J Pharm*. **2015**, 26, 94-102. doi.org/10.14499/indonesianjpharm26iss2pp94

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(34) Zuo, J.; Gao, Y.; Bou-Chacra, N.; Löbenberg, R. Evaluation of the DDSolver software applications. *Biomed Res Int.* **2014**, *2014*, 1-10. doi: 10.1155/2014/204925

(35) Zhang, Y.; Huo, M.; Zhou, J.; Zou, A.; Li, W.; Yao, C.; Xie, S. DDSolver: An add-in program for modeling and comparison of drug dissolution profiles. *AAPS J.* **2010**, *12*, 263–271. doi.org/10.1208/s12248-010-9185-1

(36) Dash, S.; Murthy, P.N.; Nath, L.; Chowdhury, P. Kinetic modeling on drug release from controlled drug delivery systems. *Acta Pol Pharm - Drug Res.* **2010**, *67*, 217-223



338x190mm (96 x 96 DPI)

Response to Reviewer comments

Comment of Reviewer 1

The paper 'Citric acid-locust bean gum as a negative matrix for controlled release tablet' can be accepted after major revision. The following comments should be addressed.

Comments:

1. 'HPMC as hydrogel matrix and CA-LBG as negative matrix on controlled-release tablet formulation. In addition, the study was to determine the effect of CA-LBG and HPMC':

Here already it is said positive effect of HPMC.....so why again it is said to determine the effect of CA-LBG and HPMC?

Response:

Thank you for the comment and the suggestions. The influence in question is specific. The higher the concentration of CA-LBG or HPMC, the increases or decreases drug release. The coefficient value of the polynomial equation for each response parameter. If there is a positive sign (+) in the equation is concluded to increase and a negative sign (-) is concluded to decrease. If the higher the coefficient value is, the dominance of the influence is higher.

An example of a ketoprofen release equation:

$$Y = 52.48 A + 99.44 B - 26.36 AB$$

The CA-LBG coefficient value (+99.44) was the most dominant factor in increasing ketoprofen release, followed by HPMC (+52.48). The combination of both (-26.36) was the most dominant factor in reducing the release of ketoprofen.

2. 'granulation method dan ketoprofen' There is typo error.

Response:

Thank you for the comment and the suggestions. The correction has been fixed as follows: 'granulation method **and** ketoprofen'

3. Why Solubility study of CA-LBG was done? The method which is adopted, has any reference.

Response:

Thank you for the comment and the suggestions. CA-LBG solubility studies were carried out to ensure the physicochemical properties (solubility) of CA-LBG were available before being used in tablets. This is a pre-formulation study usually carried out before the formulation of pharmaceutical preparations.

4. The similar works have already been done by authors. What is the novelty of this paper?

Response:

Thank you for the comment and the suggestions. Compared to previous articles, the update in this manuscript is that CA-LBG is applied as a negative matrix in combination with HPMC to control drug release from tablets. This manuscript demonstrates the specific effect of HPMC or

CA-LBG on the quality of tablets and controlling drug release. In addition, the manuscript indicates the optimum concentration of HPMC and CA-LBG in tablets to control drug release. Previous article:

Hadinugroho et al., 2019 determined the optimum conditions for making CA-LBG and its characterization. In addition, we show the potential of CA-LBG singly to control drug release compared to LBG (locust bean gum).

Hadinugroho et al., 2021 produce CA-LBG according to the optimum conditions and its characterization. In addition, we are applying CA-LBG singly as a tablet disintegrating agent. These three topics are ongoing experiments to explore the potential of CA-LBG in pharmaceutical formulations.

5. Why flow ability and tap index were measured for tablet mass instead of granules?

Response:

Thank you for the comment and the suggestions. Granules are solid grains containing HPMC and CA-LBG. The tablet mass is granules (HPMC & CA-LBG) mixed with ketoprofen particles. Materials that can be compressed into tablets have good flow properties. In this experiment, the material to be compressed into tablets was granules (HPMC & CA-LBG) mixed with ketoprofen particles. Hence, the tablet mass had to be evaluated for its flow quality.

6. 'dissolution apparatus II USP paddle model' IT will be USP II

Response:

Thank you for the comment and the suggestions. The correction has been fixed as follows: dissolution apparatus **USP II** paddle model'

7. release of ketoprofen is expressed as Dr. Can it modified?

Response:

Thank you for the comment and the suggestions. 'Dr' was fixed by replacing '**Ketoprofen released**'

8. Can HPMC and CA-LBG network will interpenetrate? If it is so, then discuss on this. [citations removed by the editorial office].


Response:

Thank you for the comment and the suggestions. HPMC and CA-LBG particles can mix physically. Random distribution of HPMC and CA-LBG particles in granules. When these particles expand, the network of the two types of polymers can physically interact with each other (penetrate each other). In this condition, ketoprofen particles can be between these tissues so that these tissues control the release of ketoprofen. Ketoprofen release via diffusion or erosion mechanisms. The release of ketoprofen was studied through the kinetics of drug release.

9. This paper needs one graphical abstract.

Response:

Thank you for the comment and the suggestions. We have provided a graphical abstract for this paper, as follows:



10. simplex lattice design of two factors used eight runs should be shown in the manuscript.

Response:

Thank you for the comment and the suggestions. The simplex lattice design of two factors of eight runs (G1-G8) according to the Design Expert software is shown in Table 2. The concentration of HPMC and CA-LBG (Columns 3 & 4) as optimization factors. The proportions of the two factors were randomized according to the Design Expert design. Columns 4-10 are the results of evaluating the physical quality of the mass of tablets, tablets, and released ketoprofen. The evaluation parameters that become the optimization response are the angle of repose (column 5), tap index (column 6), hardness (column 8), friability (column 9), and released ketoprofen (column 10). All responses were analyzed according to Design Expert to produce polynomial equations, optimal proportions of optimization factors (Go) (columns 2 & 3), and predictions of optimization responses (Go) (columns 5, 6, 8, 9, & 10). As a result of the analysis, the concentrations of the two factors were verified by experiment (Ga-Gc) (columns 2 & 3). Results of the evaluation of the verification experiment (Ga-Gc) (columns 4-10). The value of each optimization response verification experiment was tested for similarity by t-test.

Additional Questions:

Is the technical quality of the research reported within valid and appropriate?: Yes

Please evaluate the degree of novelty and originality of the research reported: Good

Are the conclusions adequately supported by the data presented?: Yes

Are the literature references appropriate and up to date?: No

Response:

Thank you for the comment.

Comment of Reviewer 2

Journal: ACS Omega

Manuscript ID: ao-2022-07432u

Title of the Manuscript: Citric acid-locust bean gum as a negative matrix for controlled release tablet

In general, the present work determines the optimum concentration of HPMC as hydrogel matrix and citric acid-locust bean gum as negative matrix on controlled-release tablet formulation. The LGB and CA-LBG are characterized by the FTIR and NMR. Further, these tablets are evaluated by the dan ketoprofen drug release applications. As over all the work is well organed; results and discussions are well adequate. Hence the manuscript is recommended for publication with minor revision.

In specific

1. HPMC need be elaborated at once in starting of the manuscript and also need to appear in the title of the manuscript.

Response:

Thank you for the comment and the suggestions. The correction has been fixed at the beginning of the manuscript and the title of the manuscript.

The start of the manuscript**before revision**

This study aimed to determine the optimum concentration of HPMC as hydrogel matrix and citric acid-locust bean gum (CA-LBG) as negative matrix on controlled-release tablet formulation.

after revision

This study aimed to determine the optimum concentration of **hydroxypropyl methylcellulose** (HPMC) as hydrogel matrix and **citric acid-locust bean gum** (CA-LBG) as negative matrix on controlled-release tablet formulation.

Manuscript title**before revision**

Citric acid-locust bean gum as a negative matrix for controlled release tablet

after revision

Hydroxypropyl methylcellulose as hydrogel matrix and citric acid-locust bean gum as a negative matrix for controlled release tablet

2. Page 2 line 25 'dan ketoprofen'? check this.

Response:

Thank you for the comment and the suggestions. The correction has been fixed as follows: 'and ketoprofen'

3. Page no 5 line 12 "Manufacture of CA-LBG" it is need to correct as 'Preparation of CA-LBG matrix'; 'manufacture' word may be removed for the manuscript and use appropriate word.

Response:

Thank you for the comment and the suggestions. We have corrected the sentence "Manufacture of CA-LBG" in the manuscript with the sentence "Preparation of CA-LBG matrix"

4. It is not clear that 'CA-LBG gel' structure, either is chemical crosslinking or physical crosslinking, need to discuss in detail.

Response:

Thank you for the comment and the suggestions. We have added a description of the reaction mechanism in the section on Fourier transform infrared spectroscopy.

The reaction mechanism for making CA-LBG is a chemical esterification reaction. The reaction begins with the citric acid carbonyl group undergoing protonation and reacting with the hydroxyl group (OH) on the C-6 mannose and galactose atoms to form a tetrahedral cation. Oxygen in the OH undergoes protonation ($^+OH_2$) to form loose OH so that the loss of H_2O and an ester (CA-LBG) is formed (Hadinugroho, et al., 2019). Illustrations of the reaction mechanism can be studied further in previous studies (Hadinugroho, et al., 2019).


5. In the FTIR, X-axis need to labled as 'Wavenumber (cm-1)'; H1 NMR spectrum need to provide 0-10 ppm also need to provide the units on X-axis

Response:

Thank you for the comment and the suggestions. A third institution conducted the evaluation using NMR due to the unavailability of instruments at our institution. The signal interval (ppm) of the spectra shown in the manuscript corresponds to the printout provided by the examining agency. Signal interval recording is performed only at signal intervals that appear optimum. We attach the original spectra. Sorry for the limitations of this condition.

We have corrected the correction on the X-axis by adding the identity $[\delta]$ and units [ppm].

Original spectra



¹H NMR original spectra

before revision




Figure 1. Infrared spectra of CA-LBG and LBG. The CA-LBG spectra have a carbonyl ester group (C=O) at a wavelength of 1736.02 cm^{-1} , presented by a blue line. LBG as control, presented with a red line.

after revision




Figure 1. Infrared spectra of CA-LBG and LBG. The CA-LBG spectra have a carbonyl ester group (C=O) at a wavelength of 1736.02 cm^{-1} , presented by a blue line. LBG as control, presented with a red line.

before revision




Figure 2. NMR observation spectra of CA-LBG. CA characters present in CA-LBG resented peaks 1, 2, 3, 4, and 5.
after revision




Figure 2. NMR observation spectra of CA-LBG. CA characters present in CA-LBG resented peaks 1, 2, 3, 4, and 5.

Additional Questions:

Is the technical quality of the research reported within valid and appropriate?: Yes

Please evaluate the degree of novelty and originality of the research reported: Good

Are the conclusions adequately supported by the data presented?: Yes

Are the literature references appropriate and up to date?: Yes

Response:

Thank you for the comment.

Hadinugroho, Wuryanto ao-2022-07432u.R1 - Manuscript Revision Request - Formatting Changes 06-Feb-2023

Dari: ACS Omega (onbehalf@manuscriptcentral.com)

Kepada: wuryanto.hadinugroho@gmail.com

Tanggal: Senin, 6 Februari 2023 pukul 17.18 GMT+7

06-Feb-2023

Journal: ACS Omega

Manuscript ID: ao-2022-07432u.R1

Title: "Hydroxypropyl methylcellulose as hydrogel matrix and citric acid-locust bean gum as a negative matrix for controlled release tablet"

Author(s): Hadinugroho, Wuryanto; Martodihardjo, Suwaldi; Fudholi, Achmad; Riyanto, Sugeng; Prasetyo, Jefri

Dear Dr. Hadinugroho:

Thank you for submitting your manuscript to ACS Omega.

We are pleased to inform you that your manuscript ao-2022-07432u.R1 is about to be accepted for publication in ACS Omega. Prior to formal acceptance please perform the following formatting changes:

- Remove color from the Manuscript file text.
- In reviewing the files it came to our attention that there is a title discrepancy:

In Paragon Plus and Manuscript file it appears as:

Hydroxypropyl methylcellulose as hydrogel matrix and citric acidlocust bean gum as a negative matrix for controlled release tablet

In Supporting file it appears as:

Citric acid-locust bean gum as a negative matrix for controlled release tablet

Please address this issue.

To revise your manuscript, log into ACS Paragon Plus with your ACS ID at <http://acsparagonplus.acs.org/> and select "My Authoring Activity". There you will find your manuscript title listed under "Revisions Requested by Editorial Office." Your original files are available to you when you upload your revised manuscript. If you are replacing files, please remove the old version of the file from the manuscript before uploading the new file.

Please upload manuscript file that is free of any annotations or highlights.

I would be pleased to receive the revised manuscript by 10-Feb-2023 at the latest, with the corrections of the mentioned issues.

Funding Sources: Authors are required to report ALL funding sources and grant/award numbers relevant to this manuscript. Enter all sources of funding for ALL authors relevant to this manuscript in BOTH the Open Funder Registry tool in ACS Paragon Plus and in the manuscript to meet this requirement. See http://pubs.acs.org/page/4authors/funder_options.html for complete instructions.

ORCID: Authors submitting manuscript revisions are required to provide their own validated ORCID iDs before completing the submission, if an ORCID iD is not already associated with their ACS Paragon Plus user profiles. This iD may be provided during original manuscript submission or when submitting the manuscript revision. You can provide only your own ORCID iD, a unique researcher identifier. If your ORCID iD is not already validated and associated with your ACS Paragon Plus user profile, you may do so by following the ORCID-related links in the Email/Name section of your ACS Paragon Plus account. All authors are encouraged to register for and associate their own ORCID iDs with their ACS Paragon Plus profiles. The ORCID iD will be displayed in the published article for any author on a manuscript who

has a validated ORCID iD associated with ACS Paragon Plus when the manuscript is accepted. Learn more at <http://www.orcid.org>.

In publishing only original research, ACS is committed to deterring plagiarism, including self-plagiarism. ACS Publications uses Crossref Similarity Check Powered by iThenticate to screen submitted manuscripts for similarity to published material, and other software to screen previous submissions to ACS journals. Note that your manuscript may be screened during the submission process.

We look forward to seeing your paper in ACS Omega.

Sincerely,

Dr. Krishna Ganesh
Coeditor
ACS Omega
Phone: (202) 657-6323
Email: Ganesh-office@omega.acs.org

PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at pubs-comms-unsub@acs.org if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

Hadinugroho, Wuryanto ao-2022-07432u.R2 - Revised Manuscript Submission to ACS Omega 06-Feb-2023

Dari: ACS Omega (onbehalfof@manuscriptcentral.com)

Kepada: wuryanto.hadinugroho@gmail.com

Cc: wuryanto.hadinugroho@gmail.com; waldi_ugm@yahoo.com; fudholi_fa@ugm.ac.id; sugeng_riyanto51@yahoo.com; jefri@ukwms.ac.id

Tanggal: Senin, 6 Februari 2023 pukul 23.27 GMT+7

06-Feb-2023

Journal: ACS Omega

Manuscript ID: ao-2022-07432u.R2

Title: "Hydroxypropyl methylcellulose as hydrogel matrix and citric acid-locust bean gum as a negative matrix for controlled release tablet"

Authors: Hadinugroho, Wuryanto; Martodihardjo, Suwaldi; Fudholi, Achmad; Riyanto, Sugeng; Prasetyo, Jefri

Manuscript Status: Submitted

Dear Dr. Hadinugroho:

Your manuscript has been successfully submitted to ACS Omega, a multidisciplinary, open access journal for the publication of original and scientifically valid research. The journal offers expedited editorial decision-making and immediate open availability. Authors can rapidly publish their important research results and broadly distribute them to the global scientific community. Please note that there are publishing charges associated with this journal. Details can be found at <http://acsopencscience.org>. Should your manuscript be accepted, you will be required to pay for the Article Publishing Charges prior to publication. Authors may qualify for discounts. Article Publishing Charges are waived for invited Editorials and Perspectives.

Please reference the above manuscript ID in all future correspondence. If there are any changes in your contact information, please log in to ACS Paragon Plus with your ACS ID at <http://acsparagonplus.acs.org/> and select "Edit Your Profile" to update that information.

You can view the status of your manuscript by checking your "Authoring Activity" tab on ACS Paragon Plus after logging in to <http://acsparagonplus.acs.org/>.

Thank you for submitting your manuscript to ACS Omega.

Sincerely,

Dr. Krishna Ganesh and Dr. Deqing Zhang
ACS Omega

PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at pubs-comms-unsub@acs.org if you do not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

Hydroxypropyl methylcellulose as hydrogel matrix and citric acid-locust bean gum as a negative matrix for controlled release tablet

Journal:	ACS Omega
Manuscript ID	ao-2022-07432u.R2
Manuscript Type:	Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Hadinugroho, Wuryanto; Widya Mandala Catholic University Surabaya, Faculty of Pharmacy Martodihardjo, Suwaldi; Gadjah Mada University, Faculty of Pharmacy Fudholi, Achmad; Gadjah Mada University, Faculty of Pharmacy Riyanto, Sugeng; Gadjah Mada University, Faculty of Pharmacy Prasetyo, Jefri; Widya Mandala Catholic University Surabaya, Faculty of Pharmacy

SCHOLARONE™
Manuscripts

Hydroxypropyl methylcellulose as hydrogel matrix and citric acid-locust bean gum as a negative matrix for controlled release tablet

Wuryanto Hadinugroho^{1*}, Suwaldi Martodihardjo², Achmad Fudholi², Sugeng Riyanto², and Jefri Prasetyo¹

1 Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Kalisari Selatan no. 1 Pakuwon City, Surabaya, Indonesia.

2 Faculty of Pharmacy, Gadjah Mada University, Sekip Utara, Yogyakarta, Indonesia.

*Corresponding authors:

Dr. Wuryanto Hadinugroho, Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Kalisari Selatan no. 1 Pakuwon City, Surabaya, 60112, Indonesia.

Email address: wuryanto.hadinugroho@gmail.com

Abstract

Purpose: This study aimed to determine the optimum concentration of hydroxypropyl methylcellulose (HPMC) as hydrogel matrix and citric acid-locust bean gum (CA-LBG) as negative matrix on controlled-release tablet formulation. In addition, the study was to determine the effect of CA-LBG and HPMC. CA-LBG accelerates the disintegration of tablets into granules so that the HPMC granule matrix swells immediately and controls drug release. The advantage of this method is that the tablets do not produce large HPMC gel lumps without drug (ghost matrix) but form HPMC gel granules which can be rapidly degraded after all the drug is released.

Methods: The experiment followed the simplex lattice design to obtain the optimum tablet formula with CA-LBG and HPMC concentrations as optimization factors. Tablets production by wet granulation method and ketoprofen is the model of the active ingredient. The kinetics of ketoprofen release was studied using several models.

Results: Based on the coefficients of each polynomial equation that HPMC and CA-LBG increased the value of angle of repose (29.91 : 27.87), tap index (18.99 : 18.77), hardness (13.60 : 13.32), friability (0.41 : 0.73), and release of ketoprofen (52.48 : 99.44). Interaction of HPMC and CA-LBG increased the value of angle of repose (3.25), tap index (5.64), and hardness (2.42). Interaction of HPMC and CA-LBG too decreased the value friability (-1.10), and release of ketoprofen (-26.36). The Higuchi, Korsmeyer-Peppas, and Hixson-Crowell model is the kinetics of eight experimental tablet formulas.

Conclusion: The optimum concentrations of HPMC and CA-LBG for controlled release tablets are 32.97% and 17.03%. HPMC, CA-LBG, and a combination of both affect the physical quality of tablet and tablet mass. CA-LBG is a new excipient candidate that can control drug release from tablets by matrix disintegration mechanism on the tablet.

Keywords:

CA-LBG, citric acid, locust bean gum, control release, optimization

Introduction

Controlled-release tablets are drug delivery systems to prolong the therapeutic effect. The drug is released slowly and continuously over some time. Ion exchange resins, osmotic pumps, and reservoirs are examples of controlled release systems.^{1,2} HPMC is one of the polymers often used to control drug release because the HPMC matrix can trap drug particles and release them slowly. HPMC matrices alone or with other polymers are often used to control drug release.³⁻⁵

CA-LBG is a new ester polymer derived from locust bean gum. CA-LBG is synthesized using a hydrochloric acid (HCl) catalyst and an ultraviolet light (UV 254 nm) energy source. O atoms of the carbonyl group of CA are to be protonated to form positive C atoms because of acid conditions created by HCl. The ester bond occurs at the OH (C-6) mannose and galactose groups in LBG with a positive C atom from the carbonyl group in CA to form a tetrahedral cation. OH were protonated to $^+\text{OH}_2$, continued loss of H_2O to form CA-LBG (ester).⁶⁻¹¹ Previous experiments reported that CA-LBG has an ester carbonyl group which LBG does not. The viscosity and solubility of CA-LBG are lower than that of LBG.⁷ The CA-LBG character has the potential to control drug release.

This study aimed to determine the optimum concentration of HPMC and CA-LBG on the tablet. on controlled-release tablet formulation. In addition, the study was to determine the effect of CA-LBG and HPMC. The activity of CA-LBG as a negative matrix with HPMC matrix to control drug release was studied by drug release kinetics. The novelty of this experiment is that the formulation using CA-LBG is a new polymer ester with low solubility. The CA-LBG as a negative matrix causes the tablets to disintegrate into granules. HPMC matrix gel derived from granules controls drug release. A negative matrix (CA-LBG) is a substance that causes the tablet's positive matrix (HPMC) to disintegrate into granules. The mechanism of action on tablets is that the wetted tablet surface causes disintegration into granules due to low solubility of CA-LBG and repulsion between CA-LBG particles. Granules containing HPMC swell to control drug release. CA-LBG controls drug release because CA-LBG is poorly soluble and has low viscosity, so CA-LBG inhibits

the wetting and dissolution of drug particles. The advantage of this method is that the tablets do not produce large hydroxypropyl methylcellulose (HPMC) gel lumps without drug (ghost matrix) but form HPMC gel granules which can be rapidly degraded after all the drug is released. Ketoprofen (100 mg) (see supplementary information Chapter S1) is a drug model added to the granules and compressed into tablets (400 mg). HPMC was chosen as the matrix because HPMC is a polymer that can swell when hydrated with water with a viscosity to control drug release.^{1,5} Lactose monohydrate is a suitable filler for tablets because it has good compatibility and high density (1.545 g/cm³).⁵ These character can be suitable for wet granulation methods, so tablets are hard and of the ideal size. Ketoprofen is used in the drug model because ketoprofen has a dose of 25-200 mg and an elimination half-life of 2-4 hours.^{12,13} Making tablets using the wet granulation method can improve the flow properties by increasing the particle size and the compatibility of the tablet mass. CA-LBG particles are shaped like coral-corrugated, HPMC particles like a rhizome, and irregularly shaped lactose monohydrate particles.^{5,7} The experiment followed the simplex lattice design to obtain the optimum tablet formula. This method is quite simple for experiments by mixing internal factors (ingredients) in a formula without the influence of internal factors (process or technology). In addition, this method is quite effective for synthesized materials such as CA-LBG in limited quantities. The optimization factor is the concentration of CA-LBG and HPMC. The optimization response is the angle of repose, tap index, hardness, friability, and ketoprofen release.

Material and methods

Raw materials and chemicals

The materials used in this experiment include locust bean gum (Viscogum, Cargill, France), citric acid monohydrate (Brand KgaA, Darmstadt, Germany), hydrochloric acid (Sigma-Aldrich Chemie, GmbH, USA), distilled water (Sterilized Water For Injection, PT. Otsuka Indonesia), acetone (Cawan Anugerah Chemika, Indonesia), hydroxypropyl methylcellulose (Methocel K4M CR

Premium USP/EP, Colorcon, Singapore), lactose monohydrate (Leprino Foods, UDM, USA), ketoprofen (PT Kalbe Farma Tbk, Indonesia), potassium dihydrogen phosphate (KGaA Darmstadt Germany Brand), and sodium hydroxide (KGaA Darmstadt Germany Brand).

Preparation of CA-LBG matrix

The preparation of CA-LBG adopted the preparation method in the previous study. The LBG (3.55×10^{-6} mol) was swelled in 50 mL of warm distilled water (55-60 °C), added CA (21.00×10^{-3} mol), and HCl (57.40×10^{-3} mol), homogenized for 10 minutes. The gel was irradiated with UV 254 nm for 100 min (8-Watt, CH-4132 Muttentz, Camag, Switzerland), then precipitated (acetone) and washed off (distilled water-acetone). The CA-LBG residue was dried at room temperature.^{7,14}

The success of CA-LBG production was confirmed through the Fourier transform infrared spectroscopy (FTIR) characterization, nuclear magnetic resonance (NMR), solubility, and viscosity. Production is carried out for three batches to determine reproducibility through standard deviation.

Fourier transform infrared spectroscopy

The structure and specific groups of CA-LBG were identified by Fourier transform infrared spectroscopy (UATR Perkin Elmer Spectrum Version 10.4.3.). The observations show that a spectrum wavelength is $4000\text{--}450\text{ cm}^{-1}$. A certain amount of powder is placed on a diamond plate and pressed with a stick on the instrument. Spectra are visible on the monitor and recorded.

Nuclear magnetic resonance

The NMR spectroscopic examination confirmed the structure and specific group of CA-LBG. An amount of CA-LBG powder (5-10 mg) was dispersed in H₂O (deuterium) and stirred for 45 minutes at a vortex. The filtrate was transferred to a glass tube and analyzed by NMR spectroscopy (JEOL RESONANCE ECZ 500R Japan).

Esterified CA

The amount of esterified CA was determined by the degree of esterification. Determination of the degree of esterification adopts the previous experiment.^{7,14} Samples were derived from CA-LBG precipitating solven and washing solution (acetone and distilled water-acetone). Measurements using potentiometry with titrant NaOH (0.2 N) standardized by oxalic acid. The titrant volume endpoint determines the dissolved acid's total concentration [mEq]. The dissolved CA concentration [mEq] was obtained from the difference between the total acid concentration and the HCl concentration. The dissolved CA [gram] weight was obtained from the conversion of dissolved CA [mEq]. The reacted CA was obtained from the difference between the initial CA weight and dissolved CA. The degree of esterification [%] is the ratio of CA reacted with initial CA.

Solubility study

The CA-LBG powder (500 mg) was dispersed in distilled water (50 mL) and stirred for 24 hours (Wd). The swelled powder and filtrate are carefully separated. The filtrate was dried in a water bath (70°C and reweighed (Wds) (Mettler Toledo AL204, Switzerland). The dissolved CA-LBG was determined according to Equation 1:

$$S [\%] = \frac{Wds}{Wd} \cdot 100 \% \quad \text{Equation 1}$$

where the solubility (S), the soluble weight (Wds), and initial dry weight (Wd).¹⁵

Viscosity

The viscosity of CA-LBG was determined by a viscometer (Brookfield LVDV-I Prime, Middleboro, MA, USA). The CA-LBG powder (3% w/v) was swelled in warm distilled water (300 mL, 50-60°C) and allowed to cool to ambient temperature. Spindle No. S61 mounted on Brookfield was dipped on swollen mass and rotated (100 rpm). Viscosity is shown on the monitor and recorded.

Manufacture of tablets

In this experiment, the method of making tablets by wet granulation adopted the previous study with the necessary adjustments.¹⁴ Preparing granules by wet granulation contains HPMC and lactose monohydrate (50 %) according Table 2 (cubic mixer, rotary motor (Erweka)). A homogeneous mixture was moistened with CA-LBG dispersed in distilled water (\pm 5 mL) while being compressed to form a wet granule mass and sieved (mesh No. 18) to form granules. The wet granules were dried in an oven (50⁰C; 15 min; RH 2-5%) (moisture analyzer OHAUS) and re-sieved (mesh No. 20). The granules were mixed with ketoprofen (100 mg) (3:1) and evaluated for the mass quality of the tablets. The tablet mass was compressed to form a 400 mg tablet and hardness \geq 13 kp (single punch, Korch, Germany), assessed for the physical quality of the tablet and dissolution.

Optimization

Optimization of the granule formula according to the simplex lattice design of two factors used eight runs randomized of formulas, model quadratic, and optimization software (Design Expert ver. 10.0.8.0; Stat-Ease Inc., Minneapolis, MN, USA). Comparison of the proportion of HPMC and CA-LBG for each formula based on optimization software (Table 2), including 0:1 (2 formulas); 0.25:0.75 (1 formula); 0.50:0.5 (2 formulas); 0.75:0.25 (1 formula); and 1:0 (2 formulas). The concentration of HPMC in proportion 0 (30%) and proportion 1 (40%), while the concentration of CA-LBG in proportion 0 (10%) and proportion 1 (20%). The HPMC concentration and the CA-LBG concentration were optimization factors. The angle of repose, tap index, hardness, friability, and released ketoprofen were optimization responses. The values of the optimization response parameters were processed using optimization software to obtain polynomial equations and predict the optimum concentrations of HPMC and CA-LBG in granules.

Flowability

The mass of the tablet was weighed at about 50 g and placed on the funnel of a flowability tester (Erweka, Germany). The funnel valve opens, and the tablet mass flows freely. The flowability tester monitor observed the measured flow time of the tablet mass. The cone from tablet mass was measured using infrared to determine the angle of repose and watched on the flowability tester monitor.

Tap Index

The tablet mass was put in a measuring cup (50 mL). The measuring cup was tilted and filled with tablet mass. The filled measuring cup was placed on the volumenometer tap density and tapped 500 taps. Tap index (TI) was determined from the difference between the volume before and after tapping compared to the volume before tapping (Equation 2).^{16–19}

$$TI [\%] = \frac{V_0 - V_1}{V_0} \times 100\% \quad \text{Equation 2}$$

Weight

From randomly selected tablets (20), and each tablet was weighed using an analytical balance (Mettler Toledo, Switzerland).

Hardness

Tablet hardness test used randomly selected tablets (6 tablets).²⁰ The tablets were placed on a board in a hardness tester (Schleuniger, Netherlands), then a metal block pressed on the tablet until the tablet cracks. The tablet hardness was observed on the monitor hardness tester.

Friability

The tablet friability test used randomly selected tablets with a total weight of comparable tablets of 6500 mg.²⁰ Each tablet was cleaned from dust, then all tablets were weighed (W0). All tablets were placed in a drum friability tester (Erweka, Germany) and rotated (4 min; 25 rpm). All tablets were removed, cleaned from dust, and reweighed (W1). The friability (F) of tablets is determined according to Equation 3.

$$Fr (\%) = \frac{W0 - W1}{W0} 100\% \tag{Equation 3}$$

Drug release

The release of ketoprofen was tested using a dissolution apparatus USP II paddle model.^{12,13} The dissolution media used phosphate buffer pH 6.8 (900 mL; 37°C; 50 rpm) (Electrolab TDT-08L, India). Samples were taken at 0.5; 1; 1.5; 2; 2.5; 3; 4; 5; 6; 8; and 10 hour. Ketoprofen released from the tablet determined absorption value read by UV spectrophotometer (260 nm) (Hitachi U-1900, Japan).^{13,21}

Kinetics of ketoprofen release

The release kinetics of ketoprofen from tablets was influenced by HPMC and CA-LBG in the granules. The kinetics of drug release is determined by the following equations:²²⁻²⁵

Zero order : $Q_t = Q_o + K_o.t$ Equation 4

First order : $\ln Q_t = \ln Q_o + K_o.t$ Equation 5

Qt: the amount of drug dissolved at the time (t), Qo: the amount of the initial drug, and Ko: drug release constant.

Higuchi : $Q_t = K_H.\sqrt{t}$ Equation 6

Qt: the amount of drug dissolved at the time (t), KH: Higuchi constant, and t: time.

$$\text{Korsmeyer-Peppas} : Q_t/Q_\infty = K_k \cdot t^n \quad \text{Equation 7}$$

Q_t/Q_∞ : fraction of drug released, K_k : Korsmeyer-Peppas constant, and n : diffusion exponential.

$$\text{Hixson-Crowell} : Q_0^{1/3} - Q_t^{1/3} = K_s \cdot t \quad \text{Equation 8}$$

Q_0 : the amount of initial drug, Q_t : the amount of drug remaining at the time (t), and K_s : dissolution rate constant.

$$\text{Weibull} : \log [\ln - (1 - m)] = b \log (t - T_i) - \log a \quad \text{Equation 9}$$

$(1-m)$: fraction of insoluble drug, T_i : the lag time before dissolution, b : shape parameter obtained from the slope of the obtained curve. The value of $b = 1$ means that the curve is exponential. The importance of $b > 1$ is the shape of the sigmoid curve.

The release kinetics of ketoprofen from tablets of each granule formula was analyzed using DDSolver software.

Result and Discussion

Fourier transform infrared spectroscopy

Infrared spectra of CA-LBG and LBG are presented in Figure 1. Peaks at wavelengths of 3318.20 cm^{-1} and 3285.80 cm^{-1} indicate the hydroxyl (OH) groups of mannose and galactose. Peaks at wavelengths of 2923.66 cm^{-1} and 2936.00 indicate C-H bonds, where CA-LBG is sharper than LBG due to the influence of symmetrical C-H bonds from CA.^{25,26} The specific peak of CA-LBG at 1736.02 cm^{-1} indicates an ester carbonyl group. Previous studies reported that the peak wavelength of the OH group appears at 3300 cm^{-1} , C-H appears at around 2900 cm^{-1} , and C=O appears at about 1750-1735 cm^{-1} . The reaction mechanism for making CA-LBG is a chemical esterification reaction. The reaction begins with the citric acid carbonyl group undergoing protonation and reacting with the hydroxyl group (OH) on the C-6 mannose and galactose atoms to form a tetrahedral cation. Oxygen

in the OH undergoes protonation ($^+\text{OH}_2$) to form loose OH so that the loss of H_2O and an ester (CA-LBG) is formed.⁷ The results of the infrared analysis were further confirmed using NMR.




Figure 1. Infrared spectra of CA-LBG and LBG. The CA-LBG spectra have a carbonyl ester group ($\text{C}=\text{O}$) at a wavelength of 1736.02 cm^{-1} , presented by a blue line. LBG as control, presented with a red line.

Nuclear magnetic resonance

The NMR examination further confirms the FTIR examination and is carried out representatively for the three manufacturing batches. The CA-LBG NMR spectra are presented in Figure 2. The ^1H NMR spectra, paired twin peaks at $\delta = 2.926\text{ ppm}$ and $\delta = 2.894\text{ ppm}$, $\delta = 2.746$ and ppm , $\delta = 2.714\text{ ppm}$ correspond to the presence of CH_2 (5) of CA in LBG. The sharp peak at $\delta = 3.996\text{--}3.309\text{ ppm}$ corresponds to the H atoms of mannose and galactose in LBG. Previous experiments reported that the paired twin peaks of CH_2 were seen at $\delta = 2.7\text{--}3.0\text{ ppm}$. Sharp peaks of H atoms from mannose and galactose appear at $\delta = 4.5\text{--}3.0\text{ ppm}$.^{6,7}




Figure 2. NMR observation spectra of CA-LBG. CA characters present in CA-LBG resented peaks 1, 2, 3, 4, and 5.

The ¹³C NMR spectra of CA-LBG at the peak $\delta = 176.905$ ppm and $\delta = 173.507$ ppm indicated the carbonyl group (C=O) (1,2), which was a specific group of CA-LBG. The central C atom of CA is shown at $\delta = 73.354$ ppm (3). CH₂ of CA is shown at $\delta = 43.349$ ppm (4). The C atoms that make up mannose and galactose from LBG are shown at $\delta = 100.182$ ppm, $\delta = 96.477$ ppm, $\delta = 76.570$ ppm, $\delta = 75.053$ ppm, $\delta = 71.453$ ppm, $\delta = 69.966$ ppm, $\delta = 69.323$ ppm, $\delta = 61.001$ ppm, $\delta = 60.540$ ppm. Previous experiments show C=O group at $\delta = 180$ -170 ppm, central C atom at $\delta = 80$ -70 ppm, CH₂ appears at $\delta = 44$ -43 ppm.^{6,7,27} The C atoms make up mannose, and galactose appears at $\delta = 105$ -60 ppm.^{7,28-30} Finally, the peaks in the spectra indicate the success of the synthesis.

Esterified CA

The degrees of esterification in each batch are shown in Table 1. All batches had similar degrees of esterification, indicating reproducible manufacturing conditions. The experimental esterification degree of 29.30-29.55% corresponds to the previous experimental report of around 9.13%.^{7,14} The degree of esterification of all batches indicated that the esterification conditions were stable and reproducible. The acidic condition created by HCl induces the O atom in the carbonyl group of CA to be protonated to a positive C atom. The OH group on C6 of mannose and galactose will react with a positive C atom.

Table 1. Evaluation degree of esterification, solubility, and viscosity of CA-LBG

Batch Code	Degree of esterification		Solubility		Viscosity	
	[%]	SD	[%]	SD	[cP]	SD
1	29.33	0.20	29.65	0.27	9.48	0.01
2	29.30	0.21	29.81	0.18	9.46	0.02
3	29.55	0.10	29.51	0.42	9.43	0.02

Solubility

The solubility of CA-LBG in each batch is presented in Table 1. All batches showed similar solubility and indicated reproducible manufacturing. The solubility is 29.51-29.81%, according to the solubility in the previous experiment (22.64-36.63%).¹⁴ The ester bond of CA molecules influences the solubility of CA-LBG in LBG. The positive C atom of the carboxylate group (CA) binds to the O atom at C-6, inhibiting the interaction of CA-LBG with distilled water CA-LBG and reducing solubility.

Viscosity

Table 1 shows the respective viscosity of CA-LBG has similar values and indicates reproducible manufacturing. The viscosity shows a value of 9.43-9.48 cPs following the viscosity in the previous experiment (7.76-11.20 cPs).¹⁴ Viscosity is influenced by the carbonyl ester group

formed from the positive C atom of the carboxylic group (CA) with the O atom at C-6 in mannose and galactose so that the ability of CA-LBG to trap distilled water decreases.

Flowability

The results of testing the flow time and angle of repose of the tablet mass for each formula are presented in Table 2. Each formula produces a flow time of about 4.60-5.00 seconds and an angle of repose 27.89-30.04⁰, indicating the tablet mass good flows because ≤ 10 seconds for 100 g and $\leq 40^0$ ¹⁷. The tablet mass can occupy the die space inside the tablet machine. The tablet mass can be continued to be compressed to form a tablet (400 mg). The response of the angle of repose according to the simplex lattice design is obtained by Equation 10.

$$Y = 29.91 A + 27.87 B + 3.25 AB \quad \text{Equation 10}$$

The coefficient value of each component in the equation shows that HPMC (+29.91) is the most dominant factor in increasing the angle of repose, followed with CA-LBG (+27.87), and a combination of both (+3.25). The CA-LBG is an ester polymer that is difficult to hydrate with distilled water, so CA-LBG inhibits the formation of bonds between the granule constituent particles and produces fine granules. A large number of refined grains inhibits the tablet mass flow. HPMC is a polymer that can absorb moisture from the surrounding environment.⁵ The HPMC in the granules increases moisture impedes flow, forming high mounds. Combining CA-LBG with HPMC, which can absorb moisture, increases the tablet mass flow time. Flow time is one parameter that determines the diversity of weights in the tablet manufacturing process.

Based on the ANOVA analysis (see supplementary information Table S1), the response angle of repose has a Pred R-Squared (0.9596), similar to Adj R-Squared (0.9742) with less than 0.2. Meanwhile, the Adeq Precision (23.8130) greater than 4, indicating this model is acceptable.

Tap Index

The tablet mass tap index for each formula is presented in Table 2. Each formula has a tap index of about 18.50-20.00%, indicating that the tablet mass has good homogeneity because $\leq 20\%$ ¹⁷, so the space between the granules is filled with particles or fines. In addition, this condition shows that the tablet mass has good compressibility and creates low porosity tablets. The tap index for each formula is processed according to the simplex lattice design to obtain Equation 11.

$$Y = 18.99 A + 18.77 B + 5.64 AB$$
 Equation 11

The value of the HPMC coefficient (+18.99) is the dominant factor in increasing the tap index, followed with CA-LBG (+18.77) and a combination of both (+5.64). HPMC can reduce the sensitivity of the granules because the HPMC particles absorb moisture so that the granules change shape when granules receive mechanical stress. The difficulty of hydrating CA-LBG particles in the granulation process causes the bond between the granules to be not good so that the granules release fines and receive mechanical stress. The combination of the two factors can increase the tap index because the HPMC reduces the sensitivity due to moisture absorption. In addition, it is supported by less strong bonds between particles in the granules due to the difficulty of hydrating during the granulation process.

Based on the ANOVA analysis (see supplementary information Table S1), the response tap index has a Pred R-Squared (0.7862), similar to Adj R-Squared (0.8928) with less than 0.2. Meanwhile, the Adeq Precision (10.7420) greater than 4, indicates this model is acceptable.

Weight

The tablet weight of all formulas is shown in Table 2. Tablet mass was compressed into tablets with a weight of about 400 mg. The tablet mass of all formulas is free to flow and fill the die chamber, so tablet weight is according to design. The compression success is suitable for the value of flow time, angle of repose, and tap index.

Table 2. Details of HPMC and CA-LBG concentration, quality of the tablet mass, quality of the tablet, and ketoprofen released

Formula code	HPMC [%]	CA-LBG [%]	Flow time [sec.]	Angle of repose [°]	Tap index [%]	Weight [mg]	Hardness [kp]	Friability [%]	Ketoprofen released [10 hr.] [%]
G1	40.00	10.00	4.80 ± 0.06	29.92 ± 0.10	19.00	401.34 ± 1.69	13.61 ± 0.70	0.39	53.75 ± 0.89
G2	32.50	17.50	4.60 ± 0.10	28.98 ± 0.08	20.00	400.87 ± 1.25	13.84 ± 1.05	0.45	83.34 ± 0.70
G3	35.00	15.00	5.00 ± 0.06	29.47 ± 0.18	20.00	402.08 ± 1.50	14.08 ± 0.84	0.28	69.33 ± 0.93
G4	40.00	10.00	4.60 ± 0.10	29.86 ± 0.53	18.50	400.07 ± 1.16	13.60 ± 0.61	0.43	51.71 ± 0.71
G5	30.00	20.00	4.80 ± 0.06	27.86 ± 0.18	19.00	399.69 ± 1.45	13.33 ± 0.46	0.74	99.21 ± 1.04
G6	37.50	12.50	4.80 ± 0.15	30.04 ± 0.06	20.00	400.12 ± 1.65	14.01 ± 0.83	0.34	58.16 ± 0.89
G7	35.00	15.00	5.00 ± 0.15	29.93 ± 0.94	20.00	400.36 ± 0.89	14.06 ± 0.87	0.28	69.82 ± 0.33
G8	30.00	20.00	5.00 ± 0.10	27.89 ± 0.54	19.00	399.67 ± 1.21	13.32 ± 0.84	0.73	99.32 ± 0.46
Ga	32.97	17.03	4.80 ± 0.06	29.17 ± 0.12	20.00	401.27 ± 1.15	13.97 ± 0.64	0.40	80.08 ± 0.60
Gb	32.97	17.03	4.60 ± 0.15	29.08 ± 0.23	20.00	399.00 ± 1.20	14.01 ± 0.58	0.41	80.44 ± 1.17
Gc	32.97	17.03	5.00 ± 0.10	29.22 ± 0.99	19.50	400.67 ± 0.79	13.86 ± 0.85	0.39	80.45 ± 0.55
Go	32.97	17.03	-	29.16	20.01	-	13.91	0.41	80.00

The proportion of HPMC and CA-LBG are G1 (1 : 0); G2 (0.25 : 0.75) G3 (0.5 : 0.5); G4 (1 : 0); G5 (0 : 1); G6 (0.75 : 0.25); G7 (0.5 : 0.5); G8 (0 : 1); Ga (0.30 : 0.70); Gb (0.30 : 0.70); Gc (0.30 : 0.70); and Go (0.30 : 0.70).

Hardness

The tablet hardness of each formula is presented in Table 2. Tablets of each formula have a hardness are around 13.32-14.08 kp, indicating that the tablet has strong resistance and good physical stability. The hardness of tablets comes from strong interlocking between the granules/particles making up the tablet when receiving compression so that the porosity of the tablet is low. The hardness of each formula is processed according to the simplex lattice design to obtain Equation 12.

$$Y = 13.60 A + 13.32 B + 2.42 AB \qquad \text{Equation 12}$$

The coefficient value of HPMC (+13.60) is the most dominant factor in increasing hardness, followed with CA-LBG (+13.32) and a combination of both (+2.42). HPMC can absorb moisture and is used as an adhesive between the deformation of granules/particles to produce a solid interlocking bond. The tablets have good stability to humidity even though the granules contain HPMC because the moisture absorption activity is inhibited by decreasing the absorption surface area in the tablets form than the granules. Although CA-LBG is difficult to hydrate, the deformation of the particles can form solid interlocking bonds. In addition, the presence of CA-LBG on the tablet surface inhibits moisture absorption. The combination of both can increase the hardness because the characters of HPMC and CA-LBG complement each other. The tablet has a solid interlocking bond between the deformation of the granules/particles, and the tablet can retain moisture. In addition, the tap index shows that the tablet mass has low porosity and good compressibility so that when compressed tablet mass produces a compact tablet.

Based on the ANOVA analysis (see supplementary information Table S1), the response hardness has a Pred R-Squared (0.9976), similar to Adj R-Squared (0.9985) with less than 0.2. Meanwhile the Adeq Precision (100.1700) greater than 4, indicates this model is acceptable.

Friability

The tablet friability of all formulas is presented in Table 2. Each formula has a friability of 0.28-0.74% ($\leq 1\%$)¹⁷, indicating that the tablet surface is strong enough to withstand mechanical movements because of solid interlocking bonds between the deformation of the particles on the tablet surface. Friability of all formulas is according to the simplex lattice design to obtain Equation 13.

$$Y = 0.41 A + 0.73 B - 1.10 AB \quad \text{Equation 13}$$

The coefficient value of CA-LBG (+0.73) is the most dominant factor in increasing friability, followed by HPMC (+0.41) and a combination of both decreasing friability (-1.10). HPMC can absorb moisture and is used as an adhesive between the deformation of granules/particles to produce a solid interlocking bond. The tablets have good stability to humidity even though the granules contain HPMC because the moisture absorption activity is inhibited by decreasing the absorption surface area in the tablets form than the granules. Although CA-LBG is difficult to hydrate, the deformation of the particles can form solid interlocking bonds. In addition, the presence of CA-LBG on the tablet surface inhibits moisture absorption. The combination of the two can reduce the friability of the tablet because the HPMC and CA-LBG particles fill the space between the lactose monohydrate particles. The strong interlocking bonds of the granule mass components form compact and low-porosity granules. When compressed formed a tablet resistant to mechanical movement. The friability quality of this tablet is in line with the hardness quality of the tablet.

Based on the ANOVA analysis (see supplementary information Table S1), the response friability has a Pred R-Squared (0.9593) similar to Adj R-Squared (0.9747) with less than 0.2. Meanwhile, the Adeq Precision (24.6860) greater than 4, indicates this model is acceptable.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. The ketoprofen dissolution profile of various tablet formulas contains HPMC [%] and CA-LBG [%]: G1 (40 : 10); G2 (32.5 : 17.5); G3 (35 : 15); G4 (40 : 10); G5 (30 : 20); G6 (37.5 : 12.5); G7 (35 : 15); G8 (30 : 20); and Ga (32.97 : 17.03).

Ketoprofen release

The concentration and profile of ketoprofen release for each tablet formula after 10 hours are presented in Table 2, Figure 3, and supplementary information Table S2-S3. All tablets of ketoprofen release around 51.71-99.32%, showing that HPMC and CA-LBG can control ketoprofen release from tablets. HPMC is a polymer that swells when hydrating by the dissolution medium. Ketoprofen release is inhibited because HPMC swells trap ketoprofen particles. The CA-LBG is a polymer that is difficult to hydrate and has low solubility. The CA-LBG character causes the tablet to disintegrate

and become granule. Releases of ketoprofen-controlled granule swelling form a gel. Based on the experimental design, ketoprofen released for 10 hours is $\geq 80\%$ (see supplementary information Chapter 1). The processed concentration value of each tablet formula is according to the simplex lattice design to obtain Equation 14.

$$Y = 52.48 A + 99.44 B - 26.36 AB \quad \text{Equation 14}$$

The CA-LBG coefficient value (+99.44) was the most dominant factor in increasing ketoprofen release, followed with HPMC (+52.48). The combination of both (-26.36) was the most dominant factor in reducing the release of ketoprofen. The deformation of CA-LBG particles on the tablet refuses each other when submerged in the dissolution medium, causing tablet disintegration. The granule porosity surface is used as a space for penetration of the dissolution medium into the granule, dissolved ketoprofen particles, and diffuses out of the granule. The high concentration of CA-LBG accelerates of disintegration of the tablet and forms HPMC gel. Combining the HPMC with CA-LBG can reduce the release of ketoprofen because the moisture of the deformation of the HPMC particles can bind hardly to the interlocking deformation of the CA-LBG and other particles, so that the tablet disintegrates longtime. In addition, the direct interaction of CA-LBG with particles inhibits the swelling of HPMC and hydrating of ketoprofen by the dissolution medium. HPMC and CA-LBG particles can mix physically. Random distribution of HPMC and CA-LBG particles in granules. When these particles expand, the network of the two types of polymers can physically interact with each other (penetrate each other). In this condition, ketoprofen particles can be between these tissues so that these tissues control the release of ketoprofen. Ketoprofen release via diffusion or erosion mechanisms. The release of ketoprofen was studied through the kinetics of drug release.

Based on the ANOVA analysis (see supplementary information Table S1), the response to the release of ketoprofen has a Pred R-Squared (0.9956), similar to Adj R-Squared (0.9978) with a difference of less than 0.2. Meanwhile the Adeq Precision (85.0460) greater than 4, indicates this model is acceptable.




Figure 4. Comparison of actual (dotted line) and predicted (solid line) optimization response profiles. The red dot indicates the response value for each formula based on the respective proportions of HPMC and CA-LBG. The overlay shows the meeting point of all responses according to the predicted optimal proportions of HPMC and CA-LBG.

Optimum tablet formula

Determination of the optimum formula begins with the initial 8 experimental formula designs (G1-G8). The optimization factors and response parameter values were analyzed using design expert software using a simplex lattice design. The experimental comparison profiles and the predictions of each optimization response (Figure 4) show that the actual profiles are similar to the predictions. This profile follows the results of ANOVA analysis for each optimization response (flowability, tap index, hardness, friability, and release of ketoprofen). The optimization response overlay predicts the optimum proportion point to achieve the optimum response prediction. Design expert provides several alternative options for the optimum formula. The selected formula was determined from the response parameter specifications (angle of repose 27.86-30.04; tap index 18.5-20.5; hardness 13.32-

14.08 kp; friability 0.28-0.74%; drug release > 80%). Verification to the prediction of the optimum formula proportion (Go) to obtain the optimum formula was carried out in three batches (Ga, Gb, Gc) (Table 2 and Figure 3).




Figure 5. Drug release kinetics model (HPMC [%] : CA-LBG [%]): G1 (40 : 10) (Korsmeyer-Peppas); G2 (32.5 : 17.50) (Korsmeyer-Peppas); G3 (35 : 15) (Hixson-Crowell); G4 (40 : 10) (Korsmeyer-Peppas); G5 (30 : 20) (Hixson-Crowell); G6 (37.50 : 12.50) (Higuchi); G7 (35 : 15) (Hixson-Crowell); G8 (30 : 20) (Hixson-Crowell); Ga (32.97 : 17.03) (Zero order); Gb (32.97 : 17.03) (Zero order); and Gc (32.97 : 17.03) (Zero order).

One sample T-test results compare the experimental response formula verification with the predictive response. The values T of each parameter is T angle of repose (0.008), T tap index (1.096), T hardness (0.728), T friability (1.559), and T release of ketoprofen (2.657). The response parameter values between the prediction (Go) and the verification experiment (Ga-Gc) were not significantly different. These results indicate that the polynomial equations of each response parameter are valid for predicting the effect of HPMC, CA-LBG, and their combination. In addition, the selected optimum formula shows reproducibility in producing tablets and controlling ketoprofen's release. The variation of release shown by G1-G8 proves that tablets with irrelevant variations in physical quality produce varied drug releases.

Kinetics of ketoprofen release

The kinetics of ketoprofen release from the tablet is a non-linear approach using DDSolver (Table 3, Figure 5, and supplementary information Figure S1-S11). The kinetics parameters of ketoprofen release include high Rsqr_adj, low Mean Square Error-Root (MSE_root), and low Akaike Information Criterion (AIC). The Rsqr_adj is the correlation value between dissolution time and released ketoprofen. MSE_root indicates the error value in correlation analysis. AIC is the value suitability to the equation to determine the release kinetics.^{31–35} The results of DDSolver processing are presented in Table 3 and Figure 5.

The release kinetics of ketoprofen from tablets G1, G2, and G4 followed the Korsmeyer-Peppas kinetics. The exponential value (n) for tablets G1 (0.62), G2 (0.60), and G4 (0.58) indicates a non-Fickian diffusion mechanism (anomalous diffusion).³⁶ The release of ketoprofen released by diffusion is proportional to erosion. The surface of the granules forms a thin gel and cannot withstand the dissolution medium, so ketoprofen dissolves quickly. The ketoprofen release is not only through diffusion but also due to erosion of the surface of the gel formed. The CA-LBG is not tightly

integrated into the tablet and granule. This condition causes the dissolution rate to be faster with the increase in the dissolution medium that enters the tablet and granule.

The release kinetics of ketoprofen from tablets G3, G5, G7, and G8 followed Hixson-Crowell kinetics. The ketoprofen release was caused by hydrating the tablet surface, so the tablet disintegrated and become granule. This condition causes ketoprofen to be dissolved constantly. HPMC low concentration can tablet disintegration quickly when particles swell to form a gel and push against other particles. In addition, CA-LBG on the granule accelerates the decomposition of the HPMC gel because the repulsion forces between CA-LBG particles are difficult to dissolve.

The tablet G6 followed the release kinetics of Higuchi's model. The high viscosity gel of HPMC controlled the diffusion of ketoprofen from the granules. CA-LBG on the granule surface inhibited granule hydration and ketoprofen diffusion.

The release kinetics of ketoprofen from Ga, Gb, and Gc tablets followed zero order. HPMC on the tablet surface swells to form a gel when in contact with the dissolution medium. The trapped ketoprofen particles dissolve and are saturated, then diffuse from the gel. Simultaneously the rate of CA-LBG disintegrating tablets into granules is proportional to gel formation. The dissolving of ketoprofen comes from the ketoprofen particles in contact with the gel surface. The balanced concentrations of HPMC and CA-LBG formed a gel with a constant thickness. These conditions can control the diffusion and maintain the availability of saturated ketoprofen dissolved in the gel.

Table 3. The value of the kinetics parameters of the release of ketoprofen from tablets.

Formula code	Parameter	Zero order		First order		Higuchi		Korsmeyer-Peppas		Hixson-Crowell		Weibull		Kinetics model
		average	SD	average	SD	average	SD	average	SD	average	SD	average	SD	
G1	Rsqr_adj	0.8762	0.02	0.9441	0.01	0.9585	0.00	0.9776	0.01	0.9279	0.01	0.9333	0.00	Korsmeyer-Peppas
	MSE_root	5.2625	0.35	3.5357	0.26	3.0468	0.20	2.2216	0.34	4.0144	0.29	3.8687	0.11	
	AIC	70.5951	1.56	61.0431	1.72	57.4597	1.61	50.6125	3.52	64.0907	1.71	64.8308	0.66	
G2	Rsqr_adj	0.8049	0.01	0.9687	0.00	0.9861	0.00	0.9948	0.00	0.9426	0.01	0.9536	0.00	Korsmeyer-Peppas
	MSE_root	10.6069	0.28	4.2456	0.22	2.8232	0.37	1.7379	0.16	5.7451	0.32	5.1742	0.23	
	AIC	87.4453	0.63	65.4533	1.28	55.5400	3.24	44.8284	2.23	72.7095	1.35	71.7991	1.08	
G3	Rsqr_adj	0.9395	0.00	0.9296	0.01	0.8689	0.01	0.9113	0.01	0.9401	0.01	0.8651	0.01	Hixson-Crowell
	MSE_root	4.5672	0.13	4.9223	0.35	6.7233	0.38	5.5235	0.47	4.5427	0.27	6.8225	0.28	
	AIC	67.2211	0.72	68.9849	1.70	76.4828	1.36	72.5897	2.03	67.0722	1.38	78.4392	0.96	
G4	Rsqr_adj	0.8597	0.02	0.9358	0.01	0.9657	0.01	0.9777	0.01	0.9171	0.01	0.9414	0.01	Korsmeyer-Peppas
	MSE_root	5.4444	0.33	3.6827	0.21	2.6858	0.34	2.1496	0.36	4.1855	0.25	3.5175	0.31	
	AIC	71.4154	1.46	62.0355	1.40	54.3575	3.04	49.7755	3.97	65.1033	1.48	62.4881	2.17	
G5	Rsqr_adj	0.8594	0.01	0.6528	0.10	0.8570	0.01	0.9057	0.00	0.9231	0.00	0.9025	0.00	Hixson-Crowell
	MSE_root	13.6548	0.48	21.3289	3.31	13.7776	0.45	11.1888	0.34	10.1039	0.28	11.3789	0.30	
	AIC	93.5029	0.85	104.0112	3.90	93.7193	0.79	89.5817	0.73	86.2787	0.67	90.7234	0.63	
G6	Rsqr_adj	0.6618	0.02	0.8583	0.01	0.9945	0.00	0.9935	0.00	0.8093	0.01	0.9762	0.00	Higuchi
	MSE_root	9.9176	0.17	6.4175	0.16	1.2626	0.07	1.3745	0.10	7.4459	0.16	2.6266	0.17	
	AIC	85.8359	0.41	75.3863	0.60	36.3490	1.26	39.2239	1.71	78.9547	0.53	55.5081	1.61	
G7	Rsqr_adj	0.9360	0.01	0.9304	0.00	0.8758	0.01	0.9093	0.01	0.9398	0.00	0.8675	0.00	Hixson-Crowell
	MSE_root	4.7248	0.28	4.9359	0.11	6.5870	0.32	5.6328	0.20	4.5899	0.09	6.8079	0.13	
	AIC	68.0154	1.40	69.0873	0.55	75.9974	1.20	73.1077	0.84	67.3448	0.45	78.3976	0.46	
G8	Rsqr_adj	0.8582	0.01	0.7246	0.05	0.8753	0.01	0.9180	0.00	0.9286	0.01	0.9112	0.00	Hixson-Crowell
	MSE_root	13.3691	0.17	18.5895	1.66	12.5351	0.46	10.1662	0.37	9.4845	0.43	10.5795	0.28	
	AIC	93.0042	0.30	100.8549	2.10	91.4435	0.88	87.2783	0.87	84.7498	1.10	88.9752	0.63	

continue to the next page

Table 3. The value of the kinetics parameters of the release of ketoprofen from tablets.

Formula code	Parameter	Zero order		First order		Higuchi		Korsmeyer-Peppas		Hixson-Crowell		Weibull		Kinetics model
		average	SD	average	SD	average	SD	average	SD	average	SD	average	SD	
Ga	Rsqr_adj	0.9241	0.01	0.8628	0.01	0.7995	0.02	0.8441	0.02	0.8883	0.01	0.7823	0.03	Zero order
	MSE_root	5.7889	0.30	7.7879	0.24	9.4113	0.50	8.2963	0.58	7.0194	0.51	9.8002	0.73	
	AIC	72.8966	1.22	80.0290	0.73	84.5579	1.28	82.3715	1.68	77.5002	1.76	87.0994	1.81	
Gb	Rsqr_adj	0.9273	0.00	0.8670	0.01	0.8107	0.01	0.8481	0.02	0.8956	0.01	0.7874	0.03	Zero order
	MSE_root	5.6548	0.09	7.6500	0.20	9.1233	0.40	8.1484	0.47	6.7739	0.32	9.6602	0.66	
	AIC	72.3524	0.40	79.6025	0.62	83.8190	1.06	81.9522	1.39	76.6707	1.14	86.7613	1.66	
Gc	Rsqr_adj	0.9273	0.01	0.8648	0.01	0.8044	0.01	0.8408	0.02	0.8920	0.01	0.7809	0.03	Zero order
	MSE_root	5.6764	0.38	7.7581	0.22	9.3364	0.37	8.4134	0.49	6.9321	0.30	9.8658	0.69	
	AIC	72.4101	1.62	79.9382	0.68	84.3764	0.94	82.7199	1.40	77.2270	1.07	87.2649	1.70	

The ketoprofen release kinetics model of various tablet formulas contains HPMC [%] and CA-LBG [%]: G1 (40 : 10); G2 (32.5 : 17.5); G3 (35 : 15); G4 (40 : 10); G5 (30 : 20); G6 (37.5 : 12.5); G7 (35 : 15); G8 (30 : 20); Ga (32.97 : 17.03); Gb (32.97 : 17.03); and Gc (32.97 : 17.03).

Conclusion

HPMC and CA-LBG increased the value of angle of repose, tap index, hardness, friability, and release of ketoprofen. The combination of HPMC with CA-LBG increased the angle of repose, tap index, and hardness. Besides, the combination decreased friability and release of ketoprofen. The optimum concentrations of HPMC and CA-LBG for controlled-release tablets is 32.97% and 17.03%, resulting in the angle of repose of 29.16⁰; tap index of 20.01%; hardness of 13.91 kp; friability of 0.41%; and the drug release (10 hours) of 80%. The drug release kinetics from optimum tablets followed zero order. The constant thickness of gel can control the diffusion and maintain the saturated ketoprofen in the gel. CA-LBG as a negative matrix disintegrates tablets into granules. HPMC as a gel matrix controlled ketoprofen release by diffusion and erosion. The tablets did not produce a ghost matrix because the gel matrix came from granules which degraded quickly after all the ketoprofen was released.

Associated Content

Supporting Information

Tablet dosage calculation; Statistical analysis of ketoprofen tablets; The release of ketoprofen from tablets (G1-G8); The release of ketoprofen from optimum tablets (Ga-Gc); and The kinetics profile of ketoprofen release from tablets (G1-G8) (Ga-Gb)

Acknowledgment

The author would like to thank PT. Makmur Food (Indonesia) has assisted with locust bean gum (viscogum); LPPT Gadjah Mada University (Indonesia) for NMR testing; Faculty of Pharmacy, Gadjah Mada University (Indonesia) for pharmaceutical technology facilities; Faculty of Pharmacy Widya Mandala Surabaya Catholic University (Indonesia) for testing FTIR, viscometer, and

pharmaceutical technology equipment; and Widya Mandala Surabaya Catholic University (Indonesia) for funding the publication (7417/WM01/N/2022).

Declarations

Competing interest statement

The authors declare that authors have no conflict of interest.

Author contribution statement

Wuryanto Hadinugroho: designed the experiments, performed the experiments, analyzed and interpreted the data, wrote the manuscript. Suwaldi Martodihardjo, Achmad Fudholi, Sugeng Riyanto and, Jefri Prasetyo: analyzed and interpreted the data.

Author Information

Corresponding author

Wuryanto Hadinugroho - Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Kalisari Selatan no. 1 Pakuwon City, Surabaya, Indonesia; orcid.org/0000-0001-9245-2802; Email: wuryanto.hadinugroho@gmail.com.

Authors

Suwaldi Martodihardjo - Faculty of Pharmacy, Gadjah Mada University, Sekip Utara, Yogyakarta, Indonesia; Email: waldi_ugm@yahoo.com

Achmad Fudholi - Faculty of Pharmacy, Gadjah Mada University, Sekip Utara, Yogyakarta, Indonesia; Email: fudholi_fa@ugm.ac.id

Sugeng Riyanto - Faculty of Pharmacy, Gadjah Mada University, Sekip Utara, Yogyakarta, Indonesia; Email: sugeng_riyanto51@yahoo.com

Jefri Prasetyo - Faculty of Pharmacy, Widya Mandala Surabaya Catholic University, Kalisari
Selatan no. 1 Pakuwon City, Surabaya, Indonesia; Email: jefri@ukwms.ac.id

REFERENCES

- (1) Li, C.L.; Martini, L.G.; Ford, J.L.; Roberts, M. The use of hypromellose in oral drug delivery. *J Pharm Pharmacol.* **2010**, *57*, 533-546. doi: 10.1211/0022357055957
- (2) Oliveira, P.R.; Mendes, C.; Klein, L.; Sangoi, M.D.S.; Bernardi, L.S.; Silva, M.A.S. Formulation development and stability studies of norfloxacin extended-release matrix tablets. *Biomed Res Int.* **2013**, *2013*, 1-9. doi: 10.1155/2013/716736
- (3) Contreras, L.; Melgoza L.M.; Leyva A.A.D.; Caraballo I. Collaboration between HPMC and NaCMC in order to reach the polymer critical point in theophylline hydrophilic matrices. *Sci World J.* **2012**, *2012*, 1-8. doi: 10.1100/2012/171292
- (4) Enayatifard, R.; Saeedi, M.; Akbari, J.; Tabatabaee, Y.H. Effect of hydroxypropyl methylcellulose and ethyl cellulose content on release profile and kinetics of diltiazem HCl from matrices. *Trop J Pharm Res.* **2009**, *8*, 425-432. doi: 10.4314/tjpr.v8i5.48086
- (5) Sheskey, P.J.; Cook, W.G.; Cable, C.G. Handbook of Pharmaceutical Excipients 8th. Pharmaceutical Press and American Pharmacists Association: London-Washington DC, **2017**; pp.282-284
- (6) Hadinugroho, W.; Martodihardjo, S.; Fudholi, A.; Riyanto, S. Study of a catalyst of citric acid crosslinking on locust bean gum. *J Chem Technol Metall.* **2017**, *52*, 1086-1091
- (7) Hadinugroho, W.; Martodihardjo, S.; Fudholi, A.; Riyanto, S.; Esterification of citric acid with locust bean gum. *Heliyon.* **2019**, *5*, 1-9. doi: 10.1016/j.heliyon.2019.e02337
- (8) Santiago, E.V.; Lopez, S.H.A.; Romero, A.R. Photochemical cross-linking study of polymers containing diacetylene groups in their main chain and azobenzene compounds as pendant groups. *Superf y vacío.* **2006**, *19*, 1-7

- (9) Tamaki, Y.; Teruya, T.; Tako, M. The chemical structure of galactomannan isolated from seeds of *Delonix regia*. *Biosci Biotechnol Biochem.* **2010**, *74*, 1110-1112. doi: 10.1271/bbb.90935
- (10) Tjandraatmadja, G.F.; Burn, L.S.; Jollands, M.J. The effects of ultraviolet radiation on polycarbonate glazing. *Proc 8th Int Conf Durab Build Constr Mater Vancouver, Canada.* **1999**, *30*, 884-898
- (11) Yeh, C.C.; Chen, C.N.; Li, Y.T.; Chang, C.W.; Cheng, M.Y.; Chang, H.I. The effect of polymer molecular weight and UV radiation on physical properties and bioactivities of PCL films. *Cell Polym.* **2011**, *30*, 261-276. doi: 10.1177/026248931103000503
- (12) Lam, M.; Nokhodchi, A. Producing High-Dose Liqui-Tablet (Ketoprofen 100 mg) for Enhanced Drug Release Using Novel Liqui-Mass Technology. *J Pharm Innov.* **2021**, 1-13. doi: 10.1007/s12247-021-09561-6
- (13) Kaleemullah, M.; Jiyauddin, K.; Thiban, E.; Rasha, S.; Al-Dhalli, S.; Budiasih, S.; Gamal, O.E.; Fadli, A.; Eddy, Y. Development and evaluation of Ketoprofen sustained release matrix tablet using *Hibiscus rosa-sinensis* leaves mucilage. *Saudi Pharm J.* **2017**, *25*, 770-779. doi: 10.1016/j.jsps.2016.10.006
- (14) Hadinugroho, W.; Martodihardjo, S.; Fudholi, A.; Riyanto S. Preparation of Citric Acid-Locust Bean Gum (CA-LBG) for the Disintegrating Agent of Tablet Dosage Forms. *J Pharm Innov.* **2021**, 1-16. doi: 10.1007/s12247-021-09591-0
- (15) Gulrez, S.K.H.; Al-Assaf, S, Phillips, G.O. Hydrogels: Methods of Preparation, Characterisation and Applications. In: *Progress in Molecular and Environmental Bioengineering - From Analysis and Modeling to Technology Applications.* **2011**. doi: 10.5772/24553
- (16) Davies, P. Oral Solid Dosage Forms. In: *Pharmaceutical Preformulation and Formulation.* 2nd, vol 199. Gibson, M. (Ed). New York: Informa Healthcare USA, Inc; **2009**; pp. 368-369 doi: 10.1201/b14413-17

- (17) Aulton, E.; Taylor, K.M.G. *Aulton's Pharmaceutics The Design and Manufacture of Medicines*. Churchill Livingstone Elsevier: New York, **2017**; pp. 187-199
- (18) Mercku, P.; Lindqvist, A.S.; Leiviska, K.; Yliruusi, J. Influence of granulation and compression process variables on flow rate of granules and on tablet properties, with special reference to weight variation. *Int J Pharm.* **1994**, *102*, 117-125. doi: 10.1016/0378-5173(94)90046-9
- (19) Szumilo, M.; Belniak, P.; Swiader, K.; Holody, E.; Poleszak, E. Assessment of physical properties of granules with paracetamol and caffeine. *Saudi Pharm J.* **2017**, *25*, 900-905. doi: 10.1016/j.jsps.2017.02.009
- (20) The United States Pharmacopeial Convention. *Pharmacopeia 41-National Formulary 36*. Twinbrook Parkway: Rockville, **2018**; pp.7634-7635
- (21) Wahab, A.; Khan, G.M.; Akhlaq, M.; Khan, N.R.; Hussain, A.; Khan, M.F.; Ur-Rehman, N.; Khan, A. Formulation and evaluation of controlled release matrices of ketoprofen and influence of different co-excipients on the release mechanism. *Pharmazie.* **2011**, *66*, 677–683. doi.org/10.1691/ph.2011.1040
- (22) Craciun, A.M.; Barhalescu, M.L.; Agop, M.; Ochiuz, L. Theoretical Modeling of Long-Time Drug Release from Nitrosalicyl-Imine-Chitosan Hydrogels through Multifractal Logistic Type Laws. *Comput Math Methods Med.* **2019**, *2019*, 1-9. doi.org/10.1155/2019/4091464
- (23) Panotopoulos, G.P; Haidar, Z.S. Mathematical modeling for pharmacokinetic predictions from controlled drug release nano systems: A comparative parametric study. *Biomed Pharmacol J.* **2018**, *11*, 1801–1806. doi.org/10.13005/bpj/1552
- (24) Simionato, L.D.; Petrone, L.; Baldut, M.; Bonafede, S.L.; Segall, A.I. Comparison between the dissolution profiles of nine meloxicam tablet brands commercially available in Buenos Aires, Argentina. *Saudi Pharm J.* **2018**, *26*, 578-84. doi: 10.1016/j.jsps.2018.01.015
- (25) Jahromi, L.P.; Ghazali, M.; Ashrafi, H.; Azadi, A. A comparison of models for the analysis of the kinetics of drug release from PLGA-based nanoparticles. *Heliyon.* **2020**, *6*, 1-9. doi:


- 10.1016/j.heliyon.2020.e03451
- (26) Nandiyanto, A.B.D.; Oktiani, R. Ragadhita, R. How to read and interpret ftir spectroscopy of organic material. *Indones J Sci Technol.* **2019**, *4*, 97-118. doi: 10.17509/ijost.v4i1.15806
- (27) Coates J. Interpretation of Infrared Spectra A Practical Approach. In: *Encycl Anal Chem.* Meyers, R.A (Ed). John Wiley & Sons Ltd: Chichester. **2000**; pp.10815-37. doi: 10.1002/9780470027318.a5606
- (28) Azero, E.G.; Andrade, C.T. Characterisation of Prosopis juliflora seed gum and the effect of its addition to κ -carrageenan systems. *J Braz Chem Soc.* **2006**, *17*, 844-850. doi: 10.1590/S0103-50532006000500005
- (29) Parvathy, K.S.; Susheelamma, N.S.; Tharanathan, R.N.; Gaonkar, A.K. A simple non-aqueous method for carboxymethylation of galactomannans. *Carbohydr Polym.* **2005**, *62*, 137-141. doi: 10.1016/j.carbpol.2005.07.014
- (30) Gillet, S.; Aguedo, M.; Blecker, C.; Jacquet, N.; Richel, A. Use of ^{13}C -NMR in Structural Elucidation of Polysaccharides: Case of Locust Bean Gum. *Young Belgium Magnetic Resonance Scientist*. Liège. 2014.
- (31) Gu, Y.; Wei, H.L.; Balikhin, M.M. Nonlinear predictive model selection and model averaging using information criteria. *Syst Sci Control Eng.* **2018**, *6*, 319-28. doi: 10.1080/21642583.2018.1496042
- (32) Mircioiu, C.; Voicu, V.; Anuta, V.; Tudose, A.; Celia, C.; Paolino, D.; Fresta, M.; Sandulovici, R.; Mircioiu, I. Mathematical modeling of release kinetics from supramolecular drug delivery systems. *Pharmaceutics.* **2019**, *11*, 1-45. doi.org/10.3390/pharmaceutics11030140
- (33) Siswanto, A.; Fudholi, A.; Nugroho, A.K.; Martono, S. in Vitro Release Modeling of Aspirin Floating Tablets Using DDSolver. *Indones J Pharm.* **2015**, *26*, 94-102. doi.org/10.14499/indonesianjpharm26iss2pp94
- (34) Zuo, J.; Gao, Y.; Bou-Chacra, N.; Löbenberg, R. Evaluation of the DDSolver software

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

applications. *Biomed Res Int.* **2014**, *2014*, 1-10. doi: 10.1155/2014/204925

(35) Zhang, Y.; Huo, M.; Zhou, J.; Zou, A.; Li, W.; Yao, C.; Xie, S. DDSolver: An add-in program for modeling and comparison of drug dissolution profiles. *AAPS J.* **2010**, *12*, 263–271. doi.org/10.1208/s12248-010-9185-1

(36) Dash, S.; Murthy, P.N.; Nath, L.; Chowdhury, P. Kinetic modeling on drug release from controlled drug delivery systems. *Acta Pol Pharm - Drug Res.* **2010**, *67*, 217-223



338x190mm (96 x 96 DPI)

Hadinugroho, Wuryanto ao-2022-07432u.R2 - Manuscript Accepted 07-Feb-2023

Dari: ACS Omega (onbehalf@manuscriptcentral.com)

Kepada: wuryanto.hadinugroho@gmail.com

Tanggal: Selasa, 7 Februari 2023 pukul 21.24 GMT+7

07-Feb-2023

Journal: ACS Omega

Manuscript ID: ao-2022-07432u.R2

Title: "Hydroxypropyl methylcellulose as hydrogel matrix and citric acid-locust bean gum as a negative matrix for controlled release tablet"

Author(s): Hadinugroho, Wuryanto; Martodihardjo, Suwaldi; Fudholi, Achmad; Riyanto, Sugeng; Prasetyo, Jefri

Manuscript Status: Accept

Dear Dr. Hadinugroho:

We are pleased to inform you that your manuscript has been accepted for publication in ACS Omega.

You will soon receive an email invitation from the ACS Journal Publishing Staff that contains a link to the online Journal Publishing Agreement. Please sign and submit the journal publishing agreement within 48 hours.

You will be contacted in approximately a week by the ACS Journal Publishing Staff regarding the proofs for your manuscript. Although production of your manuscript will start immediately, your manuscript will not be published until you pay the Article Publishing Charges, <https://acsopencscience.org/open-access/pricing/>. You may qualify for discounts. You will also be contacted shortly with information on how to pay your publishing charges. Article Publishing Charges are waived for invited Editorials and Perspectives.

After you submit corrections for your proofs and pay the article publishing charges, your manuscript will be published on the Web in approximately 48 hours. In view of this fast publication time, it is important to review your proofs carefully. Once a manuscript appears on the Web, it is considered published. Any change to the manuscript once it appears on the Web will need to be submitted to the journal office as a separate Addition & Correction manuscript via the ACS Paragon Plus environment.

Once your paper is published, you can track downloads and citations of your work by logging into the ACS Publishing Center (<https://pubs.acs.org/publish/dashboard>) and selecting "Published."

Sincerely,

Dr. Krishna Ganesh

Coeditor

ACS Omega

Phone: (202) 657-6323

Email: Ganesh-office@omega.acs.org

PLEASE NOTE: This email message, including any attachments, contains confidential information related to peer review and is intended solely for the personal use of the recipient(s) named above. No part of this communication or any related attachments may be shared with or disclosed to any third party or organization without the explicit prior written consent of the journal Editor and ACS. If the reader of this message is not the intended recipient or is not responsible for delivering it to the intended recipient, you have received this communication in error. Please notify the sender immediately by e-mail, and delete the original message.

As an author or reviewer for ACS Publications, we may send you communications about related journals, topics or products and services from the American Chemical Society. Please email us at pubs-comms-unsub@acs.org if you do

not want to receive these. Note, you will still receive updates about your manuscripts, reviews, or future invitations to review.

Thank you.

Action required: Journal Publishing Agreement for ao-2022-07432u

Dari: mpreceipt@acs.org

Kepada: wuryanto.hadinugroho@gmail.com

Tanggal: Selasa, 7 Februari 2023 pukul 22.05 GMT+7

February 07, 2023

Journal: ACS Omega

Manuscript No.: ao-2022-07432u

Title: Hydroxypropyl methylcellulose as hydrogel matrix and citric acid-locust bean gum as a negative matrix for controlled release tablet

Authors: Wuryanto Hadinugroho, Suwaldi Martodihardjo, Achmad Fudholi, Sugeng Riyanto, Jefri Prasetyo

Status: Manuscript Accepted - Signature for journal publishing agreement required

Dear Wuryanto Hadinugroho:

Congratulations on the recent acceptance of your article for publication in ACS Omega. As the final step in the acceptance process, we now need you to complete and sign an ACS journal publishing agreement, accessible via this link:

<https://jpawizard.acs.org/jpawizard/home?x=DfDdO55SYRxuK9SN3eiWIA&t=20230207100524>

Please note: An ACS ID is required to access this site. If you do not have an ACS ID, visit <https://pubs.acs.org/publish/> to register for an account. This ACS ID must be linked to your ACS Paragon Plus account prior to initiating a journal publishing agreement. If you do not have an ACS Paragon Plus account or need help linking your ACS ID to your ACS Paragon Plus account, please contact support@services.acs.org.

Please complete and sign a journal publishing agreement form as soon as possible. We cannot publish your article until we have a valid, signed journal publishing agreement on record with the manuscript.

If you have any questions about the publishing process for this manuscript, please contact mpreceipt@acs.org.

Sincerely,

ACS Journal Production Team

Most Trusted. Most Cited. Most Read.

<https://pubs.acs.org>

Confirmation of receipt of publishing agreement for ao-2022-07432u

Dari: mpreceipt@acs.org

Kepada: wuryanto.hadinugroho@gmail.com

Tanggal: Rabu, 8 Februari 2023 pukul 04.39 GMT+7

February 07, 2023

Journal: ACS Omega

Manuscript No.: ao-2022-07432u

Title: Hydroxypropyl methylcellulose as hydrogel matrix and citric acid-locust bean gum as a negative matrix for controlled release tablet

Authors: Wuryanto Hadinugroho, Suwaldi Martodihardjo, Achmad Fudholi, Sugeng Riyanto, Jefri Prasetyo

Manuscript Status: Manuscript accepted - Journal publishing agreement received

Dear Wuryanto Hadinugroho:

Thank you for submitting your ACS Journal Publishing Agreement for this manuscript. The completed form is attached for your records. Our team will contact you should any further action be required.

If you have any questions about the publishing process for this manuscript, please contact mpreceipt@acs.org.

Please note if you signed a journal publishing agreement requiring you to publish your manuscript as Open Access an order and payment must be completed prior to publication. If you have questions or require assistance with the Open Access transaction process please contact oaops@acs.org.

Sincerely,
ACS Journal Production Team
Most Trusted. Most Cited. Most Read.
<https://pubs.acs.org>



ao-2022-07432u_jpa.pdf

159.8kB

The authors identified below (the “Authors”) have prepared a manuscript for publication tentatively entitled:

Hydroxypropyl methylcellulose as hydrogel matrix and citric acid-locust bean gum as a negative matrix for controlled release tablet

And are submitting the manuscript for consideration for publication as an article including the non-text material such as figures or charts (the “Article”) to the journal *ACS Omega* published by the American Chemical Society (the “Publisher”) including in some instances in conjunction with another organization.

The parties are consequently entering into this publishing agreement under which the Authors will retain their copyright interests in the Article (the “Agreement”).

The Authors confirm the information in the “manuscript details” box below.

Manuscript details:

Journal Copyright Notice: © 2023 The Authors. Published by American Chemical Society

Article ID: ao-2022-07432u

Received Date: 19 November 2022

Journal: *ACS Omega*

Article: Hydroxypropyl methylcellulose as hydrogel matrix and citric acid-locust bean gum as a negative matrix for controlled release tablet

Submitting Corresponding Author:

Wuryanto Hadinugroho (wuryanto.hadinugroho@gmail.com)

Co-Author(s):

Suwaldi Martodihardjo (waldi_ugm@yahoo.com)

Achmad Fudholi (fudholi_fa@ugm.ac.id)

Sugeng Riyanto (sugeng_riyanto51@yahoo.com)

Jefri Prasetyo (jefri@ukwms.ac.id)

1. Author Choice Open Access payment and public use license options

The Authors have chosen to publish the Article in an Open Access format under the ACS OA Author Choice policy, meaning that any member of the public with access to the Publisher’s online site will have free (unfettered) access to the Article, with the publishing charges paid by the Authors, or the Authors will arrange for their research or institutional funder to provide this payment. Information about such charges and payments can be found here ([ref. https://pubs.acs.org/page/4authors/authorchoice/index.html](https://pubs.acs.org/page/4authors/authorchoice/index.html)).

This form of agreement is used when the Authors wish to retain copyright but provide the

Publisher with a license to publish, on the terms outlined herein, along with the selection by the Authors of a public use license to attach to the online version of the Article (which indicates that users are able to access the Article for all purposes but may be limited in their ability to copy and re-use the Article).

Note that if the Authors later decide not to publish under the Author Choice Open Access model they will be asked to sign an alternative publishing agreement, the terms of which will supersede these terms.

ACS Author Choice program options for the public use license include:

Creative Commons CC BY public use license (Plan S compliant)	Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/)
Creative Commons CC BY-NC-ND public use license	Permits non-commercial access & re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Note that some funding agencies, and some institutional read and publish agreements, require the use of a particular public use license, such as CC BY (as required by Plan S). The Publisher may communicate with the Authors in the publishing process about any such relevant requirements. The Authors will be asked during the publishing process to choose the particular form of public use license (such as CC BY) that they prefer or that may be required by institutional policies.

Please note the following: If your institution has a read and publish agreement with the Publisher that requires a specific public use license, or if the Publisher has an arranged procedure with a given funding agency concerning the use of a specific license, then the Publisher will automatically apply that license.

2. License

The Authors hereby grant an exclusive publishing and distribution rights license to the Publisher, or alternatively to the entity or entities included above in the copyright notice or as shown in the relevant “about the Journal” section on the Publisher’s web site. This license includes the right to distribute and make available, create derivative works or use new distribution technologies, enforce such rights as against third parties, and the right to grant or sublicense other entities for some or all of these rights. The Authors retain their moral rights and additionally may post certain versions of the Article on scholarly sites or otherwise provide other researchers with such versions, and may create certain derivative works as noted in the Publisher policy (https://pubs.acs.org/page/copyright/journals/posting_policies.html), and may otherwise use the Article in the same fashion as any member of the general public consistent with the public use license chosen by the Author. If the manuscript ultimately is not published, then this license and this Agreement will be null and void.

The Authors may provide, and may in some instances be required by the editor to provide, supplemental information and research data sets (that in the judgment of the editor are relevant even if not integral to the Article), which information and data will be used in the evaluation of the submission and may be subsequently made publicly available (on the basis that both the Authors

and the Publisher have unlimited and non-exclusive licenses for posting, distribution and further re-use, in whole or in part). Further information can be in the individual journal Author Guidelines. The relevant Guidelines can be found at <https://publish.acs.org/publish/> after selecting the appropriate journal.

3. Author Responsibilities

The Authors have reviewed this Agreement and the publishing guidelines and policies identified herein, agree with their terms, and accept the responsibilities as outlined below (and as sometimes described in more detail in the referenced guidelines and policies), and have selected a Corresponding Author to act on their behalf as described below in 5(a):

- a. The Article is the original work of the Authors with respect to the preparation of the manuscript, and all contributors who have been involved in such research or preparation have been appropriately identified (please refer to the relevant Author Guidelines).
- b. Any third party quotations or figures have been appropriately noted in the Article and fully identified in the references, and in the case of illustrations in particular the Authors have obtained full permission (distribution rights in all media and in all territories) from the illustrator or their agent for re-publication in the Article. The same permissions process would be required for any re-use of any substantial third party text elements (beyond 50 words).
- c. All institutional approvals and protocols have been obtained and followed in conjunction with the research and the preparation of the manuscript and submission to the journal. Similarly, any related requirements of relevant research funding agencies have been followed. Any funding agencies providing support for the underlying research have been identified.
- d. Any unusual hazards inherent in the chemicals, equipment or procedures used in the underlying research as described in the Article are clearly identified therein as hazardous and have been disclosed to the editor.
- e. In the preparation of the manuscript the Authors have noted any unusual or contradictory results and otherwise placed the work in its appropriate context for the scientific field (see the relevant Author Guidelines).
- f. The Authors have used appropriate research terms and descriptions of compounds, as outlined in the relevant Author Guidelines.
- g. The Authors have reviewed and agree to abide by the publishing ethics code outlined and approved by the Publisher (see <https://pubs.acs.org/page/policy/ethics/index.html>), including the disclosure of potential competing interests to the journal editor (note that Authors must provide disclosures or indicate that there are no competing interests to disclose).
- h. The Authors hereby warrant that nothing in the Submitted Work is defamatory, libelous, or otherwise unlawful, violates any right of privacy, or infringes any duty of confidentiality which the Author(s) may owe to another party or violates any contract, express or implied, that the Author(s) may have entered into.
- i. The Authors will cooperate with the Publisher concerning the enforcement of the exclusive

license granted to the Publisher and if necessary, will execute such documents and take other steps as the Publisher deems reasonably necessary for such enforcement. The Publisher agrees that any enforcement actions it takes will take into account the permitted uses of the Article as outlined in the public use license chosen by the Author.

4. Publisher Responsibilities

The Publisher has selected the journal editor and editorial board members and supported the peer review and Publication Process outlined below in Section 5, and will exercise professional responsibility over such processes. While the Publisher agrees that the consideration of any submitted manuscript should be fair and objective, it notes that the editorial responsibility for the journal rests with the editor and editorial board members, including the peer review process.

5. Publishing Process

The Authors have followed the submission and review processes identified for the journal, as generally described below, or as more specifically described in the ACS step-by-step submission guide (https://pubs.acs.org/page/4authors/submission_guide) or in the relevant Author Guidelines, namely:

- a. The Authors have selected a Corresponding Author and authorized the Corresponding Author (or designee) to agree to and execute this Agreement on their behalf, and to prepare the information required for the publishing process as outlined herein. The Corresponding Author has communicated in writing (which may be in email form) the terms and conditions outlined herein to the other Authors, and can make those communications available to the Publisher on request.
- b. The parties agree that the laws of the District of Columbia will govern the interpretation of this Agreement and that, without giving effect to the principles of conflict of laws thereof, they consent to the jurisdiction of the courts of the District of Columbia in any action arising under this Agreement. This Agreement, together with any referenced policy documents, constitutes the entire understanding of the parties concerning the publication of the Article, and supersedes all prior and contemporaneous agreements or proposals concerning the Article.
- c. During the publishing process the Authors will have provided the identity and contact information for all co-authors and other contributors, along with acknowledgements of relevant funding agency sources, and the selection of a public use license as described above in Section 1.
- d. The Authors will respond in timely fashion to editorial communications such as those concerning reviews and revisions.
- e. The Authors understand and agree that certain personal information about them including contact information will be used by the editor and the Publisher to communicate concerning the submission and review process. It is the practice of the Publisher when identifying an author in the introductory section of an article to note the author's institutional affiliation and contact email address. The Authors will be asked whether they wish to opt out of any other promotional information by the Publisher.

Contact Email Address: wuryanto.hadinugroho@gmail.com

Contact Postal Address: Kalisari Selatan No.1 Pakuwon City, Surabaya, East Java
60112 Indonesia

Corresponding Author Name (or designee): Wuryanto Hadinugroho



Signature: Wuryanto Hadinugroho

07 February 2023

Invitation to Review Proofs for ao-2022-07432u

Dari: acsproof@acs.org

Kepada: wuryanto.hadinugroho@gmail.com

Tanggal: Rabu, 15 Februari 2023 pukul 16.35 GMT+7

February 15, 2023

Journal: ACS Omega

Manuscript No.: ao-2022-07432u (acsomega.2c07432)

Title: Hydroxypropyl methylcellulose as hydrogel matrix and citric acid-locust bean gum as a negative matrix for controlled release tablet .

Authors: Wuryanto Hadinugroho, Suwaldi Martodihardjo, Achmad Fudholi, Sugeng Riyanto, Jefri Prasetyo .

Manuscript Status: Accept - Review Proof

Dear Wuryanto Hadinugroho,

You are invited to review the proof for your article.

ACS Publications is excited to offer a new author service for your proof corrections, **ACS Direct Correct**. This service allows you to make text corrections and comments directly in your proof file, much like editing in word-processing software, including the ability to see changes made in the file. Our suite of author services is available, including the ability to upload new graphics and/or Supporting Information, make changes to funding information, and order reprints.

To access the proof and associated materials, please click on the link below:

<https://proof-review.acs.org/apss/index.html?x=DfDdO55SYRxuK9SN3eiWIA>

Please note: An ACS ID is required to access proof materials. If you do not have an ACS ID, you will be prompted to create one or go to <https://pubs.acs.org/publish/> to register.

Please carefully review your proof as soon as possible, ideally within 48 hours. An e-mail reminding you that this task is overdue will be sent in 5 days. We will not publish your paper until we receive your corrections or your permission to publish as-is. All recommended corrections should be submitted in one correspondence.

Your article may now be cited using the DOI assigned to it. The DOI assigned to this article is <https://doi.org/10.1021/acsomega.2c07432> and is an accepted form of citation.

Sincerely,
ACS Journal Production Team
Most Trusted. Most Cited. Most Read.
<https://pubs.acs.org>

Corrections Received for ao-2022-07432u

Dari: acsproof@acs.org

Kepada: wuryanto.hadinugroho@gmail.com

Cc: wuryanto.hadinugroho@gmail.com

Tanggal: Kamis, 16 Februari 2023 pukul 08.29 GMT+7

February 15, 2023

Journal: ACS Omega

Manuscript No.: ao-2022-07432u (10.1021/acsomega.2c07432)

Title: Hydroxypropyl methylcellulose as hydrogel matrix and citric acid-locust bean gum as a negative matrix for controlled release tablet

Authors: Wuryanto Hadinugroho, Suwaldi Martodihardjo, Achmad Fudholi, Sugeng Riyanto, Jefri Prasetyo

Manuscript Status: Review Proof - Corrections Received

Dear Wuryanto Hadinugroho,

Your corrections/comments for this paper have been received by the ACS Publications Journal Production Office. Your manuscript will be corrected and published in final form, usually within 24-72 hours of receipt of proof.

The Journal Production Office can be reached via e-mail at acsproof@acs.org. Thank you for publishing with ACS Publications.

Sincerely,

ACS Journal Production Team

Most Trusted. Most Cited. Most Read.

<https://pubs.acs.org>

Publication for ao-2022-07432u

Dari: support@services.acs.org

Kepada: wuryanto.hadinugroho@gmail.com

Tanggal: Jumat, 17 Februari 2023 pukul 00.29 GMT+7

February 16, 2023

Journal: ACS Omega

Manuscript No.: ao-2022-07432u (10.1021/acsomega.2c07432)

Title: Hydroxypropyl Methylcellulose as Hydrogel Matrix and Citric Acid-Locust Bean Gum as Negative Matrix for Controlled Release Tablet

Authors: Wuryanto Hadinugroho, Suwaldi Martodihardjo, Achmad Fudholi, Sugeng Riyanto, Jefri Prasetyo .

Manuscript Status: Published

Dear Wuryanto Hadinugroho,

Your article is now published on the ACS Omega website. The DOI assigned to this article is 10.1021/acsomega.2c07432, and is an accepted form of citation from publication to perpetuity. To view your article, please click on the DOI link below:

<http://doi.org/10.1021/acsomega.2c07432>

The link seamlessly directs readers to the full text version of the article on the ACS Publications website. Because ACS Omega is an open access journal, readers will have full and immediate access to your research paper.

To retrieve ACS Articles on Request links for any of your published ACS articles, login to the ACS Publishing Center (<https://pubs.acs.org/publish/dashboard>) and select 'Published'. You can then share any of your publications by clicking the 'Share full text' link below each of your publications. You may also find your ACS Articles on Request links on your ACS Paragon Plus Author Dashboard 24 hours after the ASAP Article is posted.

To order high-quality reprints of the article for convenient distribution, please click the link below:

<http://pubstore.acs.org/file.aspx?&m=ao2c07432>

You may order between 50 and 300 copies, and orders can be shipped globally.

Please note that ACS also offers a Citation Alert feature. Registering for an ACS ID allows you to, among other things, track all citations to your paper, lets you set your alert preferences, and gives you the option of maintaining a list of Favorite Articles and Saved Searches.

Thank you for choosing to publish with ACS Journals and ACS Omega.

If you have questions or require assistance, please contact the ACS Help Desk:

E-mail: support@services.acs.org

Phone: +1 800-227-9919 (U.S. only)

+1 202-872-4357 (outside the U.S.)

6:00 AM to 7:00 PM EST

Sincerely,

ACS Publications Team

Most Trusted. Most Cited. Most Read.

<https://pubs.acs.org>